US8481517B2 - Pyrrolidine compounds,pharmaceutical compositions containing the same, devices containing the same, and methods of treating asthma or chronic obstructive pulmonary disease by administering the same - Google Patents

Pyrrolidine compounds,pharmaceutical compositions containing the same, devices containing the same, and methods of treating asthma or chronic obstructive pulmonary disease by administering the same Download PDF

Info

Publication number
US8481517B2
US8481517B2 US13/020,988 US201113020988A US8481517B2 US 8481517 B2 US8481517 B2 US 8481517B2 US 201113020988 A US201113020988 A US 201113020988A US 8481517 B2 US8481517 B2 US 8481517B2
Authority
US
United States
Prior art keywords
hydroxy
alkyl
group
compound
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US13/020,988
Other versions
US20110201580A1 (en
Inventor
Eleonora Ghidini
Andrea Rizzi
Andrea Virdis
Fabio RANCATI
Anna RENCUROSI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Assigned to CHIESI FARMACEUTICI S.P.A. reassignment CHIESI FARMACEUTICI S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GHIDINI, ELEONORA, RANCATI, FABIO, RIZZI, ANDREA, RENCUROSI, ANNA, VIRDIS, ANDREA
Publication of US20110201580A1 publication Critical patent/US20110201580A1/en
Application granted granted Critical
Publication of US8481517B2 publication Critical patent/US8481517B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0052—Nitrogen only at position 16(17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Definitions

  • the present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series.
  • the present invention also relates to methods of preparing such a compound, pharmaceutical compositions which contain such a compound, combinations which contain such a compound, and therapeutic uses of such a compound, composition, or combination. More particularly, the present invention relates to glucocorticosteroids that are derivatives of pyrrolidine.
  • Corticosteroids are potent anti-inflammatory agents, which are able to decrease the number, activity, and movement of inflammatory cells. Corticosteroids are commonly used to treat a wide range of chronic and acute inflammatory conditions including asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, rheumatoid arthritis, inflammatory bowel disease, and autoimmune diseases.
  • COPD chronic obstructive pulmonary disease
  • Corticosteroids mediate their effects through the glucocorticoid receptor (GR).
  • GR glucocorticoid receptor
  • the binding of corticosteroids to GR induces its nuclear translocation which, in turn, affects a number of downstream pathways via DNA-binding-dependent (e.g. transactivation) and -independent (e.g. transrepression) mechanisms.
  • Corticosteroid for treating chronic inflammatory conditions in the lung such as asthma and COPD, are currently administered through inhalation.
  • ICS inhaled corticosteroids
  • ICS treatment can yield important benefits, especially in asthma, it is important to minimise ICS systemic exposure which leads to the occurrence and severity of unwanted side effects that may be associated with chronic administration. Moreover, the limited duration of action of ICS currently available in the clinical practice contributes to suboptimal management of the disease. While the inhaler technology is the key point to target the lung, the modulation of the substituents on the corticosteroids molecular scaffold is important for the optimization of pharmacokinetic and pharmacodynamic properties in order to decrease oral bioavailability, confine pharmacological activity only in the lung (prodrugs and soft drugs) and increase systemic clearance.
  • ICS activity in the lung is highly desirable, as once daily administration of ICS would allow the reduction of the frequency of administration and, thus, substantially improve patient compliance and, as a result, disease management and control.
  • ICS there is a pressing medical need for developing ICS with improved pharmacokinetic and pharmacodynamic characteristics.
  • Fluticasone furoate is an example of enhanced affinity glucocorticoid that has been developed as topical therapy for allergic rhinitis with a unique combination of pharmacodynamic and physicochemical properties which render this compound long acting in the lung and rapidly inactivated by hepatic metabolism to reduce systemic side effects (see, Salter et al., American Journal of Physiology, vol. 293, no. 3, L660-L667, 2007).
  • the present invention is also directed to pharmaceutically acceptable acid addition salts of compounds of general formula (I) and (I′), to methods of preparing such compounds, to combinations with one or more active ingredients selected from the classes of ⁇ 2-agonist, antimuscarinic agents, PDE4 inhibitors, P38 MAP kinase inhibitors and IKK2 inhibitors, to pharmaceutical compositions comprising them and to therapeutic uses thereof.
  • the pyrrolidine glucocorticoids of the present invention are profiled in vitro by potency and efficacy in: a) binding to the GR; b) inducing nuclear translocation of GR; and c) inhibiting inflammatory responses in macrophages.
  • the optimization of pharmacokinetics/pharmacodynamic properties is pursued with the aim of improving the anti-inflammatory potency, efficacy and duration of action in the lung and to reduce systemic side effects.
  • the pyrrolidine glucocorticoids of the present invention are characterized by a good anti-inflammatory potency and efficacy which is associated with a long duration of action and a limited systemic exposure.
  • the present invention is directed to compounds of general formula (I):
  • R 1 is (CH 2 ) n —V—(CH 2 ) n′ —Z—R 4 , wherein:
  • halogen atoms as used herein includes fluorine, chlorine, bromine and iodine.
  • (C 1 -C 6 )alkyl refers to linear or branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to 6. Examples of alkyl groups are methyl, ethyl, n-propyl, isopropyl, t-butyl, n-pentyl and n-hexyl.
  • (C 1 -C 6 )alkoxy refers to alkyl-oxy (e.g. alkoxy) groups.
  • halo(C 1 -C 6 )alkyl refers to (C 1 -C 6 )alkyl wherein one or more hydrogen atoms are replaced by halogen atoms.
  • halo(C 1 -C 6 )alkoxy refers to (C 1 -C 6 )alkoxy wherein one or more hydrogen atoms are replaced by halogen atoms.
  • (C 2 -C 6 )alkenyl refers to unsaturated straight or branched carbon chains wherein the number atoms is in the range 2 to 6.
  • (C 3 -C 8 )cycloalkyl refers to cyclic non-aromatic hydrocarbon groups. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • hetero(C 3 -C 8 )cycloalkyl refers to “(C 3 -C 8 )cycloalkyl” in which at least one ring atom is a heteroatomic group selected from the group consisting of N, NH, S, and O.
  • (C 1 -C 6 )alkylsulfanyl refers, respectively, to alkyl-S—, alkyl-SO— and alkyl-SO 2 -groups.
  • aryl refers to mono, bi- or tricyclic ring systems which have 5 to 20 ring atoms, preferably from 5 to 15 and wherein at least one ring is aromatic.
  • heteroaryl refers to mono, bi- or tricyclic ring systems which have 5 to 20 ring atoms, preferably from 5 to 15, in which at least one ring is aromatic and in which at least one ring atom is a heteroatomic group selected from the group consisting of N, NH, S, and O.
  • Suitable monocyclic systems include thiophene, cyclopentadiene, benzene, pyrrole, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, pyridine, imidazolidine, piperidine and furan radicals such as tetrahydrofuran.
  • bicyclic systems examples include naphthalene, biphenyl, purine, pteridine, benzotriazole, quinoline, isoquinoline, indole, isoindole, benzofuran, benzodioxane and benzothiophene radicals.
  • Suitable tricyclic systems include fluorene radicals.
  • arylalkyl and aryl(C 3 -C 8 )cycloalkyl refer to a “(C 1 -C 6 )alkyl” and “(C 3 -C 8 )cycloalkyl” being substituted by aryl as above defined.
  • Suitable arylalkyl groups include benzyl and diphenylmethyl.
  • heteroarylalkyl groups examples include thiophenylmethyl.
  • one or more hydrogen atoms can be replaced by a group selected from halogen atoms, hydroxy, nitrile, amino, (C 1 -C 6 )alkylamino, dialkylamino, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylsulfonyl, carboxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylcarbonyloxy, (C 1 -C 6 )alkyloxy, (C 1 -C 6 )alkylsulfinyl, (C 1 -C 6 )alkyloxycarbonyl, (C 1 -C 6 )alkylaminocarbonyl, (C 1 -C 6 )arylalkoxy and ox
  • compounds of general formula (I) contain at least asymmetric centers at the positions 4a, 4b, 5, 6a, 6b, 9a, 10a, 10b and, depending on substituents, also at position 9 and 12.
  • compounds of general formula (I) may exist as many optical stereoisomers and mixtures thereof.
  • Preferred compounds are those of general formula (I) wherein the configuration of some of stereogenic centers is fixed and specifically wherein the configuration of the carbon atom in position 5 is S, in position 6a is S, in position 6b is S, in position 9a is R, in position 10a is S, in position 10b is S, in position 4a is S when X is halogen or 4a is R when X is hydrogen, in position 4b is R when X is halogen or 4b is S when X is hydrogen, and in position 12 is S when X is halogen, which are represented by the formula (I′) below:
  • Compounds of general formula (I) and (I′) may be capable of forming acid addition salts, particularly pharmaceutically acceptable acid addition salts.
  • Pharmaceutically acceptable acid addition salts of the compounds of formula (I) and (I′) include those of inorganic acids, for example hydrohalic acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydroiodic acid, as well as nitric acid, sulfuric acid, phosphoric acid; and organic acids, for example aliphatic monocarboxylic acids such as formic acid, acetic acid, trifluoroacetic acid, and propionic acid; aliphatic hydroxyl acids such as lactic acid, citric acid, tartaric acid or malic acid; dicarboxylic acids such as maleic acid or succinic acid; aromatic carboxylic acids such as benzoic acid; aromatic hydroxyl acids, and sulfonic acids.
  • hydrohalic acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydroiodic acid
  • pharmaceutically acceptable salts of the compounds of formula (I) and (I′) include those of bases, such as amines.
  • salts may be prepared from compounds of formula (I) and (I′) by known salt-forming procedures.
  • a preferred group of compounds of general formula (I′) is that wherein R 1 is (CH 2 ) n —V—(CH 2 ) n′ —Z—R 4 , n and n′ are independently 0, 1 or 2; V is absent or is selected from the group consisting of O, S, OCOO and NH; Z is a single bond or is selected from the group consisting of O, carbonyl, carboxyl, (C 3 -C 8 )cycloalkyl, —S— and —NR 5 , wherein R 5 is H or is selected from the group consisting of (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, aryl, aryl(C 1 -C 6 )alkyl, aryl(C 3 -C 8 )cycloalkyl and heteroaryl, optionally substituted by CN; R 4 is selected from the group consisting of H, CN, OH, COR 8 , halogen, (
  • R 1 is hydroxy-methyl, acetoxy, carboxyl 2-methoxy-ethyl ester, carbonyl 2-oxo ethyl ester, carboxyl 2-hydroxy-ethyl ester, carboxylbenzyl amide, carboxyl (1-phenyl-cyclopropyl)-amide or chloromethyloxy
  • R 2 is H, benzyl, ethyl butyl, chloro-benzyl, propionyl 2 oxo-ethyl, 4-chloro-benzyl, 3-chloro-benzyl, phenylpropyl, thiophen-2-ylmethyl, benzoyl, methyl-furan-2-ylmethyl, 3-fluoro-benzyl, 4-fluoro-benzyl, 4-trifluoromethyl-benzyl, 4-methoxybenzyl, difluorobenzyl, 2-oxo-2-phenyl-e
  • R 6 is H; (C 1 -C 6 )alkyl; (C 3 -C 8 )cycloalkyl; S(O) 2 R 11 , wherein R 11 is (C 1 -C 6 )alkyl, (C 1 -C 6 )alkylaryl or heteroaryl; aryl; heteroaryl; CSNR 9 R 10 or CONR 9 R 10 , wherein R 9 is H and R
  • R 6 is H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, aryl, heteroaryl, or —OR 7 , wherein R 7 is (C 1 -C 6 )alkyl or (C 1 -C 6 )alkylaryl.
  • R 6 is —OR 7 , wherein R 7 is (C 1 -C 6 )alkylaryl, W′ and M are absent.
  • the compounds of general formula (I′) may be prepared conventionally according to methods disclosed in the art. Some of the processes which can be used are described below and reported in Scheme 1.
  • the present invention is also directed to a process for the preparation of compounds of general formula (I′) wherein R 3 ⁇ COOH, by reacting a compound of formula (IX):
  • the present invention is also directed to a process for the preparation of compounds of general formula (XVI) wherein R 4 ⁇ H, by generating a compound of general formula (XVI) with R 4 ⁇ I and by reducing this intermediate in the presence of iodide salts.
  • the present invention is also directed to the preparation of compounds of general formula (I), starting from a suitable different stereoisomer of compounds of formula (II) and following the same synthetic routes described in Scheme 1 for compounds of general formula (I′).
  • the present invention also provides pharmaceutical compositions comprising a compound of general formula (I) or (I′) and one or more pharmaceutically acceptable carriers and/or excipients.
  • the present invention also provides combinations of a compound of general formula (I) or (I′) with one or more active ingredients selected from the classes of 132-agonists, antimuscarinic agents, PDE4 inhibitors, P38 MAP kinase inhibitors, and IKK2 inhibitors.
  • the present invention also provides combinations of a compound of general formula (I) or (I′) with a ⁇ 2-agonist selected from the group consisting carmoterol, GSK-642444, indacaterol, milveterol, arformoterol, formoterol, salbutamol, levalbuterol, terbutaline, AZD-3199, BI-1744-CL, LAS-100977, bambuterol, isoproterenol, procaterol, clenbuterol, reproterol, fenoterol, and ASF-1020.
  • a ⁇ 2-agonist selected from the group consisting carmoterol, GSK-642444, indacaterol, milveterol, arformoterol, formoterol, salbutamol, levalbuterol, terbutaline, AZD-3199, BI-1744-CL, LAS-100977, bambuterol, isoproterenol, procaterol, cle
  • the present invention also provides combinations of a compound of general formula (I) or (I′) with an antimuscarinic agent selected from the group consisting of aclidinium, tiotropium, ipratropium, trospium, glycopyrronium, and oxitropium.
  • an antimuscarinic agent selected from the group consisting of aclidinium, tiotropium, ipratropium, trospium, glycopyrronium, and oxitropium.
  • the present invention also provides combinations of a compound of general formula (I) or (I′) with a PDE4 inhibitor selected from the group consisting of cilomilast, roflumilast, BAY19-8004, and SCH-351591.
  • the present invention also provides combinations of a compound of general formula (I) or (I′) with a P38 inhibitor selected from the group consisting of semapimod, talmapimod, pirfenidone, PH-797804, GSK-725, minokine, and losmapimod.
  • a P38 inhibitor selected from the group consisting of semapimod, talmapimod, pirfenidone, PH-797804, GSK-725, minokine, and losmapimod.
  • the present invention provides combinations of a compound of general formula (I) or (I′) with a IKK2 inhibitor.
  • the present invention also provides compounds of general formula (I) or (I′) for use as a medicament.
  • the present invention provides a method for prevention and/or treatment of any disease wherein the decrease in the number, activity and movement of inflammatory cells is implicated, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of general formula (I) or (I′), alone or combined with one or more active ingredients.
  • the above diseases wherein the decrease in the number, activity and movement of inflammatory cells is implicated, comprise diseases of the respiratory tract characterized by airway obstruction such as asthma and COPD.
  • the present invention also provides pharmaceutical preparations of compounds of general formula (I) or (I′) suitable for administration by inhalation, by injection, orally or intranasally.
  • Inhalable preparations include inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations.
  • the present invention is also directed to a device which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler or a soft mist nebulizer comprising a compound of general formula (I) or (I′).
  • the present invention is also directed to a kit comprising the pharmaceutical compositions of compounds of general formula (I) or (I′) alone or in combination with or in admixture with one or more pharmaceutically acceptable carriers and/or excipients, and a device which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler or a soft mist nebulizer.
  • the compounds of general formula (I′) may be prepared, for example, following synthetic pathways described in Scheme 1.
  • the compounds of general formula (I′) may be prepared according to different routes described in Scheme 1, depending on the substituents R 1 , R 2 , R 3 , X and Y.
  • the ylide is generated in situ from a suitable precursor for example a compound of general formula (V).
  • the reaction involves the use of 1 to 7 equivalents of azomethine ylide precursor and it is usually performed in a high boiling point solvent such as THF, dioxane, toluene, or xylene.
  • the reaction usually proceeds in a range of temperature from 50 to 150° C. over a period of 1 to 5 hours and may be promoted by an acid such as trifluoroacetic acid, trimethylsilyl iodide or trimethylsilyl trifluoromethanesulfonate.
  • Sodium, potassium or cesium fluoride could also be effective in catalyzing the reaction.
  • the 1,3-DC reaction can be performed under classical batch reaction conditions, or can be conducted under flow conditions.
  • a flowing solution of compound of general formula (IX) in a suitable solvent such as for example THF or dioxane, containing 0.01 to 1% of TFA or other acid is mixed with a flowing solution of compound of general formula (V) and quickly pumped through a hot reaction chamber at such a rate that allows the reaction mixture to spend from 1 to 10 minutes at the reaction temperature.
  • Azomethine ylide precursors of general formula (V) are commercially available or can be prepared as described in the literature, for example following the procedure described in J. Chem .- Soc., Perkin Trans., 1, 1998, pp. 3867-3872, which is incorporated herein by reference in its entirety.
  • the compounds of formula (IX) may be prepared hydrolyzing the compounds of formula (IV). This reaction is preferably carried out by subjecting compounds (IV) to the action of an enzyme, such as for example immobilized Lipase from Candida Antarctica (Sigma Aldrich) ( Tetrahedron, 1994, Vol. 50, No. 46, 13165-13172), which is incorporated herein by reference in its entirety.
  • an enzyme such as for example immobilized Lipase from Candida Antarctica (Sigma Aldrich) ( Tetrahedron, 1994, Vol. 50, No. 46, 13165-13172), which is incorporated herein by reference in its entirety.
  • Compounds of general formula (IV) may be conveniently prepared according to standard procedures reported in the literature. For instance they may be prepared by treatment of compounds of general formula (III) with a base such as potassium acetate. This reaction is usually performed in a suitable polar solvent (e.g. DMF) and typically proceeds at a temperature range from 80 to 110° C., over a period of 0.5 to 4 hours.
  • a suitable polar solvent e.g. DMF
  • the benzyl group can be removed by catalytic hydrogenation, using palladium on charcoal as catalyst, or through chemical dealkylation of tertiary amines with acyl chlorides, phosgene analogues or preferably chloroformates such as vinylchloroformate.
  • the reaction is usually performed in a suitable solvent such as dichloromethane (DCM), tetrahydrofuran (THF) or acetonitrile at temperature range from room temperature (RT) to 60° C.
  • DCM dichloromethane
  • THF tetrahydrofuran
  • acetonitrile at temperature range from room temperature (RT) to 60° C.
  • the reaction requires the presence of a base such as alkali carbonates or bicarbonates or an organic base such as pyridine and usually completes over a time range from 0.5 to 2 hours.
  • the carbamate obtained from the first step of the reaction is deprotected under carbamate deprotection of amine, conditions well known for those skilled in the art and well described in the literature (Wiley-VCH; Wuts, Peter G. M./Greene, Theodora W., Greene's Protective Groups in Organic Synthesis , Fourth Edition, John Wiley and Sons, 2007, p 503 and following, which is incorporated herein by reference in its entirety).
  • a compound of general formula (VII) can be treated with acyl chloride and converted into corresponding amide.
  • the conditions for the reaction of pyrrolidines with acyl chlorides are widely described in the literature and involve the use of a solvent such as DCM or THF.
  • the reaction normally requires a base such as triethylamine (TEA), N,N-diisopropylethylamine (DIPEA) or pyridine and it is performed at RT over a period of 1 to 24 hours.
  • acyl chloride In the case the acyl chloride is not available it could be easily obtained from the corresponding carboxylic acid by treatment with for example oxalyl chloride or thionyl chloride.
  • the reaction is performed in a solvent such as DCM, a temperature from 0 to 40° C. and can be accelerated by traces of dimethylformamide.
  • the same compounds can be obtained by activating a carboxylic acid with an acid activating agent such as carbonyldiimidazole (CDI).
  • an acid activating agent such as carbonyldiimidazole (CDI).
  • CDI carbonyldiimidazole
  • the activation with CDI is a well known reaction of carboxylic acids and it is usually performed at temperature range from 0 to 80° C. in a suitable solvent such as DCM, THF or DMF.
  • reaction of compounds of general formula (VII) with chloroformates can be performed as described for the reaction of acyl chloride in a solvent such as DCM or THF in the presence of a base (e.g. TEA or DIPEA).
  • a base e.g. TEA or DIPEA.
  • the reaction usually proceeds at RT and over 0.5 to 24 hours.
  • reaction of compounds of general formula (VII) with isocyanates or isothiocyanates can be accomplished by dissolving reagents in suitable solvent such DCM, THF, acetonitrile at RT or up to 80° C.
  • suitable solvent such as DCM, THF, acetonitrile at RT or up to 80° C.
  • the reaction can be facilitated by the presence of a base (e.g. TEA, DIPEA or pyridine) and completes in 1 to 24 hours.
  • a base e.g. TEA, DIPEA or pyridine
  • the treatment of compounds of general formula (VII) with sulfonyl chlorides is the standard reaction for the preparation of sulfonamides.
  • the reaction occurs in a solvent such as DCM, THF or pyridine and may require the presence of a base (e.g. TEA or DIPEA) and completes over a period of 0.5 to 4 hours at RT.
  • a base e.g. TEA or DIPEA
  • Aryl or heteroaryl groups can be introduced at N atom of pyrrolidine ring by following described procedures for the N arylation of pyrrolidines.
  • Compounds of general formula (VII) can be reacted under metal catalyzed arylation conditions. The reaction is promoted by copper (I) salts, nickel(II) phosphine complexes and palladium complexes and often a base such as sodium or potassium terbutylate is required. The reaction occurs in a solvent such as DMF, dimetilacetamide (DMA), acetonitrile, dioxane, THF, toluene, N-methylpyrrolidone (NMP) at a temperature range from 40 to 200° C. by conventional thermal heating or by microwaves.
  • DMF dimetilacetamide
  • NMP N-methylpyrrolidone
  • the reaction can occur by simple heating, from 20 to 150° C., of a solution of compound of general formula (VII) and a suitable aryl or heteroaryl derivative, such as halides or trifluoromethane sulfonates (triflate), in a solvent such as ethanol, THF, acetonitrile, DMF, DMA, dioxane or NMP for a period of time from 0.5 to 24 hours.
  • this compound can be prepared by reacting the pyrrolidine intermediate of general formula (VII) with a benzyne. This very reactive species can be generated in situ from a suitable precursor following methods described in the literature.
  • a valid protocol involves the treatment of 2-trimethylsilyl-phenyl trifluoromethane sulfonates with cesium fluoride.
  • the reaction occurs at RT in a polar solvent such as acetonitrile and completes over a period from 1 to 72 hours.
  • a polar solvent such as acetonitrile
  • the reaction can lead to a mixture of two regioisomers.
  • the alkylation of compounds of general formula (VII) can be performed applying the conditions for the alkylation of pyrrolidines.
  • the reaction involves the use of alkyl halides, methane sulfonates, tosylates or other alkyl derivatives suitable for amine alkylation and requires the presence of a base such as TEA, DIPEA or pyridine to complete. It proceeds at a temperature from RT to 100° C. over 1 to 48 hours in a suitable solvent such as DCM, THF, acetonitrile or DMF.
  • a suitable solvent such as DCM, THF, acetonitrile or DMF.
  • the presence of sodium or potassium iodide can in some cases accelerate the reaction rate.
  • the same class of derivatives can be obtained reacting compounds of general formula (VII) under reductive amination reaction conditions with a suitable aldehyde in a solvent such as methanol, ethanol, THF, DCM, toluene, acetonitrile or mixture of them.
  • a suitable aldehyde in a solvent such as methanol, ethanol, THF, DCM, toluene, acetonitrile or mixture of them.
  • the imine intermediate is usually in situ reduced by treatment with reducing agents, such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride at a temperature range from 0 to 20° C., over 1 to 48 hours, or such as formic acid and its salts at a temperature range from 70 to 150° C., over 10 to 30 minutes.
  • products obtained feature an acetoxy moiety at position 6b of the steroid scaffold.
  • This moiety can be easily hydrolyzed by treatment with a base such as LiOH, NaOH, KOH, or K 2 CO 3 solid or dissolved in water, in organic solvents such as methanol, ethanol or THF or alternatively with an aqueous acid solution (for example HCl) in a suitable organic solvent such as THF or dioxane at 40 to 80° C. over a period of 1 to 8 hours.
  • a base such as LiOH, NaOH, KOH, or K 2 CO 3 solid or dissolved in water
  • organic solvents such as methanol, ethanol or THF
  • an aqueous acid solution for example HCl
  • suitable organic solvent such as THF or dioxane
  • sequence of reactions can be inverted performing first the hydrolysis of the acetyl group at position 6b of the steroid scaffold and then one of the functionalizations described above, if the second step is compatible with the presence of a primary alcohol moiety.
  • N-alkyl derivatives of compounds of formula (VII) obtained through its alkylation and subsequent hydrolysis of acetic ester at position 6b of steroid scaffold as described above in Route A2 can be obtained by 1,3-dipolar cycloaddition from intermediates (IX) and (V) as described in Route A1. All compounds obtained through Route A1 or Route A2 can undergo the sequence of reactions shown in Scheme 1 Route A that describes the functionalization of the hydroxyl moiety at position 6b of the steroid scaffold.
  • a suitable solvent for example pyridine
  • the reaction is usually performed in a suitable solvent (e.g. DCM, THF or DMF), in a range of temperature from ⁇ 40 to 80° C. over a period of 1 to 5 hours and may be promoted by a base such as sodium or potassium carbonate or sodium hydride.
  • the obtained product may be further functionalized modifying the moiety introduced by the described nucleophilic substitution reaction.
  • suitable acylating agents such as
  • This reaction is usually performed in open air at RT over a period of 12 to 48 hours, in a suitable solvent such as THF in the presence of an aqueous solution of an inorganic base, such as for example sodium or potassium hydroxide.
  • the reaction is usually performed in a suitable polar solvent (e.g. DMF), in a range of temperature from 0 to 80° C. over a period of 1 to 2 hours.
  • a suitable polar solvent e.g. DMF
  • the activated acid may be reacted with a nucleophile, readily apparent to those skilled in the art, such as alcohols, thiols, thioacids and amines.
  • the reaction may be promoted by a base such as sodium or potassium carbonate, sodium hydride and proceeds at a temperature ranging from 0 to 20° C. over a period of 1 to 24 hours.
  • the compounds of formula (XI) may be converted into the corresponding acyl chloride under well known conditions, using for example oxalyl chloride in a suitable solvent such as DCM.
  • the activated compound may be reacted with a nucleophile, readily apparent to those skilled in the art, such as alcohols, thiols, thioacids, amines and carbanions such as alkyl, aryl and heteroaryl cuprates or other metalloorganic compounds reported in the literature to be suitable for the conversion of acyl chlorides into the corresponding ketones.
  • a nucleophile readily apparent to those skilled in the art, such as alcohols, thiols, thioacids, amines and carbanions such as alkyl, aryl and heteroaryl cuprates or other metalloorganic compounds reported in the literature to be suitable for the conversion of acyl chlorides into the corresponding ketones.
  • the use of protecting groups must be considered in this reaction in order to avoid undes
  • Route B2 conversion of compounds of formula (XI) into compounds of general formula (XII), derived from reaction of acid (XI) with for example carbonyldiimidazole or N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridine-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU), followed by reaction with the sodium salt of thioacetic acid or with sodium hydrogensulfide.
  • the reaction is usually performed adding the solution of the preformed salt in the reaction solvent to the solution of the activated acid, at a temperature ranging from 0 to 20° C.
  • alkylating reagent such as bromoalkanes
  • bromoalkane such as bromo-chloromethane
  • the reaction is performed in DCM at RT over a period of time from 36 to 72 hours.
  • the obtained compound is treated with diethyl amine at reflux temperature for a period of time from 8 to 12 hours to give a compound of general formula (XII) that may be further functionalized as described above.
  • an alkylating reagent such as bromofluoromethane
  • a suitable solvent such as DMF
  • compound of general formula (XIII) can be prepared by a two step reaction of intermediate of general formula (IX) with ethylisocyanoacetate followed by reduction of the pyrroline so formed.
  • the cycloaddition of the isonitrile occurs in solvents such as tetrahydrofuran or dioxane at a temperature from 50 to 90° C. over a period of time from 1 to 5 hours. It is catalyzed by a base such as cuprous oxide.
  • the reduction of the formed pyrroline can be performed by treating this intermediate with a suitable reducing agent such as NaCNBH 3 in methanol or ethanol in a temperature range from 0° C. to RT. It will be apparent to those skilled in the art that following the procedure described a mixture of stereoisomers is obtained.
  • Compounds of general formula (XIII) can be further functionalized. For example they can undergo all reactions already described for the functionalization of compound (VII) and well known for those skilled in the art.
  • the ethyl ester at position 9 of compound of general formula (XIII) can be hydrolyzed and converted into the corresponding carboxylic acid.
  • the reaction can be conveniently performed treating with a base such as sodium of potassium hydroxide in suitable solvent such as methanol, ethanol or THF.
  • a base such as sodium of potassium hydroxide in suitable solvent such as methanol, ethanol or THF.
  • the reaction occurs at a temperature from 0° C. to RT over a period of time ranging from 4 to 24 hours.
  • the sequence comprises the reaction of compounds of general formula (VI) with vinylchloroformate as previously described (Route A1), the hydrolysis of the acetyl group is performed under basic conditions using potassium carbonate in methanol at 0° C.
  • the compounds of general formula (I′) may be administered for example, at a dosage of 0.001 to 1000 mg/day, preferably 0.1 to 500 mg/day.
  • the dosage of the compounds of general formula (I) is advantageously 0.01 to 20 mg/day, preferably 0.1 to 10 mg/day.
  • the compounds of general formula (I) alone or combined with other active ingredients may be administered for the prevention and/or treatment of any obstructive respiratory disease such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD).
  • any obstructive respiratory disease such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the compounds of general formula (I) may be administered for the prevention and/or treatment of any disease wherein the decrease in the number, activity and movement of inflammatory cells is implicated.
  • diseases include: diseases involving inflammation such as asthma and other allergic disorders, COPD, acute rhinitis; reverse acute transplant rejection and acute exacerbations of selected autoimmune disorders, graft-versus-host disease in bone-marrow transplantation; autoimmune disorders such as rheumatoid and other arthritis; skin conditions such as systemic lupus erythematosus, systemic dermatomyositis, psoriasis; inflammatory bowel disease, inflammatory ophthalmic diseases, autoimmune hematologic disorders, and acute exacerbations of multiple sclerosis; kidney, liver, heart, and other organ transplantation; Behçet's acute ocular syndrome, endogenous uveitis, atopic dermatitis, and nephrotic syndrome; Hodgkin's disease and non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia (CLL); autoimmune hemolytic anemia and thrombocytopenia
  • the compounds of general formula (I′) may be administered for the prevention and/or treatment of respiratory diseases such as from mild to acute severe conditions of asthma and COPD.
  • the reaction mixture is poured in ice/water (130 ml), and the resulting mixture is extracted with DCM (2 ⁇ 100 ml) and AcOEt (2 ⁇ 100 ml). The combined organic extracts are dried over anhydrous Na2SO4 and concentrated. The crude material is purified by flash chromatography on silica gel, in gradient elution from DCM to DCM/AcOEt 50:50 to give the title compound (2.22 g, quantitative yield).
  • reaction mixture is cooled at RT and then poured into ice and brine (200 ml), and the aqueous layer is extracted with AcOEt (3 ⁇ 150 ml). The combined organic extracts are washed with water and brine, dried over Na 2 SO 4 and concentrated to afford 2.55 g of crude title compound which is used in the next step without further purification.
  • Compound 44 is prepared from intermediate 20 by alkylation with bromomethyl-cyclopropane following Method A, as previously described in Example 6 for compound 23.
  • reaction mixture is partitioned between AcOEt and brine, the aqueous phase is extracted with AcOEt and the combined organic layers are dried over Na 2 SO 4 and filtered. After evaporation of the solvent, the crude is purified by preparative HPLC (CH3CN/H2O, No CF3COOH) to afford the title compound (52 mg, 0.096 mmol, 26.8% yield).
  • reaction mixture is partitioned between AcOEt and brine; the aqueous phase is separated and extracted with AcOEt. The combined organic layers are washed with brine, dried over Na 2 SO 4 and filtered. The solvent is evaporated to give an oil which is purified by silica gel chromatography (DCM/AcOEt 95/5) to afford the title compound (164 mg, 24.3%).
  • LPS Lipopolysaccharide
  • the potency of the compounds described in the present invention was evaluated in vivo in an acute model of lung inflammation following a method described by A. Miller-Larsson and coworkers ( Am. J. Respir. Crit. Care Med ., vol 162. pp, 1455-1461, 2000, which is incorporated herein by reference in its entirety) with minor modifications.
  • the tests were performed on Sprague-Dawley male rats (200 g). Intratracheal instillation of LPS resulted in a statistically significant increase in neutrophil concentration in BALF, a hallmark of acute ongoing pulmonary inflammation.
  • glucocorticoid producing a 75% inhibition (ED75 dose) assessment test For the dose of glucocorticoid producing a 75% inhibition (ED75 dose) assessment test, compounds (0.01-3 ⁇ moles/Kg of body weight) were administered intratracheally as suspension (0.2% Tween 80 in NaCl 0.9%) 1 hour before LPS challenge. A dose-response curve of the inhibitory effect of the test compounds on LPS-induced lung neutrophilia was performed and the ED75 dose of glucocorticoid was taken as a measure of potency in this bioassay.
  • the ED75 dose values for the most potent compounds described in this patent are comprised between 0.2 and 1.5 ⁇ moles/Kg of body weight.
  • a quantitative measurement of GR nuclear translocation of the compounds of the present invention was performed according to ASSAY Drug Devel. Technol., 4(3), 263-272, 2006, which is incorporated herein by reference in its entirety, through a novel cell-based GR-translocation assay in Enzyme Fragment Complementation (EFC) format developed by DiscoveRx (Fremont, Calif.).
  • EFC Enzyme Fragment Complementation
  • DiscoveRx assay uses EFC of b-galactosidase (b-gal) as an indicator of GR-translocation in engineered CHO-K1 biosensor cells.
  • the enzyme acceptor (EA) fragment of b-gal resides in the nucleus, as designed through the use of a proprietary set of sequence additions and modifications.
  • the small peptide enzyme donor (ED) fragment of b-gal is fused directly to the C-terminus of GR, and is localized in the cytoplasm is the absence of receptor signaling. Upon binding to a GR ligand, the complex translocates to the nucleus, where intact enzyme activity is restored by complementation and b-gal activity is detected.
  • CHO-K1 cells stably expressing NLS-enzyme acceptor fragment (EA) of b-gal and GR-enzyme donor (ED) fragment of b-gal were maintained in F12 medium (Invitrogen, Carlsbad, Calif.) at 37° C. under a humidified atmosphere containing 5% CO 2 and 95% air.
  • the medium contained 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin 50 ⁇ g/ml streptomycin, and 250 ⁇ g/ml hygromycin and 500 ⁇ g/ml G418 (Invitrogen).
  • GR-translocation was measured using the PathHunter Detection Kit containing cell membrane permeabilizing reagent and beta-gal substrate (DiscoveRx, Fremont, Calif.). All compounds were screened using varying concentrations ranging from 10 ⁇ 11 to 10 ⁇ 6 M. The assay was performed in 48-wells (105 cells/well). Incubation with screened compounds was performed at 37° C. for two hours. Detection was made by adding the detection buffer from the kit supplied by DiscoveRx and incubating at RT for one hour. Luminescence was detected by using a CENTRO LB 960 microplate reader (Berthold Technologies).
  • EC50s were performed by using Prism-version 3.0 Graphpad Software (San Diego, Calif.). The compounds assayed with the GR translocation assay displayed a EC50 comprised between 1 nM and 20 nM.
  • An in vitro model based on macrophagic murine cell line RAW 264.7 was used for testing the anti-inflammatory effects of the corticosteroids of the present invention.
  • large amounts of nitric oxide (NO) are generated by the inducible isoforms of NO synthase (iNOS).
  • Bacterial lipopolysaccaride (LPS) is commonly used in experimental settings to stimulate inflammatory responses in macrophages.
  • Cells were grown in a culture medium (RPMI supplemented with heat-inactivated 10% fetal calf serum, 2 mM glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin) without phenol red. Cell stimulation was elicited by incubating cells for 24 hours with LPS to final concentrations ranging from 100 ng/ml. Treatments with the compounds of the invention were carried out by adding such compounds vehicled in DMSO (0.1% final concentration) to the final desired concentrations 15 minutes before LPS exposure. As an index of nitric oxide production, the concentration of nitrite was measured in the conditioned media by using the Griess colorimetric reaction ( J.
  • IC50 neuroimmunol., 150, 29-36, 2004, which is incorporated herein by reference in its entirety.
  • Statistical analysis and determinations of IC50s were performed by using Prism-version 3.0 Graphpad Software (San Diego, Calif.).
  • the IC50 values tested on the compounds of the invention are comprised between 0.2 and 20 nM.
  • MRT L Mel Residence Time in the Lung
  • C 48 L/C 0.5 L (%) i.e. the percentage of the amount of the compound in the lung 48 hours after intratracheal administration vs the amount the same compound in the lung 0.25 hours after administration.
  • MRT L and C 48 L/C 0.5 L (%) are two meaningful and predictive parameters of the duration of a drug's effect after single dose pulmonary administration.
  • the compounds of the invention showed very slow lung elimination with MRT L higher than 20 hours and C 48 L/C 0.5 L higher than 20%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses thereof. More particularly, the invention relates to glucocorticosteroids that are derivatives of pyrrolidine.

Description

CROSS REFERENCES TO RELATED APPLICATIONS
This application claims priority to European Patent Application No. 10152731.5 filed on Feb. 5, 2010, which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series. The present invention also relates to methods of preparing such a compound, pharmaceutical compositions which contain such a compound, combinations which contain such a compound, and therapeutic uses of such a compound, composition, or combination. More particularly, the present invention relates to glucocorticosteroids that are derivatives of pyrrolidine.
2. Discussion of the Background
Corticosteroids are potent anti-inflammatory agents, which are able to decrease the number, activity, and movement of inflammatory cells. Corticosteroids are commonly used to treat a wide range of chronic and acute inflammatory conditions including asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, rheumatoid arthritis, inflammatory bowel disease, and autoimmune diseases.
Corticosteroids mediate their effects through the glucocorticoid receptor (GR). The binding of corticosteroids to GR induces its nuclear translocation which, in turn, affects a number of downstream pathways via DNA-binding-dependent (e.g. transactivation) and -independent (e.g. transrepression) mechanisms.
Corticosteroid, for treating chronic inflammatory conditions in the lung such as asthma and COPD, are currently administered through inhalation. One of the advantages of employing inhaled corticosteroids (ICS) is the possibility of delivering the drug directly at the site of action, limiting systemic side-effects, thus resulting in a more rapid clinical response and a higher therapeutic ratio.
Although ICS treatment can yield important benefits, especially in asthma, it is important to minimise ICS systemic exposure which leads to the occurrence and severity of unwanted side effects that may be associated with chronic administration. Moreover, the limited duration of action of ICS currently available in the clinical practice contributes to suboptimal management of the disease. While the inhaler technology is the key point to target the lung, the modulation of the substituents on the corticosteroids molecular scaffold is important for the optimization of pharmacokinetic and pharmacodynamic properties in order to decrease oral bioavailability, confine pharmacological activity only in the lung (prodrugs and soft drugs) and increase systemic clearance. Moreover, long-lasting ICS activity in the lung is highly desirable, as once daily administration of ICS would allow the reduction of the frequency of administration and, thus, substantially improve patient compliance and, as a result, disease management and control. In sum, there is a pressing medical need for developing ICS with improved pharmacokinetic and pharmacodynamic characteristics.
Fluticasone furoate is an example of enhanced affinity glucocorticoid that has been developed as topical therapy for allergic rhinitis with a unique combination of pharmacodynamic and physicochemical properties which render this compound long acting in the lung and rapidly inactivated by hepatic metabolism to reduce systemic side effects (see, Salter et al., American Journal of Physiology, vol. 293, no. 3, L660-L667, 2007).
To the extent of our knowledge, glucocorticoids pyrrolidine derivatives have never been described in the literature.
SUMMARY OF THE INVENTION
Accordingly, it is one object of the present invention to provide novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series.
It is another object of the present invention to provide novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series with improved pharmacological properties.
It is another object of the present invention to provide novel methods of preparing such a compound.
It is another object of the present invention to provide novel pharmaceutical compositions which contain such a compound.
It is another object of the present invention to provide novel combinations which contain such a compound.
It is another object of the present invention to provide novel therapeutic uses of such a compound, composition, or combination.
It is another object of the present invention to provide novel methods of treating certain diseases and conditions by administering such a compound, composition, or combination.
These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of general formula (I), and to the corresponding compounds of general formula (I′) wherein the configuration of some stereogenic centers is fixed, which are novel pyrrolidine derivatives, belonging to glucocorticosteroid series, exhibit good pharmacological properties.
The present invention is also directed to pharmaceutically acceptable acid addition salts of compounds of general formula (I) and (I′), to methods of preparing such compounds, to combinations with one or more active ingredients selected from the classes of β2-agonist, antimuscarinic agents, PDE4 inhibitors, P38 MAP kinase inhibitors and IKK2 inhibitors, to pharmaceutical compositions comprising them and to therapeutic uses thereof.
The pyrrolidine glucocorticoids of the present invention are profiled in vitro by potency and efficacy in: a) binding to the GR; b) inducing nuclear translocation of GR; and c) inhibiting inflammatory responses in macrophages. In addition, the optimization of pharmacokinetics/pharmacodynamic properties is pursued with the aim of improving the anti-inflammatory potency, efficacy and duration of action in the lung and to reduce systemic side effects. When administered topically in the lung in experimental animal models the pyrrolidine glucocorticoids of the present invention are characterized by a good anti-inflammatory potency and efficacy which is associated with a long duration of action and a limited systemic exposure.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
According to a first aspect, the present invention is directed to compounds of general formula (I):
Figure US08481517-20130709-C00001
wherein:
R1 is (CH2)n—V—(CH2)n′—Z—R4, wherein:
    • n and n′ are independently 0, 1 or 2;
    • V is absent or is selected from the group consisting of —O—, —S—, —OCOO, and NH;
    • Z is a single bond or is selected from the group consisting of —S—, —O—, carbonyl, carboxyl, (C3-C8)cycloalkyl, —NR5—, and —NR5C(O)—, wherein R5 is H or is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl, aryl(C1-C6)alkyl, aryl(C3-C8)cycloalkylene, and heteroaryl, optionally substituted by CN;
    • R4 is selected from the group consisting of:
      • —H, —OH, —CN, —SH or halogen;
      • (C1-C6)alkyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylcarboxyl, (C1-C6)alkylcarbonyl and (C3-C8)cycloalkyl, wherein one or more of the hydrogen atoms of the alkyl groups may be optionally substituted by one or more groups selected from oxo, —CN, —SH or halogen;
      • a mono-, bi- or tricyclic saturated, partially saturated or fully unsaturated ring, such as (C3-C8)cycloalkyl, hetero(C3-C8)cycloalkyl, aryl or heteroaryl optionally substituted by one or more halogen atoms or oxo groups; and
    • wherein when R4 and R5 are both (C1-C6)alkyl, they may form a 4-8 membered heterocycle together with the nitrogen atom to which they are bonded;
      R2 is (CH2)m—W—W′-M-R6, wherein:
    • m=0 or 1 to 6;
    • W is a single bond or is selected from the group consisting of —S—, —O—, carbonyl, and thiocarbonyl;
    • W′ is absent, NH or arylene group;
    • M is absent or is selected from the group consisting of (C1-C6)alkylsulfanyl, (C1-C6)alkylsulfonyl and (C1-C6)alkylsulfinyl;
    • R6 is selected from the group consisting of:
      • —H;
      • (C1-C6)alkyl;
      • a mono-, bi-, or tricyclic saturated, partially unsaturated or fully unsaturated ring, such as (C3-C8)cycloalkyl, aryl, hetero(C3-C8)cycloalkyl, or heteroaryl having 3 to 10 ring atoms wherein the hetero(C3-C8)cycloalkyl and the heteroaryl have at least one ring atom which is a heteroatomic group selected from the group consisting of N, NH, S, and O, and wherein any of the above rings is optionally substituted by one or more groups selected from oxo, OH, CN, COOH, (C1-C6)alkoxy, halo(C1-C6)alkoxy, aryl(C1-C6)alkyl, (C1-C6)alkyl, halo(C1-C6)alkyl, cyano, OCO(C1-C6)alkyl and halogen;
      • —OR7
      • —OCOR7
      • —COR7
      • —COOR8
      • —CONR9R10
      • —CSNR9R10
      • —S(O)2R11
    • wherein R7, R8 and R11 are independently selected from the group consisting of (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C8)cycloalkyl,
    • (C1-C6)alkylaryl, aryl(C1-C6)alkyl, and a saturated, partially unsaturated or fully unsaturated optionally fused ring such as aryl, heterocyclo(C1-C6)alkyl or heteroaryl having 3 to 10 ring atoms wherein at least one ring atom is a heteroatomic group selected from the group consisting of N, NH, S, and O, which groups may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, (C1-C6)alkyl, aryl, heteroaryl, hydroxy, amino or alkoxy;
    • and wherein R9 and R10 are independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl(C1-C6)alkyl, and a saturated, partially unsaturated or fully unsaturated optionally fused ring such as aryl, heterocyclo(C1-C6)alkyl or heteroaryl having 3 to 10 ring atoms wherein at least one ring atom is a heteroatomic group selected from the group consisting of N, NH, S, and O, which groups may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, (C1-C6)alkyl, hydroxyl, and when R9 and R10 are both (C1-C6)alkyl, they may form a 4-8 membered heterocycle together with the nitrogen atom to which they are bonded;
      R3 is selected from the group consisting of:
    • —H;
    • aryl;
    • C(O)OR12 wherein R12 is selected from the group consisting of H, (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl and heteroaryl;
    • C(O)NR13R14 wherein R13 and R14 are independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl(C1-C6)alkyl and a saturated, partially unsaturated or fully unsaturated optionally fused ring such as aryl, hetero(C3-C8)cycloalkyl or heteroaryl having 3 to 10 ring atoms wherein at least one ring atom is a heteroatomic group selected from the group consisting of N, NH, S, and O, which groups may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, (C1-C6)alkyl, hydroxyl, and when R13 and R14 are both (C1-C6)alkyl, they may form a 4-8 membered heterocycle together with the nitrogen atom to which they are bonded;
      X and Y are independently selected from the group consisting of H and halogen;
      and pharmaceutically acceptable salts thereof.
The term “halogen atoms” as used herein includes fluorine, chlorine, bromine and iodine.
As used herein, the expression “(C1-C6)alkyl” refers to linear or branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to 6. Examples of alkyl groups are methyl, ethyl, n-propyl, isopropyl, t-butyl, n-pentyl and n-hexyl.
The term “(C1-C6)alkoxy” refers to alkyl-oxy (e.g. alkoxy) groups.
The expression “halo(C1-C6)alkyl” refers to (C1-C6)alkyl wherein one or more hydrogen atoms are replaced by halogen atoms.
The expression “halo(C1-C6)alkoxy” refers to (C1-C6)alkoxy wherein one or more hydrogen atoms are replaced by halogen atoms.
The expression “(C2-C6)alkenyl” refers to unsaturated straight or branched carbon chains wherein the number atoms is in the range 2 to 6.
The derived expressions “halo(C2-C6)alkenyl”, “(C2-C6)alkynyl” and halo(C2-C6)alkynyl” are to be construed in an analogous manner.
As used herein, the expression “(C3-C8)cycloalkyl” refers to cyclic non-aromatic hydrocarbon groups. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
As used herein, the expression “hetero(C3-C8)cycloalkyl” refers to “(C3-C8)cycloalkyl” in which at least one ring atom is a heteroatomic group selected from the group consisting of N, NH, S, and O.
The expressions “(C1-C6)alkylsulfanyl”, “(C1-C6)alkylsulfinyl” and “(C1-C6)alkylsulfinyl” refer, respectively, to alkyl-S—, alkyl-SO— and alkyl-SO2-groups.
As used herein, the expression “aryl” refers to mono, bi- or tricyclic ring systems which have 5 to 20 ring atoms, preferably from 5 to 15 and wherein at least one ring is aromatic.
As used herein, the expression “heteroaryl” refers to mono, bi- or tricyclic ring systems which have 5 to 20 ring atoms, preferably from 5 to 15, in which at least one ring is aromatic and in which at least one ring atom is a heteroatomic group selected from the group consisting of N, NH, S, and O.
Examples of suitable monocyclic systems include thiophene, cyclopentadiene, benzene, pyrrole, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, pyridine, imidazolidine, piperidine and furan radicals such as tetrahydrofuran.
Examples of suitable bicyclic systems include naphthalene, biphenyl, purine, pteridine, benzotriazole, quinoline, isoquinoline, indole, isoindole, benzofuran, benzodioxane and benzothiophene radicals.
Examples of suitable tricyclic systems include fluorene radicals.
As used herein, the expressions “arylalkyl” and “aryl(C3-C8)cycloalkyl” refer to a “(C1-C6)alkyl” and “(C3-C8)cycloalkyl” being substituted by aryl as above defined.
Examples of suitable arylalkyl groups include benzyl and diphenylmethyl.
Examples of suitable heteroarylalkyl groups include thiophenylmethyl.
Optionally in any of the said rings including (C3-C8)cycloalkyl, aryl, heteroaryl and the like, one or more hydrogen atoms can be replaced by a group selected from halogen atoms, hydroxy, nitrile, amino, (C1-C6)alkylamino, dialkylamino, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkylsulfonyl, carboxy(C1-C6)alkyl, (C1-C6)alkylcarbonyloxy, (C1-C6)alkyloxy, (C1-C6)alkylsulfinyl, (C1-C6)alkyloxycarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)arylalkoxy and oxo.
It will be apparent to those skilled in the art that compounds of general formula (I) contain at least asymmetric centers at the positions 4a, 4b, 5, 6a, 6b, 9a, 10a, 10b and, depending on substituents, also at position 9 and 12. As a consequence, compounds of general formula (I) may exist as many optical stereoisomers and mixtures thereof.
Therefore the invention is also directed to all of these forms of the compounds of formula (I) and mixtures thereof.
Preferred compounds, however, are those of general formula (I) wherein the configuration of some of stereogenic centers is fixed and specifically wherein the configuration of the carbon atom in position 5 is S, in position 6a is S, in position 6b is S, in position 9a is R, in position 10a is S, in position 10b is S, in position 4a is S when X is halogen or 4a is R when X is hydrogen, in position 4b is R when X is halogen or 4b is S when X is hydrogen, and in position 12 is S when X is halogen, which are represented by the formula (I′) below:
Figure US08481517-20130709-C00002
wherein the symbol
Figure US08481517-20130709-P00001

represents an unspecified bond, which indicates an asymmetric carbon atom in position 9, wherein the configuration may be R or S, and wherein the values of R1, R2, R3, X, and Y are as defined above in free or salt form.
Compounds of general formula (I) and (I′) may be capable of forming acid addition salts, particularly pharmaceutically acceptable acid addition salts. Pharmaceutically acceptable acid addition salts of the compounds of formula (I) and (I′) include those of inorganic acids, for example hydrohalic acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydroiodic acid, as well as nitric acid, sulfuric acid, phosphoric acid; and organic acids, for example aliphatic monocarboxylic acids such as formic acid, acetic acid, trifluoroacetic acid, and propionic acid; aliphatic hydroxyl acids such as lactic acid, citric acid, tartaric acid or malic acid; dicarboxylic acids such as maleic acid or succinic acid; aromatic carboxylic acids such as benzoic acid; aromatic hydroxyl acids, and sulfonic acids.
Likewise, pharmaceutically acceptable salts of the compounds of formula (I) and (I′) include those of bases, such as amines.
These salts may be prepared from compounds of formula (I) and (I′) by known salt-forming procedures.
A preferred group of compounds of general formula (I′) is that wherein R1 is (CH2)n—V—(CH2)n′—Z—R4, n and n′ are independently 0, 1 or 2; V is absent or is selected from the group consisting of O, S, OCOO and NH; Z is a single bond or is selected from the group consisting of O, carbonyl, carboxyl, (C3-C8)cycloalkyl, —S— and —NR5, wherein R5 is H or is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl, aryl(C1-C6)alkyl, aryl(C3-C8)cycloalkyl and heteroaryl, optionally substituted by CN; R4 is selected from the group consisting of H, CN, OH, COR8, halogen, (C1-C6)alkyl, aryl and hetero(C3-C8)cycloalkyl which may be optionally substituted by one or more halogen atoms or oxo and wherein R8 is (C1-C6)alkyl optionally substituted by halogen; R2 is (CH2)m—W—W′-M-R6 wherein m=0 to 4; W is a single bond or is selected from the group consisting of —O—, carbonyl or thiocarbonyl; W′ is absent, NH or is aryl; M is absent or is selected from the group consisting of (C1-C6)alkylsulfanyl and (C1-C6)alkylsulfinyl; R6 is selected from the group consisting of H, (C1-C6)alkyl, (C3-C8)cycloalkyl, hetero(C3-C8)cycloalkyl, aryl and heteroaryl, wherein (C3-C8)cycloalkyl, hetero(C3-C8)cycloalkyl, aryl and heteroaryl are optionally substituted by one or more groups selected from halogen atoms, oxo, OH, CN, COOH, (C1-C6)alkoxy, halo(C1-C6)alkoxy, aryl(C1-C6)alkyl, (C1-C6)alkyl, halo(C1-C6)alkyl, —OCO(C1-C6)alkyl or halogen; —OR7, —OCOR7, —COR7, —COOR8, —CONR9R10, —CSNR9R10, —S(O)2R11 wherein R7, R8 and R11 are independently selected from the group consisting of (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C8)cycloalkyl, aryl(C1-C6)alkyl, (C1-C6)alkylheteroaryl, aryl, hetero(C3-C8)cycloalkyl and heteroaryl having 3 to 10 ring atoms wherein at least one ring atom is a heteroatomic group selected from the group consisting of N, NH, S, and O, which groups may be optionally substituted with one or more substituents selected from the group consisting of halogen and (C1-C6)alkyl; R9 and R10 are independently selected from the group consisting of (C1-C6)alkyl and (C3-C8)cycloalkyl; R3 is selected from the group consisting of H and C(O)OR12 wherein R12 is H or (C1-C6)alkyl; X and Y are independently selected from the group consisting of H and fluorine.
An even more preferred group of compounds of general formula (I′) is that wherein R1 is hydroxy-methyl, acetoxy, carboxyl 2-methoxy-ethyl ester, carbonyl 2-oxo ethyl ester, carboxyl 2-hydroxy-ethyl ester, carboxylbenzyl amide, carboxyl (1-phenyl-cyclopropyl)-amide or chloromethyloxy; R2 is H, benzyl, ethyl butyl, chloro-benzyl, propionyl 2 oxo-ethyl, 4-chloro-benzyl, 3-chloro-benzyl, phenylpropyl, thiophen-2-ylmethyl, benzoyl, methyl-furan-2-ylmethyl, 3-fluoro-benzyl, 4-fluoro-benzyl, 4-trifluoromethyl-benzyl, 4-methoxybenzyl, difluorobenzyl, 2-oxo-2-phenyl-ethyl, 2-oxo-2-thiophen-2-yl-ethyl, 3-methyl-butyl, benzoyl, thiophene-2-carbonyl, methoxy-benzoyl, pyridine-3-carbonyl, propyl-2-sulfonyl, carbothioic cyclohexylamide, carboxyl-phenylamide, carboxyl isopropyl, carbox benzyl, benzooxazol, pyrimidin-2-yl, 2-phenoxy-ethyl, thiophen-2-sulfonyl, 2-oxo-phenyl-carbamoyl, 2-oxo-phenyl thiocarbamoyl, cyclohexylcarbamoyl, methylsulfonyl, benzylsulfonyl, furan-2-ylmethyl, thiophen-2-ylmethyl, 3-methylbutyl, butyl, furan-2-carbonyl, 2-phenylsulfanyl, phenylsulfanylethyl, phenylacetyl, thiophen-2-yl-acetyl, 2-phenoxyethyl, 2-phenylethyl, pyridin-3-ylmethyl, 3-methoxybenzyl, phenylmethanesulfonyl, cyclohexylthiocarbamoyl, acetoxyacetyl, difluoromethoxybenzyl, 4-hydroxy-phenylsulfanylmethyl)-benzyl, 4-hydroxy-phenylsulfinylmethyl)-benzyl; R3 is H, carboxyethyl or carboxyl.
Another preferred group of compounds of general formula (I′) is that wherein R1 is (CH2)n—V—(CH2)n′—Z—R4, wherein V is absent, n=0, n′=1 or 2, Z is a bond or carboxyl, R4═OH; R2 is (CH2)m—W—W′-M-R6, wherein m=0, 1 or 3, W is a bond, —O—, —S—, carbonyl or thiocarbonyl, W′ and M are absent; R6 is H; (C1-C6)alkyl; (C3-C8)cycloalkyl; S(O)2R11, wherein R11 is (C1-C6)alkyl, (C1-C6)alkylaryl or heteroaryl; aryl; heteroaryl; CSNR9R10 or CONR9R10, wherein R9 is H and R10 is aryl or heteroaryl, wherein in both aryl or heteroaryl, one or more hydrogen atoms may be optionally substituted by halogen or O(C1-C6)alkyl; R3═H or COOR12, wherein R12 is (C1-C6)alkyl; X and Y are independently selected from hydrogen or fluorine.
Another preferred group of compounds of general formula (I′) is that wherein R1 is (CH2)n—V—(CH2)n′—Z—R4, wherein n=1, n′=0, Z is —O—, R4 is (C1-C6)alkylcarbonyl or (C1-C6)alkylcarboxyl; R2 is (CH2)m—W—W′-M-R6, wherein m=0 or 1, W is a bond, carbonyl or thiocarbonyl, W′ and M are absent, R6 is H, (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl, heteroaryl, or —OR7, wherein R7 is (C1-C6)alkyl or (C1-C6)alkylaryl.
Another preferred group of compounds of general formula (I′) is that wherein R1 is (CH2)n—V—(CH2)n—Z—R4, wherein n=1, n′=0, V is absent, Z is —O— and R4 is (C1-C6)alkylcarbonyl; R2 is (CH2)m—W—W′-M-R6, wherein m=0, W is carbonyl and R6 is —OR7, wherein R7 is (C1-C6)alkylaryl, W′ and M are absent.
Another preferred group of compounds of general formula (I′) is that wherein R2 is (CH2)m—W—W′-M-R6, wherein m=1, W is a single bond, W′ is aryl, M is (C1-C6)alkylsulfanyl or (C1-C6)alkylsulfinyl and R6 is aryl optionally substituted by OH.
Another preferred group of compounds of general formula (I′) is that wherein R1 is (CH2)n—V—(CH2)n—Z—R4, wherein n and n′=0, V is absent, Z is —O— and R4 is (C1-C6)alkyl, wherein one or more hydrogen atoms are substituted by halogen.
Another preferred group of compounds of general formula (I′) is that wherein R1 is (CH2)n—V—(CH2)n—Z—R4, wherein n and n′=0, V is absent, Z is —NR5, wherein R5 is H or is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl, aryl(C1-C6)alkyl, aryl(C3-C8)cycloalkyl and heteroaryl, optionally substituted by CN.
The compounds of general formula (I′) may be prepared conventionally according to methods disclosed in the art. Some of the processes which can be used are described below and reported in Scheme 1.
The present invention is directed to a process for the preparation of compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n=0, n′=1, V is absent, Z is a bond, R4═OH, R2═(CH2)m—W—W′-M-R6, m is 1 to 6, W is a single bond, W′ and M are absent, which comprises the reaction of a compound of general formula (IX):
Figure US08481517-20130709-C00003
with a compound of general formula (V):
Figure US08481517-20130709-C00004
wherein X, Y, m and R6 are as defined above and TMS represents trimethylsilyl.
The present invention is also directed to a process for the preparation of compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n=0, n′=1, V is absent, Z is a bond, R4 is OH and R3═H, by reacting a compound of general formula (IV):
Figure US08481517-20130709-C00005
with a compound of formula (V) wherein m=1 and R6=phenyl, to obtain a compound of formula (VI):
Figure US08481517-20130709-C00006
wherein the benzyl group (Bn) can be removed by catalytic hydrogenation or through chemical dealkylation of tertiary amines and in presence of a base, to obtain compounds of formula (VII):
Figure US08481517-20130709-C00007
which can be converted into (I′) wherein X, Y, R1 and R3 are as defined above.
The present invention is also directed to a process for the preparation of compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n=1, V is O, n′=0, Z is carbonyl or carboxyl, R4 is (C1-C6)alkyl and R3═H which comprises the conversion of the hydroxyl group of 2-hydroxy acetyl moiety at position 6b of compounds of general formula (I′) wherein n=0, V is absent, n′=1, Z is a bond, R4═OH and R3═H, by reaction with acylating agents.
The present invention is also directed to a process for the preparation of compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n=0, V is absent and n′=1, which comprises the conversion of the hydroxyl group of 2-hydroxy acetyl moiety at position 6b of compounds of general formula (I′) wherein n=0, V is absent, n′=1, Z is a bond, R4═OH and R3═H.
The present invention is also directed to a process for the preparation of compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n and n′=0, V is absent, Z═S and R3═H, which comprises the reaction of compounds of formula (I′) wherein n=0, V is absent, n′=1, Z is a bond, R4═OH and R3═H in the presence of an aqueous solution of an inorganic base, to obtain the compounds of general formula (XI), wherein X, Y and R2 are as defined above,
Figure US08481517-20130709-C00008
and then treatment with dimethyl thiocarbamoyl chloride and diethyl amine.
The present invention is also directed to a process for the preparation of compounds of general formula (I′) wherein R1═(CH2), —V—(CH2)n—Z—R4, n and n′=0, V is absent and R3═H, which comprises the reaction of the compounds of formula (XI) with one or more equivalents of an acid activating agent followed by displacement by a nucleophile.
The present invention is also directed to a process for the preparation of compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n and n′=0, V is absent, Z═S, R3═H, which comprises the reaction of compounds of formula (XI) with an activating agent and then with the sodium salt of thioacetic acid or with sodium hydrogensulfide to obtain compounds of general formula (XII), wherein X, Y and R2 are as defined above,
Figure US08481517-20130709-C00009
which is reacted with an alkylating reagent.
The present invention is also directed to a process for the preparation of compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n and n′=0, V is absent, Z═O, R4 is (C1-C6)alkyl and R3═H, which comprises the reaction of compounds of formula (XI) with dimethylcarbonate or an alkylating reagent in the presence of an inorganic base.
The present invention is also directed to a process for the preparation of compounds of general formula (I′) wherein R3═COOH, by reacting a compound of formula (IX):
Figure US08481517-20130709-C00010
with ethylisocyanoacetate to obtain a compound of formula (XIII), wherein X and Y are as defined above,
Figure US08481517-20130709-C00011
which can be hydrolized and converted into compounds of general formula (I′) wherein R3 is C(O)OR13 with R13═H, which can be further converted into compounds of general formula (I′) wherein R3═CONR13R14.
The present invention is also directed to a process for the preparation of compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n=0, V is absent, n′=1, Z is a bond, R4 is halide and R3═H, starting from the conversion of the hydroxyl group of 2-hydroxy acetyl moiety at position 6b of compounds of general formula (IX), wherein n=0, V is absent, n′=1, Z is a bond, R4═OH and R3═H, into a leaving group (LG), followed by the displacement of the LG by using a nucleophile such as an halide salt to obtain compounds of general formula (XIV), wherein X and Y are as defined above,
Figure US08481517-20130709-C00012
and by reacting a compound of general formula (XIV) with a compound of general formula (V).
The present invention is also directed to a process for the preparation of compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n=0, V is absent, n′=1, Z is a bond, R4 is halide, hydrogen or thioalkyl and R3═H, which comprises the reaction of compounds of general formula (VI), wherein X and Y are as defined above,
Figure US08481517-20130709-C00013
with vinylchloroformate, the hydrolysis of the acetyl group to obtain compounds of formula (XV):
Figure US08481517-20130709-C00014
the conversion of the hydroxyl group of 2-hydroxy acetyl moiety at position 6b of compounds of general formula (XV) into a leaving group (LG), followed by the displacement of the LG by using a nucleophile to obtain compounds of general formula (XVI):
Figure US08481517-20130709-C00015
The present invention is also directed to a process for the preparation of compounds of general formula (XVI) wherein R4═H, by generating a compound of general formula (XVI) with R4═I and by reducing this intermediate in the presence of iodide salts.
The present invention is also directed to the preparation of compounds of general formula (I), starting from a suitable different stereoisomer of compounds of formula (II) and following the same synthetic routes described in Scheme 1 for compounds of general formula (I′).
Figure US08481517-20130709-C00016
Figure US08481517-20130709-C00017
Figure US08481517-20130709-C00018
The present invention also provides pharmaceutical compositions comprising a compound of general formula (I) or (I′) and one or more pharmaceutically acceptable carriers and/or excipients.
The present invention also provides combinations of a compound of general formula (I) or (I′) with one or more active ingredients selected from the classes of 132-agonists, antimuscarinic agents, PDE4 inhibitors, P38 MAP kinase inhibitors, and IKK2 inhibitors.
The present invention also provides combinations of a compound of general formula (I) or (I′) with a β2-agonist selected from the group consisting carmoterol, GSK-642444, indacaterol, milveterol, arformoterol, formoterol, salbutamol, levalbuterol, terbutaline, AZD-3199, BI-1744-CL, LAS-100977, bambuterol, isoproterenol, procaterol, clenbuterol, reproterol, fenoterol, and ASF-1020.
The present invention also provides combinations of a compound of general formula (I) or (I′) with an antimuscarinic agent selected from the group consisting of aclidinium, tiotropium, ipratropium, trospium, glycopyrronium, and oxitropium.
The present invention also provides combinations of a compound of general formula (I) or (I′) with a PDE4 inhibitor selected from the group consisting of cilomilast, roflumilast, BAY19-8004, and SCH-351591.
The present invention also provides combinations of a compound of general formula (I) or (I′) with a P38 inhibitor selected from the group consisting of semapimod, talmapimod, pirfenidone, PH-797804, GSK-725, minokine, and losmapimod.
In a preferred embodiment, the present invention provides combinations of a compound of general formula (I) or (I′) with a IKK2 inhibitor.
The present invention also provides compounds of general formula (I) or (I′) for use as a medicament.
Also provided is the use of compounds of general formula (I) or (I′), alone or combined with one or more active ingredients, for the preparation of a medicament for the prevention or treatment of any disease wherein the decrease in the number, activity and movement of inflammatory cells is implicated.
In particular, also provided, is the use of compounds of general formula (I) or (I′), alone or combined with one or more active ingredients, for the preparation of a medicament for the prevention and/or treatment of a disease of the respiratory tract characterized by airway obstruction such as asthma and COPD.
Moreover the present invention provides a method for prevention and/or treatment of any disease wherein the decrease in the number, activity and movement of inflammatory cells is implicated, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of general formula (I) or (I′), alone or combined with one or more active ingredients.
The above diseases, wherein the decrease in the number, activity and movement of inflammatory cells is implicated, comprise diseases of the respiratory tract characterized by airway obstruction such as asthma and COPD.
The present invention also provides pharmaceutical preparations of compounds of general formula (I) or (I′) suitable for administration by inhalation, by injection, orally or intranasally.
Inhalable preparations include inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations.
The present invention is also directed to a device which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler or a soft mist nebulizer comprising a compound of general formula (I) or (I′).
The present invention is also directed to a kit comprising the pharmaceutical compositions of compounds of general formula (I) or (I′) alone or in combination with or in admixture with one or more pharmaceutically acceptable carriers and/or excipients, and a device which may be a single- or multi-dose dry powder inhaler, a metered dose inhaler or a soft mist nebulizer.
Most of the compounds of the invention were found to show an in vitro activity ranging from 10−8 to 10−10 M in all the cell free and cell based assays employed and some of them turned out to be endowed with a long duration of anti-inflammatory action in the lung in rodent experimental models in vivo.
According to preferred embodiments the present invention provides the compounds reported below:
Compound Chemical Name
8 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzyl-4b,12-difluoro-5-
hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
9 (4aS,4bR,5S,6aS,6bS,9aR,8R,10aS,10bS,12S)-8-(4-chloro-benzyl)-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
10 acetic acid 2-((4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-8-benzyl-5-hydroxy-
4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl
ester
11 acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzyl-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester
12 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(3-phenyl-propyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
13 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-thiophen-2-ylmethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
14 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-8-furan-2-
ylmethyl-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
15 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(5-methyl-furan-2-ylmethyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
16 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-8-(3-fluoro-
benzyl)-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
17 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,5-difluoro-benzyl)-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
18 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-8-benzyl-5-hydroxy-6b-(2-hydroxy-
acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one
19 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-(2-acetoxy-acetyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-8-carboxylic acid vinyl ester
20 acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl
ester hydrochloride
21 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-6b-(2-acetoxy-acetyl)-5-hydroxy-
4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid
vinyl ester
22 acetic acid 2-((4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-4a,6a-
dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-
8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester hydrochloride
23 acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-8-(2-oxo-2-phenyl-ethyl)-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester
24 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(2-oxo-2-phenyl-ethyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
25 acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-8-pyridin-3-ylmethyl-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester
26 acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,5-difluoro-
benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,
9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-
a]phenanthren-6b-yl]-2-oxo-ethyl ester
27 3-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-(2-Acetoxy-acetyl)-
4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-8-ylmethyl]-benzoic acid methyl ester
28 3-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-(2-Acetoxy-acetyl)-
4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-8-ylmethyl]-benzoic acid
29 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-chloro-benzyl)-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
30 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-8-(4-fluoro-
benzyl)-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
31 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(4-trifluoromethyl-benzyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
32 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-8-(4-methoxy-benzyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
33 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(2-oxo-2-thiophen-2-yl-ethyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
34 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-8-(3-methoxy-benzyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
35 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-8-(3-chloro-benzyl)-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one
36 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(pyridin-3-ylmethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
37 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(3-methyl-butyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
38 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(3-trifluoromethoxy-benzyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
39 4-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-8-ylmethyl]-benzonitrile
40 3-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-8-ylmethyl]-benzonitrile
41 bis((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one) naphtalen disulfonate salt
42 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one methane sulfonate
43 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one hydrochloride
44 acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-
cyclopropylmethyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester
45 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-cyclopropylmethyl-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
46 3-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-8-ylmethyl]-benzoic acid methyl ester
47 3-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-8-ylmethyl]-benzoic acid trifluoroacetate
48 Propionic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-chloro-
benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester
49 Carbonic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzyl-
4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester ethyl ester
50 acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-
hydroxy-4a,6a,8-trimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl
ester
51 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a,8-trimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
52 acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-
hydroxy-8-isopropyl-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester
53 acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-cyclohexyl-
4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester
54 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-8-isopropyl-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
55 4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Cyclohexyl-4b,12-difluoro-5-
hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
56 acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,3-dimethyl-
butyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester
57 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,3-Dimethyl-butyl)-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
58 acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-8-(1-propyl-butyl)-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester
59 acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(2-ethyl-butyl)-
4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester
60 acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(4-benzyl-
benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester
61 acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-8-(5-methyl-furan-2-ylmethyl)-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester
62 acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-8-(3-methyl-butyl)-2-oxo-2,4b,5,6,6a,7,8,9,9a,
10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-
6b-yl]-2-oxo-ethyl ester
63 acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-
5-hydroxy-6b-(2-hydroxy-acetyl)-8-[4-(4-hydroxy-phenylsulfanylmethyl)-
benzyl]-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl
ester
64 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(1-propyl-butyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
65 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(2-Ethyl-butyl)-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
66 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(4-Benzyl-benzyl)-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
67 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-8-[4-(4-hydroxy-phenylsulfanylmethyl)-benzyl]-4a,6a-
dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-
aza-pentaleno[2,1-a]phenanthren-2-one
68 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-8-[4-(4-hydroxy-phenylsulfinylmethyl)-benzyl]-4a,6a-
dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-
aza-pentaleno[2,1-a]phenanthren-2-one
69 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one
hydrochloride
70 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzyl-4b,12-difluoro-5-
hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one hydrochloride
71 acetic acid 4-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-
hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-8-ylmethyl]-phenyl ester
72 acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzoyl-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester
73 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzoyl-4b,12-difluoro-5-
hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
74 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-8-(furan-2-
carbonyl)-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
75 4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(2-
hydroxy-acetyl)-4a,6a-dimethyl-8-(thiophene-2-carbonyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
76 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-8-(3-methoxy-benzoyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
77 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(pyridine-3-carbonyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
78 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzenesulfonyl-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
79 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(propane-2-sulfonyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
80 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(thiophene-2-sulfonyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
81 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-phenylmethanesulfonyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
82 acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-
cyclohexylthiocarbamoyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester
83 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-8-carbothioic acid cyclohexylamide
84 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-8-carboxylic acid phenylamide
85 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-8-carbothioic acid phenylamide
86 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-isopropoxycarbonyloxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-8-carboxylic acid isopropyl ester
87 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-8-carboxylic acid isopropyl ester
88 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-(2-acetoxy-acetyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-8-carboxylic acid benzyl ester
89 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-8-carboxylic acid benzyl ester
90 acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(benzooxazol-
2-yl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester
91 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(benzooxazol-2-yl-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
92 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(pyrimidin-2-yl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
93 (4aS,4bR,5S,6aS,6bS,9aR,10aS,12S)-8-Benzyl-4b,12-difluoro-5-hydroxy-
4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic
acid
94 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic
acid chloromethyl ester
95 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid
96 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid chloromethyl ester
97 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic
acid 2-methoxy-ethyl ester
98 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic
acid 2-hydroxy-ethyl ester
99 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
4a,6a-dimethyl-8-(3-methyl-butyl)-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid
100 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,5-Difluoro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid
101 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
4a,6a-dimethyl-8-(5-methyl-furan-2-ylmethyl)-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid
102 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,3-Dimethyl-butyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid
103 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
4a,6a-dimethyl-2-oxo-8-(3-phenyl-propyl)-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid
104 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid fluoromethyl ester
105 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
4a,6a-dimethyl-8-(3-methyl-butyl)-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid fluoromethyl ester
106 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,5-Difluoro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid fluoromethyl ester
107 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
4a,6a-dimethyl-8-(5-methyl-furan-2-ylmethyl)-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid fluoromethyl ester
108 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,3-Dimethyl-butyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid fluoromethyl ester
109 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
4a,6a-dimethyl-8-(5-methyl-furan-2-ylmethyl)-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid cyanomethyl ester
110 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,3-Dimethyl-butyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid cyanomethyl ester
111 acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-8-phenyl-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester
112 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-phenyl-2-yl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
113 acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-
hydroxy-8-(3-methoxy-phenyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester
114 Acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-
5-hydroxy-8-(4-methoxy-phenyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester
115 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-8-(3-methoxy-phenyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
116 4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-8-(4-methoxy-phenyl)-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
117 4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-m-tolyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one and
4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-8-p-tolyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
118 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,9,9a,10,10a,10b,11,12-tetradecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
119 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylc acid ethyl ester
120 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(thiophene-2-carbonyl)-
4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
121 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-8-benzoyl-5-hydroxy-6b-(2-
hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
122 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzoyl-4b,12-difluoro-5-
hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
123 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(furan-2-carbonyl)-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
124 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-8-phenylacetyl-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
125 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-8-(2-thiophen-2-yl-ac
ethyl)-2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
126 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-8-(furan-2-
ylmethyl-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
127 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-8-(thiophen-2-ylmethyl-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
128 (4aR,5S,6aS,6bS,9aR,10aS,10bS)-8-furan-2-ylmethyl-5-hydroxy-6b-(2-
hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
129 (4aR,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-
dimethyl-2-oxo-8-thiophen-2-ylmethyl-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaeno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
130 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(2-hydroxy-acetyl)-
4a,6a-dimethyl-2-oxo-8-(3-phenyl-propyl)-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
131 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-8-butyl-5-hydroxy-6b-(2-hydroxy-
acetyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-
hexadecahydro-8-aza-pentaleno[2,1-a]phenanthrene-9-carboxylic acid
ethyl ester
132 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-butyl-4b,12-difluoro-5-
hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
133 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-8-benzyl-5-hydroxy-6b-(2-hydroxy-
acetyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-
hexadecahydro-8-aza-pentaleno[2,1-a]phenanthrene-9-carboxylic acid
ethyl ester
134 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzyl-4b,12-difluoro-5-
hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
135 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-8-(2-phenylsulfanyl-ethyl)-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
136 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-8-(2-phenoxy-ethyl)-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
137 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-8-(3-phenyl-propyl)-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
138 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-8-phenylcarbamoyl-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
139 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(2-hydroxy-acetyl)-
4a,6a-dimethyl-2-oxo-8-phenylcarbamoyl-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
140 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(2-hydroxy-acetyl)-
4a,6a-dimethyl-2-oxo-8-phenylthiocarbamoyl-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
141 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-8-cyclohexylcarbamoyl-5-hydroxy-
6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
142 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzenesulfonyl-4b,12-
difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
143 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(2-hydroxy-acetyl)-8-
methanesulfonyl-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
144 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-8-benzenesulfonyl-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester
145 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzyl-4b,12-difluoro-5-
hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-
pentaleno[2,1-a]phenanthrene-9-carboxylic acid
146 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
4a,6a-dimethyl-8-(5-methyl-furan-2-ylmetyl)-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid dimethylamide
147 4aS,4bR,5S,6aS,6bS,9aR,10aS,12S)-8-Benzyl-4b,12-difluoro-5-hydroxy-
4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic
acid ethyl amide
148 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic
acid ethyl-methyl-amide
149 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic
acid benzyl amide
150 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic
acid (1-phenyl-cyclopropyl)-amide
151 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid cyanomethyl-amide
152 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic
acid dimethylamide
153 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid dimethylamide
154 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,5-Difluoro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid dimethylamide
155 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,3-Dimethyl-butyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid dimethylamide
156 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
4a,6a-dimethyl-2-oxo-8-(3-phenyl-propyl)-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carboxylic acid dimethylamide
157 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic
acid methyl ester trifluoroacetate
158 [(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-(2-Acetoxy-acetyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-8-yl]-acetic acid ethyl ester
159 [(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-8-yl]-acetic acid ethyl ester
160 (6S,8S,9R,10S,11S,13S,14S)-6,9-difluoro-17-(2-fluoroacetyl)-11-hydroxy-
10,13-dimethyl-6,7,8,9,10,11,12,13,14,15-decahydro-3H-
cyclopenta[a]phenanthren-3-one
161 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-6b-(2-
fluoro-acetyl)-5-hydroxy-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
162 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-6b-(2-fluoro-acetyl)-5-hydroxy-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
163 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-6b-(2-fluoro-
acetyl)-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-8-carboxylic acid vinyl ester
164 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-
(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-8-carboxylic acid vinyl ester
165 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-
(2-methanesulfonyloxy-acetyl)-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-8-carboxylic acid vinyl ester
166 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-6b-(2-fluoro-
acetyl)-5-hydroxy-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one
hydrochloride
167 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-6b-(2-fluoro-
acetyl)-8-(4-fluoro-benzyl)-5-hydroxy-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
168 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,5-Difluoro-benzyl)-4b,12-
difluoro-6b-(2-fluoro-acetyl)-5-hydroxy-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
169 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,3-Dimethyl-butyl)-4b,12-
difluoro-6b-(2-fluoro-acetyl)-5-hydroxy-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
170 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-6b-(2-fluoro-
acetyl)-5-hydroxy-4a,6a-dimethyl-8-(3-methyl-butyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
171 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-6b-(2-fluoro-
acetyl)-5-hydroxy-4a,6a-dimethyl-8-(5-methyl-furan-2-ylmethyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a] phenanthren-2-one
172 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-6b-(2-fluoro-
acetyl)-5-hydroxy-4a,6a-dimethyl-8-(3-phenyl-propyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
173 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-[4-(4-hydroxy-
phenylsulfanylmethyl)-benzyl]-4b,12-difluoro-6b-(2-fluoro-acetyl)-5-
hydroxy-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one
174 (4aS,4bR,5S,6aS,6bS,9aR,10aS,12S)-4b,12-Difluoro-6b-(2-fluoro-acetyl)-
5-hydroxy-4a,6a-dimethyl-8-thiophen-2-ylmethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
175 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(2-Ethyl-butyl)-4b,12-
difluoro-6b-(2-fluoro-acetyl)-5-hydroxy-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
176 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid
vinyl ester
177 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one
hydrochloride
178 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-8-(3-chloro-benzyl)-
4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
179 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-8-(3,5-difluoro-
benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
180 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-8-(5-methyl-furan-2-ylmethyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
181 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-8-(3,3-dimethyl-
butyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
182 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-8-(3-methyl-butyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
183 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-8-(3-phenyl-propyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
184 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-8-thiophen-2-ylmethyl-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
185 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
4a,6a-dimethyl-6b-(2-methylsulfanyl-acetyl)-2-oxo-
2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-8-carboxylic acid vinyl ester
186 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
4a,6a-dimethyl-6b-(2-methylsulfanyl-acetyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one hydrochloride
187 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-6b-(2-methylsulfanyl-acetyl)-
4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthren-2-one
188 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,3-Dimethyl-butyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-fluoromethyl ester
189 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
4a,6a-dimethyl-8-(3-methyl-butyl)-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-fluoromethyl ester
190 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-
4a,6a-dimethyl-8-(5-methyl-furan-2-ylmethyl)-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-fluoromethyl ester
191 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,5-Difluoro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-fluoromethyl ester
192 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-chloromethyl ester
193 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-iodomethyl ester
194 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-fluoromethyl ester
trifluoroacetate
195 (4aS,4bR,5S,6aS,6bS,9aR,10aS,12S)-8-Benzyl-4b,12-difluoro-5-hydroxy-
4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic
acid S-chloromethyl ester
196 (4aS,4bR,5S,6aS,6bS,9aR,10aS,12S)-8-Benzyl-4b,12-difluoro-5-hydroxy-
4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic
acid S-iodomethyl ester
197 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic
acid S-fluoromethyl ester trifluoroacetate
198 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-(2-oxo-propyl) ester
199 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-(2-fluoro-ethyl) ester
200 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-
difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-
2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-
pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-cyanomethyl ester
201 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic
acid S-cyanomethyl ester
202 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic
acid S-(2-oxo-tetrahydro-furan-3-yl) ester
203 (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,1S)-8-Benzyl-4b,12-difluoro-5-
hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-
tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic
acid S-ethyl ester

Procedure for the Preparation of Compounds of Formula (I) and (I′).
According to a particular embodiment of the present invention, the compounds of general formula (I′) may be prepared, for example, following synthetic pathways described in Scheme 1.
The compounds of general formula (I′) may be prepared according to different routes described in Scheme 1, depending on the substituents R1, R2, R3, X and Y.
Route A1—Compounds of general formula I′ wherein R1═(CH2)n—V—(CH2)n′—Z—R4, wherein n=0, n′=1, V is absent, Z is a bond, R4═OH, R2═(CH2)m—W—W′-M-R6 wherein m is 1 to 6, W is a single bond, W′ and M are absent and R3═H, may be conveniently prepared reacting a compound of general formula (IX) under well described conditions for the synthesis of pyrrolidine through the 1,3-dipolar cycloaddition (1,3-DC) of unsaturated compounds and azomethine ylides. The ylide is generated in situ from a suitable precursor for example a compound of general formula (V). The reaction involves the use of 1 to 7 equivalents of azomethine ylide precursor and it is usually performed in a high boiling point solvent such as THF, dioxane, toluene, or xylene. The reaction usually proceeds in a range of temperature from 50 to 150° C. over a period of 1 to 5 hours and may be promoted by an acid such as trifluoroacetic acid, trimethylsilyl iodide or trimethylsilyl trifluoromethanesulfonate. Sodium, potassium or cesium fluoride could also be effective in catalyzing the reaction.
The 1,3-DC reaction can be performed under classical batch reaction conditions, or can be conducted under flow conditions. A flowing solution of compound of general formula (IX) in a suitable solvent such as for example THF or dioxane, containing 0.01 to 1% of TFA or other acid, is mixed with a flowing solution of compound of general formula (V) and quickly pumped through a hot reaction chamber at such a rate that allows the reaction mixture to spend from 1 to 10 minutes at the reaction temperature.
Azomethine ylide precursors of general formula (V) are commercially available or can be prepared as described in the literature, for example following the procedure described in J. Chem.-Soc., Perkin Trans., 1, 1998, pp. 3867-3872, which is incorporated herein by reference in its entirety.
The compounds of formula (IX) may be prepared hydrolyzing the compounds of formula (IV). This reaction is preferably carried out by subjecting compounds (IV) to the action of an enzyme, such as for example immobilized Lipase from Candida Antarctica (Sigma Aldrich) (Tetrahedron, 1994, Vol. 50, No. 46, 13165-13172), which is incorporated herein by reference in its entirety.
Compounds of general formula (IV) may be conveniently prepared according to standard procedures reported in the literature. For instance they may be prepared by treatment of compounds of general formula (III) with a base such as potassium acetate. This reaction is usually performed in a suitable polar solvent (e.g. DMF) and typically proceeds at a temperature range from 80 to 110° C., over a period of 0.5 to 4 hours.
Compounds of formula (III) may be readily prepared from known compounds by methods well known to those skilled in the art, starting from compounds of general formula (II) (J. Med. Chem., 1982, 25, 1492-1495, which is incorporated herein by reference in its entirety).
Alternatively compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n=0, n′=1, V is absent, Z is a bond, R4 is OH and R3═H, can be prepared following Route A2, starting from the reaction of compound of general formula (IV) with the N-benzyl-N-(trimethylsilylmethyl)aminomethyl ether (V), wherein m=1 and R6=phenyl, under the 1,3-DC conditions described in Route A1, to obtain a compound of formula (VI). The benzyl group can be removed by catalytic hydrogenation, using palladium on charcoal as catalyst, or through chemical dealkylation of tertiary amines with acyl chlorides, phosgene analogues or preferably chloroformates such as vinylchloroformate. The reaction is usually performed in a suitable solvent such as dichloromethane (DCM), tetrahydrofuran (THF) or acetonitrile at temperature range from room temperature (RT) to 60° C. The reaction requires the presence of a base such as alkali carbonates or bicarbonates or an organic base such as pyridine and usually completes over a time range from 0.5 to 2 hours. The carbamate obtained from the first step of the reaction is deprotected under carbamate deprotection of amine, conditions well known for those skilled in the art and well described in the literature (Wiley-VCH; Wuts, Peter G. M./Greene, Theodora W., Greene's Protective Groups in Organic Synthesis, Fourth Edition, John Wiley and Sons, 2007, p 503 and following, which is incorporated herein by reference in its entirety).
Compounds of general formula (VII) can be easily further functionalized. For example a compound of general formula (VII) can be treated with acyl chloride and converted into corresponding amide. The conditions for the reaction of pyrrolidines with acyl chlorides are widely described in the literature and involve the use of a solvent such as DCM or THF. The reaction normally requires a base such as triethylamine (TEA), N,N-diisopropylethylamine (DIPEA) or pyridine and it is performed at RT over a period of 1 to 24 hours. In the case the acyl chloride is not available it could be easily obtained from the corresponding carboxylic acid by treatment with for example oxalyl chloride or thionyl chloride. The reaction is performed in a solvent such as DCM, a temperature from 0 to 40° C. and can be accelerated by traces of dimethylformamide.
The same compounds can be obtained by activating a carboxylic acid with an acid activating agent such as carbonyldiimidazole (CDI). The activation with CDI is a well known reaction of carboxylic acids and it is usually performed at temperature range from 0 to 80° C. in a suitable solvent such as DCM, THF or DMF.
It is well know for those skilled in the art that the conversion described above can be accomplished applying variety of other synthetic methodologies which involve the activation of the acid with specific activating reactant or mixture of reactants such as, but not limited to dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), hydroxybenzotriazole (HOBT), 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), and benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBROP).
The reaction of compounds of general formula (VII) with chloroformates can be performed as described for the reaction of acyl chloride in a solvent such as DCM or THF in the presence of a base (e.g. TEA or DIPEA). The reaction usually proceeds at RT and over 0.5 to 24 hours.
The reaction of compounds of general formula (VII) with isocyanates or isothiocyanates can be accomplished by dissolving reagents in suitable solvent such DCM, THF, acetonitrile at RT or up to 80° C. The reaction can be facilitated by the presence of a base (e.g. TEA, DIPEA or pyridine) and completes in 1 to 24 hours.
The treatment of compounds of general formula (VII) with sulfonyl chlorides is the standard reaction for the preparation of sulfonamides. The reaction occurs in a solvent such as DCM, THF or pyridine and may require the presence of a base (e.g. TEA or DIPEA) and completes over a period of 0.5 to 4 hours at RT.
Aryl or heteroaryl groups can be introduced at N atom of pyrrolidine ring by following described procedures for the N arylation of pyrrolidines. Compounds of general formula (VII) can be reacted under metal catalyzed arylation conditions. The reaction is promoted by copper (I) salts, nickel(II) phosphine complexes and palladium complexes and often a base such as sodium or potassium terbutylate is required. The reaction occurs in a solvent such as DMF, dimetilacetamide (DMA), acetonitrile, dioxane, THF, toluene, N-methylpyrrolidone (NMP) at a temperature range from 40 to 200° C. by conventional thermal heating or by microwaves. In some cases the reaction can occur by simple heating, from 20 to 150° C., of a solution of compound of general formula (VII) and a suitable aryl or heteroaryl derivative, such as halides or trifluoromethane sulfonates (triflate), in a solvent such as ethanol, THF, acetonitrile, DMF, DMA, dioxane or NMP for a period of time from 0.5 to 24 hours. Alternatively this compound can be prepared by reacting the pyrrolidine intermediate of general formula (VII) with a benzyne. This very reactive species can be generated in situ from a suitable precursor following methods described in the literature. A valid protocol involves the treatment of 2-trimethylsilyl-phenyl trifluoromethane sulfonates with cesium fluoride. The reaction occurs at RT in a polar solvent such as acetonitrile and completes over a period from 1 to 72 hours. In the case the benzyne precursor features substituents on the benzene ring, the reaction can lead to a mixture of two regioisomers.
The alkylation of compounds of general formula (VII) can be performed applying the conditions for the alkylation of pyrrolidines. The reaction involves the use of alkyl halides, methane sulfonates, tosylates or other alkyl derivatives suitable for amine alkylation and requires the presence of a base such as TEA, DIPEA or pyridine to complete. It proceeds at a temperature from RT to 100° C. over 1 to 48 hours in a suitable solvent such as DCM, THF, acetonitrile or DMF. The presence of sodium or potassium iodide can in some cases accelerate the reaction rate.
The same class of derivatives can be obtained reacting compounds of general formula (VII) under reductive amination reaction conditions with a suitable aldehyde in a solvent such as methanol, ethanol, THF, DCM, toluene, acetonitrile or mixture of them. The imine intermediate is usually in situ reduced by treatment with reducing agents, such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride at a temperature range from 0 to 20° C., over 1 to 48 hours, or such as formic acid and its salts at a temperature range from 70 to 150° C., over 10 to 30 minutes.
In all cases products obtained feature an acetoxy moiety at position 6b of the steroid scaffold. This moiety can be easily hydrolyzed by treatment with a base such as LiOH, NaOH, KOH, or K2CO3 solid or dissolved in water, in organic solvents such as methanol, ethanol or THF or alternatively with an aqueous acid solution (for example HCl) in a suitable organic solvent such as THF or dioxane at 40 to 80° C. over a period of 1 to 8 hours.
It will be apparent for those skilled in the art that the sequence of reactions can be inverted performing first the hydrolysis of the acetyl group at position 6b of the steroid scaffold and then one of the functionalizations described above, if the second step is compatible with the presence of a primary alcohol moiety.
It will be even more apparent for those skilled in the art that the N-alkyl derivatives of compounds of formula (VII) obtained through its alkylation and subsequent hydrolysis of acetic ester at position 6b of steroid scaffold as described above in Route A2, can be obtained by 1,3-dipolar cycloaddition from intermediates (IX) and (V) as described in Route A1. All compounds obtained through Route A1 or Route A2 can undergo the sequence of reactions shown in Scheme 1 Route A that describes the functionalization of the hydroxyl moiety at position 6b of the steroid scaffold.
Route A—conversion of the hydroxyl group of 2-hydroxy acetyl moiety at position 6b of compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, wherein n=0, V is absent, n′=1, Z is a bond, R4═OH and R3═H into a leaving group (LG) of compounds of general formula (VIII) can be carried out by treating compounds of formula (I′) with methanesulphonyl chloride or p-toluenesulphonyl chloride (March's, “Advanced Organic Chemistry” Fifth Edition, Michael B. Smith and Jerry March, John Wiley & Sons, Wiley-Interscience), which is incorporated herein by reference in its entirety), in a suitable solvent, for example pyridine. This reaction is usually performed at RT over a period of 1 to 5 hours.
The LG of compounds of general formula (VIII) may be easily displaced by nucleophiles such as halide anions, alcohols, thiols, thioacids, amines, amides and carbanions (J. Org. Chem., 1999, 1042; J. Steroid. Biochem., 13 1980, 311-322, which are incorporated herein by reference in their entireties), to obtain compounds of general formula (I′) wherein n=0, V is absent and n′=1. The reaction is usually performed in a suitable solvent (e.g. DCM, THF or DMF), in a range of temperature from −40 to 80° C. over a period of 1 to 5 hours and may be promoted by a base such as sodium or potassium carbonate or sodium hydride. The obtained product may be further functionalized modifying the moiety introduced by the described nucleophilic substitution reaction.
Route A3—the acylation of the hydroxyl group of 2-hydroxy acetyl moiety at position 6b of compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, wherein n=0, V is absent, n′=1, Z is a bond, R4═OH and R3═H to obtain compounds of general formula (I′) wherein n=1, V is O, n′=0, Z is carbonyl or carboxyl, R4 is (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl or heteroaryl and R3═H, is performed by reaction with the suitable acylating agents such as acetylchloride or ethylchloroformate in a suitable solvent such as DCM in the presence of an organic base, such as for example triethylamine.
Route B—reaction of compounds of formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, wherein n=0, V is absent, n′=1, Z is a bond, R4═OH and R3═H under well known oxidation conditions to afford the compounds of general formula (XI). This reaction is usually performed in open air at RT over a period of 12 to 48 hours, in a suitable solvent such as THF in the presence of an aqueous solution of an inorganic base, such as for example sodium or potassium hydroxide.
Route B1—conversion of the compounds of formula (XI) into compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, wherein n and n′=0, V is absent and R3═H, can be obtained by treating the acid (XI) with one or more equivalents of an acid activating agent such as carbonyldiimidazole. The reaction is usually performed in a suitable polar solvent (e.g. DMF), in a range of temperature from 0 to 80° C. over a period of 1 to 2 hours. The activated acid may be reacted with a nucleophile, readily apparent to those skilled in the art, such as alcohols, thiols, thioacids and amines. The reaction may be promoted by a base such as sodium or potassium carbonate, sodium hydride and proceeds at a temperature ranging from 0 to 20° C. over a period of 1 to 24 hours.
Alternatively, the compounds of formula (XI) may be converted into the corresponding acyl chloride under well known conditions, using for example oxalyl chloride in a suitable solvent such as DCM. The activated compound may be reacted with a nucleophile, readily apparent to those skilled in the art, such as alcohols, thiols, thioacids, amines and carbanions such as alkyl, aryl and heteroaryl cuprates or other metalloorganic compounds reported in the literature to be suitable for the conversion of acyl chlorides into the corresponding ketones. The use of protecting groups must be considered in this reaction in order to avoid undesired reactions.
Route B2—conversion of compounds of formula (XI) into compounds of general formula (XII), derived from reaction of acid (XI) with for example carbonyldiimidazole or N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridine-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU), followed by reaction with the sodium salt of thioacetic acid or with sodium hydrogensulfide. The reaction is usually performed adding the solution of the preformed salt in the reaction solvent to the solution of the activated acid, at a temperature ranging from 0 to 20° C. The thioacid compounds of formula (XII) readily formed is in situ reacted with an alkylating reagent, such as bromoalkanes, leading to thioesters of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, wherein n and n′=0, V is absent, Z═S, R3═H. The choice of suitable bromoalkane, such as bromo-chloromethane, may allow the preparation of compounds of formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, wherein n and n′=0, V is absent, Z═S, R3═H that may be further modified. For example, the reaction of these compounds in which R4=chloromethyl with potassium iodide, followed by treatment with silver fluoride, may allow the preparation of compounds of formula (I′) in which R4=fluoromethyl. These reactions are carried out as described in the literature for the synthesis of well known compounds such as fluticasone derivatives and are well known to those skilled in the art (J. Med. Chem., 1994, 37, 3717-3729, which is incorporated herein by reference in its entirety).
Route B3—Alternatively compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n and n′=0, V is absent, Z═S and R3═H can be obtained applying the reaction conditions for the conversion of carboxylic acids into corresponding thioacids with dimethyl thiocarbamoyl chloride. The reaction is performed in DCM at RT over a period of time from 36 to 72 hours. The obtained compound is treated with diethyl amine at reflux temperature for a period of time from 8 to 12 hours to give a compound of general formula (XII) that may be further functionalized as described above.
Route B4—Conversion of the compounds of formula (XI) into compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, wherein n and n′=0, V is absent, Z═O, R4 is (C1-C6)alkyl and R3═H can be obtained by treating the acid (XI) with dimethylcarbonate at reflux or with an alkylating reagent such as bromofluoromethane in a suitable solvent such as DMF, at RT, in the presence of an inorganic base such as sodium carbonate over a period of 1 to 24 hours. These reactions are carried out as described in the literature for the synthesis of similar compounds and are well known to those skilled in the art.
Route C—In another embodiment of the present invention, compound of general formula (XIII) can be prepared by a two step reaction of intermediate of general formula (IX) with ethylisocyanoacetate followed by reduction of the pyrroline so formed. The cycloaddition of the isonitrile occurs in solvents such as tetrahydrofuran or dioxane at a temperature from 50 to 90° C. over a period of time from 1 to 5 hours. It is catalyzed by a base such as cuprous oxide. The reduction of the formed pyrroline can be performed by treating this intermediate with a suitable reducing agent such as NaCNBH3 in methanol or ethanol in a temperature range from 0° C. to RT. It will be apparent to those skilled in the art that following the procedure described a mixture of stereoisomers is obtained.
Compounds of general formula (XIII) can be further functionalized. For example they can undergo all reactions already described for the functionalization of compound (VII) and well known for those skilled in the art.
The ethyl ester at position 9 of compound of general formula (XIII) can be hydrolyzed and converted into the corresponding carboxylic acid. The reaction can be conveniently performed treating with a base such as sodium of potassium hydroxide in suitable solvent such as methanol, ethanol or THF. The reaction occurs at a temperature from 0° C. to RT over a period of time ranging from 4 to 24 hours.
The obtained acid of general formula (I′) wherein R3═COOH can be easily further functionalized for example converted into compound of general formula (I′) wherein R3═CONR13R14 using one of the methods for the preparation of amides described herein Route A for the conversion of compound of general formula (VII) into compound of general formula (I′) (wherein R2═(CH2)m—W—W′-M-R6, wherein m=0, W is a bond, W′ and M are absent and R6═COR7), well known for those skilled in the art.
Route D—In another embodiment of the present invention, compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n=0, V is absent, n′=1, Z is a bond, R4═OH and R3═H can be prepared by a two step procedure, starting from the conversion of the hydroxyl group of 2-hydroxy acetyl moiety at position 6b of compounds of general formula (IX) into a leaving group (LG) using methanesulphonyl chloride or p-toluenesulphonyl chloride (March's, “Advanced Organic Chemistry” Fifth Edition, Michael B. Smith and Jerry March, John Wiley & Sons, Wiley-Interscience), in a suitable solvent, for example acetonitrile in the presence of an organic base such as DIPEA. This reaction is usually performed at RT over a period of 1 to 24 hours and the obtained activate intermediates are submitted to the displacement of the LG by using a nucleophile such as an halide salt to obtain compounds of general formula (XIV). This displacement is usually performed in situ for example by the addition of TBAF and/or potassium carbonate and refluxing the reaction mixture over a period of 24-26 hours. The second step is the 1-3 dipolar cycloaddition reaction of compounds of general formula (XIV) with a compound of general formula (V) performed as described above (Route A1).
Route E—In another embodiment of the present invention, compounds of general formula (I′) wherein R1═(CH2)n—V—(CH2)n′—Z—R4, n=0, V is absent, n′=1, Z is a bond, R4 is halide, hydrogen or a thioalkyl and R3═H, are obtained by a four step procedure. The sequence comprises the reaction of compounds of general formula (VI) with vinylchloroformate as previously described (Route A1), the hydrolysis of the acetyl group is performed under basic conditions using potassium carbonate in methanol at 0° C. to obtain compounds of formula (XV), the conversion of the hydroxyl group of 2-hydroxy acetyl moiety at position 6b of compounds of general formula (XV) into a leaving group (LG) such as a mesylated as previously described (Route E), the displacement of the LG by using a nucleophile such as an halide salt or an alkylthiolate salt to obtain compounds of general formula (XVI). This displacement is preformed in a suitable solvent such as acetonitrile or DMF and using potassium fluoride, TBAF or sodium methylthiolate as possible nucleofiles. Alternatively compounds of general formula (XVI) with R4═I are generated and reduced in situ in the presence of sodium iodide in a suitable solvent such as acetonitrile, under microwave irradiation at 100° C. in a period of 2 to 6 hours. While the reduction of α-iodo-ketones is well known using for example reducing agents such as zinc in acetic acid (see, U.S. Pat. No. 2,864,838; 1958, which is incorporated herein by reference in its entirety) or sodium thiosulfate in acetic acid (see, U.S. Pat. No. 2,838,545; 1958, which is incorporated herein by reference in its entirety) this iodide promoted reduction reaction is unprecedented. Compounds of general formula (XVI) are deprotected to obtain compounds of general formula (XVII) which may be further N-functionalized by acylation, alkylation, sulfonylation, reductive amination and arylation to obtain compounds of general formula (I′).
Compounds of general formula (XVII) can be easily further functionalized as previously described for intermediate (VII) (Route A2).
Advantageously, the compounds of general formula (I′) may be administered for example, at a dosage of 0.001 to 1000 mg/day, preferably 0.1 to 500 mg/day.
When they are administered by inhalation route, the dosage of the compounds of general formula (I) is advantageously 0.01 to 20 mg/day, preferably 0.1 to 10 mg/day.
Preferably, the compounds of general formula (I) alone or combined with other active ingredients may be administered for the prevention and/or treatment of any obstructive respiratory disease such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD).
However the compounds of general formula (I) may be administered for the prevention and/or treatment of any disease wherein the decrease in the number, activity and movement of inflammatory cells is implicated.
Examples of such diseases include: diseases involving inflammation such as asthma and other allergic disorders, COPD, acute rhinitis; reverse acute transplant rejection and acute exacerbations of selected autoimmune disorders, graft-versus-host disease in bone-marrow transplantation; autoimmune disorders such as rheumatoid and other arthritis; skin conditions such as systemic lupus erythematosus, systemic dermatomyositis, psoriasis; inflammatory bowel disease, inflammatory ophthalmic diseases, autoimmune hematologic disorders, and acute exacerbations of multiple sclerosis; kidney, liver, heart, and other organ transplantation; Behçet's acute ocular syndrome, endogenous uveitis, atopic dermatitis, and nephrotic syndrome; Hodgkin's disease and non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia (CLL); autoimmune hemolytic anemia and thrombocytopenia associated with CLL; leukemia and malignant lymphoma.
Preferably the compounds of general formula (I′) may be administered for the prevention and/or treatment of respiratory diseases such as from mild to acute severe conditions of asthma and COPD.
Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
EXAMPLES Example 1
Figure US08481517-20130709-C00019
Preparation of acetic acid (8S,9S,10R,13S,14S,17R)-17-(2-acetoxy-acetyl)-10,13-dimethyl-3,11-dioxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[α]phenanthren-17-yl ester (intermediate 2)
To a suspension of acetic acid 2-((8S,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3,11-dioxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester (intermediate 1) (2 g, 4.99 mmol) and PTSA (200 mg, 1.051 mmol) in acetic acid (5 ml), at 0° C., trifluoroacetic anhydride (5 ml, 35.4 mmol) is slowly added over 10 minutes. After stirring at 0° C. for 20 minutes, the reaction mixture is stirred at RT for 3 hours.
The reaction mixture is poured in ice/water (130 ml), and the resulting mixture is extracted with DCM (2×100 ml) and AcOEt (2×100 ml). The combined organic extracts are dried over anhydrous Na2SO4 and concentrated. The crude material is purified by flash chromatography on silica gel, in gradient elution from DCM to DCM/AcOEt 50:50 to give the title compound (2.22 g, quantitative yield).
LC-MS (ESI POS): 443.2 (MH+)
Preparation of acetic acid (8S,9S,10R,11S,13S,14S,17R)-17-(2-acetoxy-acetyl)-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl ester (intermediate 3)
To an ice cooled solution of intermediate 2 (2.22 g, 5.0 mmol) in tetrahydrofuran (15 ml) and MeOH (15 ml), sodium borohydride (221 mg, 5.84 mmol) is added in portions over a period of 2.5 hours. The reaction mixture is poured in 1 N HCl and ice (150 ml). The formed precipitate is extracted with AcOEt (3×100 ml), and the combined organic layers are dried over anhydrous Na2SO4 and concentrated. The crude material is crystallized from Ethyl acetate/petroleum ether. The residue from mother liquor is purified by flash chromatography on silica gel, in gradient elution from DCM to DCM/AcOEt 40:60 affording a second crop. The combined crops give the title the compound (1.85 g, 83% total yield).
1H NMR (300 MHz, CHLOROFORM-d) δ ppm 7.28 (d, 1H), 6.30 (dd, 1H), 6.05 (t, 1H), 4.92 (d, 1H), 4.69 (d, 1H), 4.48-4.58 (m, 1H), 2.75-2.91 (m, 1H), 2.61 (m, 1H), 2.37 (ddd, 1H), 2.18-2.21 (m, 3H), 2.09-2.28 (m, 3H), 2.07 (s, 3H), 1.74-1.98 (m, 3H), 1.51-1.70 (m, 1H), 1.48 (s, 3H), 1.26-1.39 (m, 2H), 1.11-1.19 (m, 1H), 1.05 (s, 3H)
LC-MS (ESI POS): 445.2 (MH+)
Example 2
Figure US08481517-20130709-C00020
Preparation of Acetic acid 2-((6S,8S,9R,10S,11S,13S,14S)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxo-ethyl ester (intermediate 5)
To a solution of butyric acid (6S,8S,9R,10S,11S,13S,14S,17R)-17-(2-acetoxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl ester (2.48 g, 4.88 mmol) in anhydrous DMF (60 ml), under nitrogen atmosphere, potassium acetate (3.83 g, 39.0 mmol) is added and the reaction mixture is stirred at 100° C. for 1.5 hours. The reaction mixture is cooled at RT and then poured into ice and brine (200 ml), and the aqueous layer is extracted with AcOEt (3×150 ml). The combined organic extracts are washed with water and brine, dried over Na2SO4 and concentrated to afford 2.55 g of crude title compound which is used in the next step without further purification.
1H NMR (300 MHz, DMSO-d6): δ ppm 7.29 (dd, 1H), 6.99 (dd, 1H), 6.29 (dd, 1H), 5.98-6.15 (m, 1H), 5.68 (dddd, 1H), 5.56 (dd, 1H), 5.10 (d, 1H), 4.92 (d, 1H), 3.98-4.23 (m, 1H), 2.56-2.83 (m, 1H), 2.26-2.44 (m, 3H), 2.14-2.26 (m, 1H), 2.09 (s, 3H), 1.71-1.87 (m, 1H), 1.55-1.65 (m, 2H), 1.53 (s, 3H), 1.15 (s, 3H)
LC-MS (ESI POS): 421.2 (MH+)
Preparation of (6S,8S,9R,10S,11S,13S,14S)-6,9-Difluoro-11-hydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15-decahydro cyclopenta[a]phenanthren-3-one (intermediate 6)
To a solution of intermediate 5 (2.55 g, 6.06 mmol) in ethanol (100 ml), Candida Antarctica Lipase (2 U/mg) (510 mg, 6.06 mmol) is added, and the reaction mixture is stirred at 37° C. overnight. The reaction mixture is filtered, washing with methanol, and the residue is purified by flash chromatography on silica gel, in gradient elution from DCM/AcOEt 90:10 to DCM/AcOEt 50:50, to afford 1.62 g of title compound (70.6% yield).
1H NMR (300 MHz, DMSO-d6): ppm 7.29 (dd, 1H), 6.87 (dd, 1H), 6.29 (dd, 1H), 6.09-6.17 (m, 1H), 5.67 (dddd, 1H), 5.53 (dd, 1H), 4.77 (t, 1H), 4.44 (dd, 1H), 4.26 (dd, 1H), 4.04-4.15 (m, 1H), 2.56-2.79 (m, 1H), 2.39 (dd, 1H), 2.25-2.35 (m, 2H), 2.09-2.25 (m, 1H), 1.76 (td, 1H), 1.55-1.66 (m, 2H), 1.53 (s, 3H), 1.17 (s, 3H)
LC-MS (ESI POS): 379.2 (MH+)
Intermediate 7 in Table 1 is prepared as previously described for intermediate 5 starting from intermediate 3.
TABLE 1
Intermediate Structure Yield Analytical
7
Figure US08481517-20130709-C00021
 		50% 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 7.32 (d, 1 H), 6.74 (dd, 1 H), 6.29 (dd, 1 H), 6.03 (t, 1 H), 5.02 (d, 1 H), 4.88 (d, 1 H), 4.36-4.51 (m, 1 H), 2.55-2.73 (m, 1 H), 2.21-2.54 (m, 5 H), 2.19 (s, 3 H), 2.05-2.18 (m, 1 H), 1.66 (dd, 1 H), 1.51 (s, 3 H), 1.28 (s, 3 H), 1.04-1.44 (m, 4 H) LC-MS (ESI POS): 385.45 (MH+)
Example 3 1,3-dipolar Cycloaddition Method A
Figure US08481517-20130709-C00022
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 8)
A mixture of intermediate 6 (95 mg, 0.185 mmol), N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine (500 mg) and then Xylene (5 ml) containing 0.01% of TFA is placed in a closed vessel and heated at 140° C. for 1 hour. The solvent is removed under vacuum, and the residue is purified by silica gel cartridge eluting with DCM to DCM:AcOEt 6:4 leading to the title compound (52 mg, 0.102 mmol, 54.9% yield).
1H NMR (300 MHz, CHLOROFORM-d): δ ppm 7.04-7.35 (m, 6H), 6.29 (dd, 1H), 6.12 (s, 1H), 5.48-5.82 (m, 1H), 5.39 (dd, 1H), 4.82 (t, 1H), 4.24 (dd, 1H), 4.10-4.17 (m, 1H), 4.12 (dd, 1H), 3.44 (s, 2H), 3.02-3.22 (m, 1H), 2.80-2.96 (m, 1H), 2.54-2.62 (m, 1H), 2.38 (d, 1H), 2.25-2.32 (m, 1H), 1.94-2.10 (m, 2H), 1.78-1.93 (m, 1H), 1.51-1.77 (m, 4H), 1.49 (s, 3H), 1.29-1.41 (m, 1H), 0.86 (s, 3H)
LC-MS (ESI POS): 512.14 (MH+)
[α]D 20=+50.8 c=0.3, MeOH)
Compound 9 listed in Table 2, is prepared as previously described for intermediate 8.
TABLE 2
Compound Structure Yield Analytical
9
Figure US08481517-20130709-C00023
 		40% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.14-7.37 (m, 5 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.48-5.79 (m, 1 H), 5.40 (dd, 1 H), 4.83 (t, 1 H), 4.24 (dd, 1 H), 4.11-4.14 (m, 1 H), 4.12 (dd, 1 H), 3.43 (s, 2 H), 3.07-3.22 (m, 1 H), 2.79-2.94 (m, 1 H), 2.55-2.67 (m, 1 H), 2.17- 2.44 (m, 3 H), 1.92-2.09 (m, 2 H), 1.84 (d, 1 H), 1.52-1.75 (m, 3 H), 1.49 (s, 3 H), 1.27-1.42 (m, 1 H), 0.86 (s, 3 H) LC-MS (ESI POS): 546.04 (MH+) [α]D 20 = +83.5 (CHCl3, c 0.23)
1,3-dipolar Cycloaddition Method B Preparation of Acetic acid 2-((4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-8-benzyl-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester (compound 10)
Figure US08481517-20130709-C00024
A solution of (intermediate 7) (200 mg, 0.520 mmol) and TFA (5 μl, 0.065 mmol) in Dioxane (15 ml) is prepared (Solution A). A solution of N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine (618 mg, 2.60 mmol) in Dioxane (15 ml) is prepared (Solution B). The two solutions are reacted in the Flow reaction System setting each flow at 0.25 ml/min at 100° C. in the 10 ml reactor (Residence time: 20 min). The solvent is removed under vacuum and then the residue is first triturated twice with AcOEt and petroleum ether and then it is purified by silica gel chromatography (DCM:AcOEt 85:15) to give the title compound (255 mg, 0.493 mmol, 95% yield).
LC-MS (ESI POS): 518.2 (MH+)
Compounds listed in Table 3 are prepared as previously described for compound 10, reacting intermediate 5 or 6 with the suitable azomethine ylide precursor.
TABLE 3
Compound Structure Yield Analytical
11
Figure US08481517-20130709-C00025
 		82% 1H NMR (300 MHz, DMSO-d6) δ ppm 6.79-7.68 (m, 6 H), 6.29 (dd, 1 H), 6.13 (s, 1 H), 5.48-5.82 (m, 1 H), 5.36-5.46 (m, 1 H), 4.95 (d, 1 H), 4.79 (d, 1 H), 4.01- 4.24 (m, 1 H), 3.47 (s, 1 H), 3.03-3.21 (m, 1 H), 2.83- 2.98 (m, 1 H), 2.54-2.61 (m, 1 H), 2.24-2.46 (m, 4 H), 2.11 (s, 3 H), 1.94-2.10 (m, 2 H), 1.85 (d, 1 H), 1.52-1.74 (m, 3 H), 1.49 (s, 3 H), 1.28-1.43 (m, 1 H), 0.92 (s, 3 H) LC-MS (ESI POS): 554.2 (MH+)
12
Figure US08481517-20130709-C00026
 		17% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.06-7.32 (m, 6 H), 6.29 (dd, 1 H), 6.10 (s, 1 H), 5.49-5.81 (m, 1 H), 5.40 (dd, 1 H), 4.82 (t, 1 H), 4.29 (dd, 1 H), 4.16-4.22 (m, 1 H), 4.13 (dd, 1 H), 3.02-3.19 (m, 1 H), 2.74-2.83 (m, 1 H), 2.54-2.61 (m, 2 H), 2.40-2.48 (m, 2 H), 2.13- 2.30 (m, 4 H), 1.93-2.08 (m, 2 H), 1.83-1.92 (m, 1 H), 1.73-1.83 (m, 1 H), 1.56-1.71 (m, 3 H), 1.49-1.55 (m, 1 H), 1.49 (s, 3 H), 1.35 (dd, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 540.44 (MH+) [α]D 20 = +37.64 (c 0.33, CHCl3)
13
Figure US08481517-20130709-C00027
 		40% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.38 (dd, 1 H), 7.25 (dd, 1 H), 6.92 (dd, 1 H), 6.88 (dd, 1 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.49-5.78 (m, 1 H), 5.40 (dd, 1 H), 4.83 (t, 1 H), 4.25 (dd, 1 H), 4.13-4.18 (m, 1 H), 4.11 (dd, 1 H), 3.65 (s, 1 H), 3.02-3.21 (m, 1 H), 2.85 (t, 1 H), 2.54-2.62 (m, 1 H), 2.19-2.41 (m, 3 H), 2.14 (dd, 1 H), 1.95-2.08 (m, 1 H), 1.84 (d, 1 H), 1.54-1.78 (m, 4 H), 1.49 (s, 3 H), 1.36 (dd, 1 H), 0.86 (s, 3 H)) LC-MS (ESI POS): 518.48 (MH+) [α]D 20 = +79.35 (C = 0.7 CHCl3)
14
Figure US08481517-20130709-C00028
 		44% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.52 (dd, 1 H), 7.25 (dd, 1 H), 6.36 (dd, 1 H), 6.29 (dd, 1 H), 6.17 (d, 1 H), 6.11 (s, 1 H), 5.48-5.74 (m, 1 H), 5.41 (dd, 1 H), 4.83 (t, 1 H), 4.26 (dd, 1 H), 4.15-4.18 (m, 1 H), 4.10 (dd, 1 H), 3.48 (d, 1 H), 3.42 (d, 1 H), 3.04-3.16 (m, 1 H), 2.91 (t, 1 H), 2.63 (d, 1 H), 2.38 (d, 1 H), 2.19- 2.31 (m, 2 H), 1.78-2.06 (m, 3 H), 1.52-1.78 (m, 3 H), 1.48 (s, 3 H), 1.32 (dd, 1 H), 0.86 (s, 3 H) LC-MS (ESI POS): 502.42 (MH+) [α]D 20 = +60.0 (c = 1 CHCl3)
15
Figure US08481517-20130709-C00029
 		20% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.25 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 6.02 (d, 1 H), 5.89-5.97 (m, 1 H), 5.50-5.77 (m, 1 H), 5.40 (dd, 1 H), 4.83 (t, 1 H), 4.27 (dd, 1 H), 4.14-4.20 (m, 1 H), 4.11 (dd, 1 H), 3.42 (d, 1 H), 3.34 (d, 1 H), 3.05-3.20 (m, 1 H), 2.92 (t, 1 H), 2.65 (d, 1 H), 2.53-2.60 (m, 1 H), 2.36 (d, 1 H), 2.20-2.27 (m, 1 H), 2.19 (s, 3 H), 1.80-2.05 (m, 3 H), 1.52-1.79 (m, 3 H), 1.48 (s, 3 H), 1.32 (dd, 1 H), 0.86 (s, 3 H) LC-MS (ESI POS): 516.07 (MH+) [α]D 20 = +75.81 (c 0.43, CHCl3)
16
Figure US08481517-20130709-C00030
 		14% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.20-7.39 (m, 2 H) 6.95-7.11 (m, 3 H) 6.29 (dd, J = 10.1, 1.9 Hz, 1 H) 6.12 (s, 1 H) 5.64-5.80 (m, 1 H) 5.38 (br. s., 1 H) 4.85 (br. s., 1 H) 4.25 (d, 1 H) 4.11- 4.18 (m, 1 H) 4.09 (d, 1 H) 3.47 (s, 2 H) 3.07-3.22 (m, 1 H) 2.87 (t, J = 8.5 Hz, 1 H) 2.53-2.67 (m, 1 H) 2.43-2.46 (m, 1 H) 2.36-2.44 (m, 1 H) 2.16-2.35 (m, 1 H) 1.92-2.11 (m, 2 H) 1.78-1.89 (m, 1 H) 1.54-1.77 (m, 3 H) 1.50 (s, 3 H) 1.35 (dd, 1 H) 0.87 (s, 3 H) LC-MS (ESI POS): 530.08 (MH+) [α]D 20 = +63.5 (c: 0.27, CHCl3)
17
Figure US08481517-20130709-C00031
 		19% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.25 (dd, 1 H), 6.99-7.12 (m, 1 H), 6.81-6.98 (m, 2 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.49-5.74 (m, 1 H), 5.41 (dd, 1 H), 4.86 (t, 1 H), 4.26 (dd, 1 H), 4.13-4.19 (m, 1 H), 4.13 (dd, 1 H), 3.51 (d, 1 H), 3.45 (d, 1 H), 3.08-3.23 (m, 1 H), 2.87 (t, 1 H), 2.55-2.62 (m, 1 H), 2.39-2.45 (m, 1 H), 2.23-2.34 (m, 1 H), 1.94-2.10 (m, 2 H), 1.80-1.89 (m, 1 H), 1.52-1.78 (m, 4 H), 1.49 (s, 3 H), 1.31-1.41 (m, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 548.24 (MH+) [α]D 20 = +63.2 (c: 0.28, CHCl3)
Example 4
Figure US08481517-20130709-C00032
Preparation of (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-8-Benzyl-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 18)
Compound 10 (130 mg, 0.251 mmol) is dissolved in Dioxane (3 ml) and HCl 3 N (1 ml) and the reaction mixture is warmed at 60° C. for 2 hours. The reaction mixture is poured in NaHCO3 and extracted with AcOEt. The organic phase is washed with brine, dried over Na2SO4 and evaporated the residue is purified by silica gel cartridge giving the title compound (20 mg, 0.042 mmol, 16.74% yield).
1H NMR (300 MHz, DMSO-d6) δ ppm 7.10-7.39 (m, 6H), 6.16 (dd, 1H), 5.93 (s, 1H), 4.77 (t, 1H), 4.66 (d, 1H), 4.16-4.29 (m, 2H), 4.10 (dd, 1H), 3.47 (d, 1H), 3.37 (d, 1H), 3.04-3.19 (m, 1H), 2.91 (t, 1H), 2.57 (d, 1H), 2.36 (d, 1H), 1.95-2.08 (m, 2H), 1.77-1.95 (m, 2H), 1.43-1.61 (m, 3H), 1.38 (s, 3H), 1.30-1.37 (m, 1H), 0.95-1.15 (m, 2H), 0.86 (s, 3H)
LC-MS (ESI POS): 476.34 (MH+)
[α]D 20=+84.8 (c=0.57, MeOH)
Example 5
Figure US08481517-20130709-C00033
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-(2-Acetoxy-acetyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid vinyl ester (compound 19)
Compound 11 (1.95 g, 3.52 mmol) and NaHCO3 (0.592 g, 7.04 mmol) are dissolved in acetonitrile (30 ml) and then vinyl chloroformate (0.599 ml, 7.04 mmol) is added. The reaction mixture is warmed at 50° C. for 2 hours. The solution is partitioned between AcOEt and brine. The organic phase is separated while the aqueous solution is extracted with AcOEt. The combined organic phases are dried over Na2SO4 and then evaporated to give a residue that is purified by silica gel column chromatography, eluting with Petroleum Ether AcOEt 6:4 to 4:6 leading to pure title compound (1.1 g, 2.062 mmol, 58.5% yield).
LC-MS (ESI POS): 554.2 (MH+)
Preparation of Acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester hydrochloride (compound 20)
Compound 19 (1.0 g, 1.874 mmol) is dissolved in dioxane (3 ml) and then HCl 2.0 M in Dioxane (5 ml, 1.874 mmol) is added. The solution is stirred at RT for 2 hours and then the solvent is evaporated and the residue is dried under vacuum for 1 hour. The solid is then dissolved in methanol and warmed at 40° C. for 1 hour. Methanol is evaporated and the residue is triturated with diethyl ether to give the title compound (0.93 g, 1.860 mmol, 99% yield).
LC-MS (ESI POS): 464.0 (MH+)
Compounds listed in Table 4 are prepared as previously described for compounds 19 and 20.
TABLE 4
Compound Structure Yield Analytical
21
Figure US08481517-20130709-C00034
 		70% LC-MS (ESI POS): 498.1 (MH+)
22
Figure US08481517-20130709-C00035
 		99% LC-MS (ESI POS): 428.1 (MH+)
Alkylation Method A Preparation of Acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-8-(2-oxo-2-phenyl-ethyl)-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester (compound 23)
Compound 20 (50.2 mg, 0.252 mmol) and K2CO3 (26.8 mg, 0.194 mmol) are dissolved in acetonitrile (2 ml) and the reaction mixture is heated at 60° C. for 6 hours. The reaction mixture is partitioned between brine and AcOEt. The organic phase is separated, dried over Na2SO4 and then evaporated. The residue is purified by silica gel cartridge to give the title compound (60 mg, 0.103 mmol, 53.1% yield).
LC-MS (ESI POS): 582.2 (MH+)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-8-(2-oxo-2-phenyl-ethyl)-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 24)
Compound 23 is hydrolyzed as described in Example 4 for the preparation of compound 18 obtaining the title compound in 66.5% yield.
1H NMR (300 MHz, DMSO-d6) δ ppm 7.80-7.96 (m, 2H), 7.36-7.66 (m, 3H), 7.26 (dd, 2H), 6.29 (dd, 2H), 6.13 (s, 2H), 5.47-5.82 (m, 2H), 5.42 (br. s., 1H), 4.71-4.90 (m, 1H), 4.01-4.44 (m, 3H), 3.71-4.01 (m, 2H), 3.03-3.21 (m, 1H), 2.84-3.03 (m, 1H), 2.58-2.69 (m, 1H), 2.10-2.26 (m, 2H), 1.91-2.06 (m, 1H), 1.73-1.91 (m, 2H), 1.48 (s, 3H), 1.36-1.46 (m, 1H), 0.87 (br. s., 3H)
LC-MS (ESI POS): 540.39 (MH+)
[α]D 20=+47.4 (c=0.5 MeOH)
Alkylation Method B
Figure US08481517-20130709-C00036
Preparation of Acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-8-pyridin-3-ylmethyl-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester (compound 25)
A mixture of Compound 20 (120 mg, 0.240 mmol), 3-(bromomethyl)pyridine hydrobromide (77 mg, 0.304 mmol) and TEA (134 μl, 0.960 mmol) in DCM (8 ml) is stirred at RT overnight. The mixture is diluted with DCM and treated with 5% NaHCO3. The organic phase is then washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated to give the title compound (130 mg, 0.24 mmol, quant. yield).
LC-MS (ESI POS): 555.3 (MH+)
Compounds listed in Table 5 are prepared as described for compound 25, by reacting compound 20 with the suitable commercially available halides.
TABLE 5
Compound Structure Yield Analytical
26
Figure US08481517-20130709-C00037
 		69% LC-MS (ESI-POS): 590.0 MH+
27
Figure US08481517-20130709-C00038
 		82% LC-MS (ESI-POS): 612.4 MH+
28
Figure US08481517-20130709-C00039
 		66% LC-MS (ESI-POS): 598.5 MH+
Compounds listed in Table 6 are prepared through the procedure previously described for compound 24 or compound 25.
TABLE 6
Compound Structure Yield Analytical
29
Figure US08481517-20130709-C00040
 		69% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.21- 7.38 (m, 4 H), 7.17 (dt, 1 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.50-5.85 (m, 1 H), 5.40 (dd, 1 H), 4.85 (t, 1 H), 4.25 (dd, 1 H), 4.13-4.18 (m, 1 H), 4.12 (dd, 1 H), 3.49 (d, 1 H), 3.43 (d, 1 H), 3.08-3.22 (m, 1 H), 2.85 (t, 1 H), 2.54-2.61 (m, 1 H), 2.42-2.48 (m, 1 H), 2.42 (d, 1 H), 2.21-2.33 (m, 1 H), 1.93-2.13 (m, 2 H), 1.79-1.90 (m, 1 H), 1.51-1.77 (m, 3 H), 1.49 (s, 3 H), 1.35 (dd, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 546.31 (MH+) [α]D 20 = +68.8 (c = 0.5 CHCl3)
30
Figure US08481517-20130709-C00041
 		57% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.17- 7.34 (m, 3 H), 6.98-7.17 (m, 2 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.49-5.74 (m, 1 H), 5.40 (dd, 1 H), 4.82 (t, 1 H), 4.24 (dd, 1 H), 4.11- 4.17 (m, 1 H), 4.12 (dd, 1 H), 3.42 (s, 2 H), 3.05-3.23 (m, 1 H), 2.86 (t, 1 H), 2.54-2.61 (m, 2 H), 2.36 (d, 1 H), 2.20-2.31 (m, 1 H), 1.91-2.10 (m, 2 H), 1.79-1.89 (m, 1 H), 1.52- 1.75 (m, 3 H), 1.50 (s, 3 H), 1.34 (dd, 1 H), 0.86 (s, 3 H) LC-MS (ESI POS): 530.34 (MH+) [α]D 20 = +79.7 (c: 0.66; CHCl3)
31
Figure US08481517-20130709-C00042
 		41% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.55- 7.74 (m, 2 H), 7.36-7.53 (m, 2 H), 7.26 (dd, 1 H), 6.29 (dd, 1 H), 6.13 (s, 1 H), 5.51-5.78 (m, 1 H), 5.40 (dd, 1 H), 4.84 (t, 1 H), 4.26 (dd, 1 H), 4.12-4.19 (m, 1 H), 4.13 (dd, 1 H), 3.54 (s, 2 H), 3.04-3.24 (m, 1 H), 2.89 (t, 1 H), 2.58 (d, 2 H), 2.41 (d, 1 H), 2.19-2.33 (m, 1 H), 1.93-2.13 (m, 2 H), 1.79-1.91 (m, 1 H), 1.51-1.76 (m, 3 H), 1.49 (s, 3 H), 1.35 (dd, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 580.36 (MH+) [α]D 20 = +72.5 (c = 0.45, MeOH)
32
Figure US08481517-20130709-C00043
 		35% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.26 (dd, 1 H), 7.12 (m, 2 H), 6.84 (m, 2 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.49-5.74 (m, 1 H), 5.40 (br. s., 1 H), 4.81 (br. s., 1 H), 4.01-4.33 (m, 3 H), 3.72 (s, 3 H), 3.36 (br. s., 2 H), 3.05-3.18 (m, 1 H), 2.79-2.96 (m, 1 H), 2.57-2.64 (m, 1 H), 2.21-2.40 (m, 3 H), 1.92-2.10 (m, 2 H), 1.77-1.91 (m, 1 H), 1.54-1.76 (m, 3 H), 1.49 (s, 3 H), 1.28- 1.41 (m, 1 H), 0.86 (s, 3 H) LC-MS (ESI POS): 542.31 (MH+) [α]D 20 = +84.5 (c = 0.34, MeOH)
33
Figure US08481517-20130709-C00044
 		55% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.90- 7.95 (m, 2 H), 7.26 (dd, 1 H), 7.15 (t, 1 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.48-5.73 (m, 1 H), 5.40 (dd, 1 H), 4.83 (t, 1 H), 4.31 (dd, 1 H), 4.12-4.20 (m, 1 H), 4.13 (dd, 1 H), 3.71 (s, 2 H), 3.08-3.22 (m, 1 H), 2.95 (t, 1 H), 2.70 (d, 1 H), 2.59 (d, 1 H), 2.32-2.45 (m, 1 H), 1.95-2.31 (m, 3 H), 1.52-1.91 (m, 4 H), 1.49 (s, 3 H), 1.27-1.39 (m, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 546.38 (MH+) [α]D 20 = +46.31 (c = 0.39, MeOH)
34
Figure US08481517-20130709-C00045
 		58% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.25 (dd, 1 H), 7.18 (t, 1 H), 6.71-6.85 (m, 3 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.49-5.79 (m, 1 H), 5.40 (dd, 1 H), 4.83 (t, 1 H), 4.24 (dd, 1 H), 4.10-4.15 (m, 1 H), 4.12 (dd, 1 H), 3.68 (s, 3 H), 3.42 (s, 2 H), 3.02-3.22 (m, 1 H), 2.85 (t, 1 H), 2.48 (d, 1 H), 2.40 (d, 1 H), 2.23-2.32 (m, 1 H), 2.04-2.12 (m, 1 H), 2.00-2.05 (m, 1 H), 1.83 (d, 1 H), 1.53-1.76 (m, 4 H), 1.49 (s, 3 H), 1.36 (dd, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 542.44 (MH+) [α]D 20 = +64.26 (c = 0.31, MeOH)
35
Figure US08481517-20130709-C00046
 		70% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.22-7.39 (m, 4 H), 7.16 (dt, 1 H), 6.16 (dd, 1 H), 5.93 (s, 1 H), 4.79 (t, 1 H), 4.66 (d, 1 H), 4.23-4.32 (m, 1 H), 4.21 (dd, 1 H), 4.09 (dd, 1 H), 3.44 (s, 2 H), 3.01-3.20 (m, 1 H), 2.87 (t, 1 H), 2.55 (d, 1 H), 2.43 (d, 1 H), 2.28-2.36 (m, 1 H), 1.77-2.08 (m, 4 H), 1.43-1.66 (m, 3 H), 1.38 (s, 3 H), 1.23-1.37 (m, 3 H), 0.97- 1.18 (m, 1 H), 0.86 (s, 3 H) LC-MS (ESI POS): 510.32 (MH+) [α]D 20 = +71.80 (c = 0.5 MeOH)
36
Figure US08481517-20130709-C00047
 		1H NMR (300 MHz, DMSO-d6) δ ppm 8.32-8.51 (m, 2 H), 7.59 (dt, 1 H), 7.31 (ddd, 1 H), 7.25 (dd, 1 H), 6.29 (dd, 1 H), 6.13 (s, 1 H), 5.48-5.79 (m, 1 H), 5.40 (dd, 1 H), 4.83 (t, 1 H), 4.24 (dd, 1 H), 4.14- 4.18 (m, 1 H), 4.12 (dd, 1 H), 3.48 (s, 2 H), 3.10- 3.22 (m, 1 H), 2.87 (t, 1 H), 2.55-2.62 (m, 1 H), 2.41 (d, 1 H), 2.21-2.34 (m, 1 H), 1.95-2.12 (m, 2 H), 1.84 (d, 1 H), 1.52-1.75 (m, 4 H), 1.49 (s, 3 H), 1.35 (dd, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 513.2 (MH+) [α]D 20 = +64.40 (c = 0.3, MeOH)
37
Figure US08481517-20130709-C00048
 		65% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.26 (d, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.47- 5.83 (m, 1 H), 5.34-5.45 (m, 1 H), 4.68-4.91 (m, 1 H), 4.03-4.43 (m, 3 H), 3.06-3.18 (m, 1 H), 2.77-2.89 (m, 1 H), 2.12-2.45 (m, 8 H), 1.71-2.05 (m, 3 H), 1.58 (s, 2 H), 1.49 (s, 3 H), 1.32 (m, 3 H), 0.86 (s, 3 H), 0.82 (d, 6 H) LC-MS (ESI POS): 491.28 (MH+) [α]D 20 = +50.48 (c = 0.5, MeOH)
38
Figure US08481517-20130709-C00049
 		31% 1H NMR (300 MHz, DMSO-d6) ppm 7.33- 7.50 (m, 1 H), 7.11-7.30 (m, 4 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.49-5.77 (m, 1 H), 5.39 (dd, 1 H), 4.83 (t, 1 H), 4.23 (dd, 1 H), 4.14- 4.18 (m, 1 H), 4.11 (dd, 1 H), 3.54 (d, 1 H), 3.49 (d, 1 H), 3.08-3.22 (m, 1 H), 2.78 (t, 1 H), 2.55-2.62 (m, 2 H), 2.45 (d, 1 H), 2.23-2.33 (m, 1 H), 1.98-2.19 (m, 2 H), 1.53-1.90 (m, 4 H), 1.49 (s, 3 H), 1.28- 1.41 (m, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 596.29 MH+ [α]D 20 = +48.5 (c = 3.1, MeOH)
39
Figure US08481517-20130709-C00050
 		41% 1H NMR (300 MHz, DMSO-d6) ppm 7.67- 7.83 (m, 2 H), 7.36-7.50 (m, 2 H), 7.25 (d, 1 H), 6.29 (dd, 1 H), 6.13 (s, 1 H), 5.50- 5.76 (m, 1 H), 5.40 (d, 1 H), 4.83 (t, 1 H), 4.26 (dd, 1 H), 4.03-4.19 (m, 2 H), 3.54 (s, 2 H), 3.10-3.22 (m, 1 H), 2.88 (t, 1 H), 2.54-2.66 (m, 2 H), 2.41 (d, 1 H), 2.19- 2.33 (m, 1 H), 1.93-2.12 (m, 2 H), 1.78- 1.88 (m, 1 H), 1.52-1.76 (m, 3 H), 1.49 (s, 3 H), 1.35 (dd, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 537.06 MH+ [α]D 25 = +69.77 (c 0.26, MeOH)
40
Figure US08481517-20130709-C00051
 		37% 1H NMR (300 MHz, DMSO-d6) ppm 7.69 (dt, 1 H), 7.63 (s, 1 H), 7.56 (dt, 1 H), 7.50 (t, 1 H), 7.25 (dd, 1 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.50-5.79 (m, 1 H), 5.40 (dd, 1 H), 4.83 (t, 1 H), 4.25 (dd, 1 H), 4.06-4.18 (m, 2 H), 3.54 (d, 1 H), 3.48 (d, 1 H), 3.09-3.21 (m, 1 H), 2.88 (t, 1 H), 2.57 (d, 1 H), 2.41- 2.46 (m, 1 H), 2.40 (d, 1 H), 1.94-2.10 (m, 2 H), 1.84 (d, 1 H), 1.52-1.75 (m, 4 H), 1.49 (s, 3 H), 1.35 (dd, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 537.34 MH+ [α]D 25 +67.70 (MeOH, c 0.33)
Example 7
Figure US08481517-20130709-C00052
Preparation of bis((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one)naphtalen disulfonate salt (compound 41)
To a solution of compound 29 (120 mg, 0.220 mmol) in dioxane (2.5 mL), a solution of naphthalene-1,5-disulfonic acid (40.8 mg, 0.110 mmol) in dioxane (2.5 mL) is added. The reaction mixture is stirred for 30 minutes, then it is concentrated to about 1 mL of volume. Water (about 6 mL) is added and a solid precipitates. After stirring for a while, the suspension is filtered and the title compound (92 mg, 0.110 mmol, 50% yield) is recovered by filtration.
1H NMR (300 MHz, DMSO-d6) d ppm 9.73 (br. s., 1H) 7.38-7.67 (m, 4H) 7.27 (d, 1H) 6.32 (dd, 1H) 6.14 (s, 1H) 5.51-5.82 (m, 1H) 5.46-5.65 (m, 1H) 4.28-4.62 (m, 3H) 4.09-4.28 (m, 2H) 3.72-3.97 (m, 1H) 3.43-3.70 (m, 1H) 3.17-3.28 (m, 1H) 3.09 (t, 1H) 2.73-2.98 (m, 1H) 2.53-2.62 (m, 1H) 2.22-2.41 (m, 1H) 1.95-2.16 (m, 1H) 1.59-1.88 (m, 4H) 1.50 (s, 3H) 1.37-1.54 (m, 1H) 0.88 (s, 3H)
1,5 naphtalen disulfonate ion: 1H NMR (300 MHz, DMSO-d6) d ppm 8.88 (dd, 1H) 7.93 (dd, 1H) 7.40 (dd, 1H)
LC-MS (ESI POS): 546.23 MH+
[α]D 25+12.5 (c 0.5 MeOH)
Example 8
Figure US08481517-20130709-C00053
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one methane sulfonate (compound 42)
Compound 29 (120 mg, 0.220 mmol) is dissolved in Dioxane (1 ml) and then a solution of methansulfonic acid (14.27 μl, 0.220 mmol) in dioxane (100 μL) is added under stirring. A precipitated forms. The stirring is continued for 1 hour and then the solid is collected by filtration obtaining the title compound (115 mg, 0.179 mmol, 81% yield).
1H NMR (300 MHz, DMSO-d6) d ppm 7.35-7.76 (m, 4H), 7.15-7.34 (m, 1H), 6.32 (dd, 1H), 6.15 (s, 1H), 5.58-5.81 (m, 1H), 5.56 (br. s., 1H), 3.60-4.56 (m, 7H), 2.97-3.17 (m, 1H), 2.79-2.94 (m, 1H), 2.33-2.44 (m, 1H), 1.98-2.24 (m, 3H), 1.59-1.90 (m, 5H), 1.50 (s, 3H), 1.39-1.48 (m, 1H), 0.88 (s, 3H)
Methansulfonate ion: 1H NMR (300 MHz, DMSO-d6) d ppm 2.31 (s, 3H)
LC-MS (ESI POS): 546.20 MH+
[α]D 25+17.2 (c 0.4 MeOH)
Example 9′
Figure US08481517-20130709-C00054
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one hydrochloride (compound 43)
Hydrochloric acid 4M in dioxane (156 μl, 0.623 mmol) is added to a clear solution of compound 29 (68 mg, 0.125 mmol) in dioxane (8 ml). A solid immediately precipitates. The mixture is stirred for 15 minutes, then the solid is filtered. The amount of recovered product is very low, so the mother liquor is evaporated and the crude material is triturated with AcOEt to give the title compound (53 mg, 0.091 mmol, 73% yield).
1H NMR (300 MHz, DMSO-d6) d ppm 10.23 (br. s., 1H), 7.05-7.83 (m, 5H), 6.32 (dd, 1H), 6.14 (s, 1H), 5.58-5.65 (m, 1H), 5.42-5.83 (m, 1H), 4.11-4.57 (m, 5H), 3.75-3.90 (m, 1H), 3.42-3.69 (m, 2H), 2.99-3.17 (m, 1H), 2.78-2.92 (m, 1H), 1.92-2.42 (m, 4H), 1.56-1.86 (m, 3H), 1.50 (s, 3H), 1.38-1.48 (m, 1H), 0.88 (s, 3H)
LC-MS (ESI POS): 546.23 MH+
[α]D 25+22.63 (c 0.35 MeOH)
Example 10
Figure US08481517-20130709-C00055
Preparation of Acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-cyclopropylmethyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester (compound 44)
Compound 44 is prepared from intermediate 20 by alkylation with bromomethyl-cyclopropane following Method A, as previously described in Example 6 for compound 23.
LC-MS (ESI POS): 518.3 MH+
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Cyclopropylmethyl-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (45)
Compound 44 (154 mg, 0.298 mmol) is dissolved in MeOH (5 mL) and the mixture is degassed with N2 for 15 minutes. After cooling to 0° C., K2CO3 (20.56 mg, 0.149 mmol) is added and the mixture is stirred for 45 minutes. The reaction mixture is partitioned between water and AcOEt, the organic layer is separated, dried over Na2SO4 and concentrated. The crude material is purified by silica gel flash chromatography (eluent DCM/MeOH from 98/2 to 95/5+TEA=1%), affording a solid that is further triturated in AcOEt and recovered by filtration to give the title compound (75 mg, 0.158 mmol, 53.0% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.25 (dd, 1H), 6.29 (dd, 1H), 6.11 (s, 1H), 5.48-5.77 (m, 1H), 5.40 (d, 1H), 4.80 (t, 1H), 4.32 (dd, 1H), 4.12-4.15 (m, 1H), 4.14 (dd, 1H), 3.08-3.19 (m, 1H), 2.99 (t, 1H), 2.69 (d, 1H), 2.54-2.63 (m, 1H), 2.39-2.47 (m, 0H), 2.32 (d, 1H), 2.20-2.27 (m, 1H), 2.15 (dd, 1H), 2.05 (dd, 1H), 1.82-2.00 (m, 3H), 1.69-1.79 (m, 1H), 1.52-1.68 (m, 2H), 1.49 (s, 3H), 1.40-1.46 (m, 0H), 1.32 (dd, 1H), 0.87 (s, 3H), 0.64-0.82 (m, 1H), 0.29-0.49 (m, 2H), −0.08-0.14 (m, 2H)
LC-MS (ESI POS): 476.25 MH+
[α]D 25+72.4 (c 0.5 MeOH)
Compounds reported in Table 7 are prepared as described for compound 45, starting from compounds 27 and 28.
TABLE 7
Compound Structure Yield Analytical
46
Figure US08481517-20130709-C00056
 		54% 1H NMR (300 MHz, DMSO-d6) ppm 7.84 (s, 1 H), 7.81 (dt, 1 H), 7.46-7.52 (m, 1 H), 7.43 (t, 1 H), 7.26 (dd, 1 H), 6.29 (dd, 1 H), 6.13 (s, 1 H), 5.47- 5.80 (m, 1 H), 5.39 (dd, 1 H), 4.83 (t, 1 H), 4.23 (dd, 1 H), 4.11-4.18 (m, 1 H), 4.11 (dd, 1 H), 3.80 (s, 3 H), 3.56 (d, 1 H), 3.48 (d, 1 H), 3.05-3.22 (m, 1 H), 2.78 (t, 1 H), 2.54-2.67 (m, 2 H), 2.37- 2.46 (m, 1 H), 2.22-2.36 (m, 1 H), 1.97-2.18 (m, 2 H), 1.78-1.90 (m, 1 H), 1.54-1.78 (m, 3 H), 1.49 (s, 3 H), 1.37 (dd, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 570.35 MH+ [α]D 25 +49.91 (c 0.23, MeOH)
47
Figure US08481517-20130709-C00057
 		31% 1H NMR (300 MHz, DMSO-d6 +Na2CO3) ppm 7.63-7.72 (m, 2 H), 7.26 (d, 1 H), 7.14 (t, 1 H), 7.06-7.10 (m, 1 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.43-5.83 (m, 1 H), 4.26 (d, 1 H), 4.11-4.15 (m, 1 H), 4.12 (d, 1 H), 3.40-3.51 (m, 2 H), 3.08-3.20 (m, 1 H), 2.87-3.02 (m, 1 H), 2.66 (d, 1 H), 2.32- 2.47 (m, 2 H), 2.20-2.31 (m, 1 H), 1.77-2.08 (m, 3 H), 1.51-1.77 (m, 3 H), 1.49 (s, 3 H), 1.29- 1.40 (m, 1 H), 0.86 (s, 3 H) LC-MS (ESI POS): 556.39 MH+
Example 11
Figure US08481517-20130709-C00058
Preparation of Propionic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-chloro-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester (compound 48)
Compound 29 (100 mg, 0.183 mmol) is dissolved in dry DCM (4 ml) and propionyl chloride (31.8 μl, 0.366 mmol) and TEA (51.1 μl, 0.366 mmol) are added. The reaction mixture is stirred at RT for 2 hours. Further propionyl chloride (31.8 μA, 0.366 mmol) and TEA (51.1 μl, 0.366 mmol) are added, and the reaction mixture is stirred at RT for 16 hours. The reaction mixture is partitioned between brine and AcOEt. The organic phase is separated dried over Na2SO4 and evaporated to give a residue that is triturated with AcOEt and Petroleum Ether. The obtained product is eluted on a silica gel cartridge with AcOEt leading to title compound (50 mg, 45.4%).
1H NMR (300 MHz, DMSO-d6) ppm 7.04-7.43 (m, 5H), 6.29 (dd, 1H), 6.12 (s, 1H), 5.48-5.79 (m, 1H), 5.41 (dd, 1H), 4.96 (d, 1H), 4.81 (d, 1H), 4.06-4.28 (m, 1H), 3.48 (s, 1H), 3.06-3.24 (m, 1H), 2.88 (t, 1H), 2.58 (d, 1H), 2.53-2.67 (m, 1H), 2.46 (d, 1H), 2.42 (q, 2H), 2.21-2.34 (m, 1H), 1.97-2.15 (m, 2H), 1.80-1.92 (m, 1H), 1.51-1.76 (m, 4H), 1.49 (s, 3H), 1.37 (dd, 1H), 1.08 (t, 3H), 0.93 (s, 3H).
LC-MS (ESI POS): 602.19 MH+
[α]D 25+58.9 (c 0.3, MeOH)
Example 12
Figure US08481517-20130709-C00059
Preparation of Carbonic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester ethyl ester (compound 49)
Compound 8 (144 mg, 0.281 mmol) is dissolved in dry DCM and cooled to 0° C., under nitrogen. N,N-dimethylpyridin-4-amine (34.4 mg, 0.281 mmol) and ethylchloroformate (30.5 mg, 0.281 mmol) are added and the mixture is stirred at 0° C. for 4 hours. The reaction mixture is partitioned between water and DCM. The organic layer is separated, dried and concentrated. The crude is purified on silica gel flash chromatography (eluent petroleum ether/AcOEt form 7/3 to 1/1). The obtained product is triturated in Et2O and recovered by filtration to afford the title compound (72 mg, 0.123 mmol, 43.8% yield). 1H NMR (300 MHz, DMSO-d6) ppm 7.05-7.41 (m, 6H), 6.29 (dd, 1H), 6.13 (s, 1H), 5.48-5.79 (m, 1H), 5.38-5.44 (m, 1H), 5.00 (d, 1H), 4.82 (d, 1H), 4.16 (q, 2H), 4.09-4.15 (m, 1H), 3.47 (s, 2H), 3.06-3.21 (m, 1H), 2.92 (t, 1H), 2.56-2.62 (m, 1H), 2.57 (d, 1H), 2.40 (d, 1H), 2.20-2.35 (m, 1H), 1.92-2.13 (m, 2H), 1.84 (d, 1H), 1.51-1.75 (m, 3H), 1.49 (s, 3H), 1.37 (dd, 1H), 1.25 (t, 3H), 0.93 (s, 3H)
LC-MS (ESI POS): 584.5 MH+
[α]D 25+120.1 (c 0.6, CHCl3)
Example 13
Figure US08481517-20130709-C00060
Preparation of Acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-4a,6a,8-trimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester (compound 50)
In a closed vessel, Compound 20 (150 mg, 0.300 mmol) is dissolved in DMSO (1.5 ml) formic acid (0.046 ml, 1.200 mmol) and formaldehyde (0.089 ml, 1.200 mmol) are added, and the mixture is heated under microwave irradiation for 30 seconds at 120 W of power (the temperature reached 220° C.). LC-MS showed that the reaction is completed. The reaction mixture is diluted with AcOEt and, after addition of TEA (0.5 mL), washed with water. The organic layer is separated, dried over Na2SO4, filtered and concentrated. The crude is purified by silica gel flash chromatography (eluent DCM/MeOH 0 98/2) to yield the title compound (87 mg, 0.182 mmol, 60.7% yield).
LC-MS (ESI POS): 478.2 (MH+)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a,8-trimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 51)
Compound 50 (85 mg, 0.178 mmol) is suspended in a dioxane (2 ml)/water (2.000 ml) mixture. HCl (0.5 ml, 6.09 mmol) is added and the mixture is heated at 80° C. for 4 hours. The reaction mixture is concentrated to dryness under reduced pressure, redissolved in a acetate/water mixture and neutralized by the addition of NaHCO3. The aqueous phase is washed with AcOEt several time and the it is freeze-dried. The solid is treated with EtOH/MeOH 9/1 mixture: the insoluble material removed by filtration while the mother liquors are concentrated to dryness and further triturated in a AcOEt/Et2O mixture. The solid is recovered by filtration affording title compound in 45.2% yield.
1H NMR (300 MHz, DMSO-d6) δ ppm 7.29 (d, 1H), 6.30 (dd, 1H), 6.13 (s, 1H), 5.48-5.87 (m, 2H), 3.60-4.60 (m, 5H), 2.86-3.04 (m, 1H), 2.74 (br. s., 3H), 1.91-2.23 (m, 4H), 1.57-1.87 (m, 6H), 1.49 (s, 3H), 1.34-1.46 (m, 1H), 0.88 (s, 3H)
LC-MS (ESI POS): 436.2 (MH+)
[α]D 20+51.73 (c=0.3 MeOH)
Intermediates listed in Table 8 are prepared as described in Example 13 for compound 50, by reacting compound 20 with the suitable commercially available ketones.
TABLE 8
Compound Structure Yield Analytical
52
Figure US08481517-20130709-C00061
 		61% LC-MS (ESI POS): 506.1 MH+
53
Figure US08481517-20130709-C00062
 		92% LC-MS (ESI POS): 546.2 MH+
Compounds listed in Table 9 are prepared from the intermediates listed in Table 8 using the procedure reported in Example 10 for the preparation of compound 45.
TABLE 9
Compound Structure Yield Analytical
54
Figure US08481517-20130709-C00063
 		83% 1H NMR (300 MHz, DMSO-d6) ppm 7.25 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.48-5.79 (m, 1 H), 5.39 (dd, 1 H), 4.80 (t, 1 H), 4.29 (m, 1 H), 4.12-4.21 (m, 1 H), 4.12 (d, 1 H), 3.03-3.18 (m, 1 H), 2.95 (t, 1 H), 2.68 (d, 1 H), 2.39-2.47 (m, 1 H), 2.32 (d, 1 H), 2.21-2.28 (m, 1 H), 2.16 (spt, 1 H), 1.91-2.03 (m, 2 H), 1.81-1.91 (m, 1 H), 1.71-1.81 (m, 1 H), 1.51-1.70 (m, 2 H), 1.49 (s, 3 H), 1.31 (dd, 1 H), 0.93 (d, 6 H), 0.86 (s, 3 H) LC-MS (ESI POS): 464.24 MH+ [α]D 25 +64 (c = 0.5, MeOH)
55
Figure US08481517-20130709-C00064
 		32% 1H NMR (300 MHz, DMSO-d6) ppm 7.25 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.47-5.79 (m, 1 H), 5.39 (dd, 1 H), 4.80 (t, 1 H), 4.26 (d, 1 H), 4.15-4.21 (m, 1 H), 4.11 (m, 1 H), 3.01-3.17 (m, 1 H), 2.85 (t, 1 H), 2.57 (d, 1 H), 2.53-2.58 (m, 1 H), 2.43 (d, 1 H), 2.18-2.32 (m, 1 H), 2.06 (dd, 1 H), 1.92-2.03 (m, 1 H), 1.72-1.92 (m, 3 H), 1.54-1.72 (m, 5 H), 1.48 (s, 3 H), 1.37-1.45 (m, 2 H), 1.25-1.36 (m, 1 H), 1.04-1.23 (m, 5 H), 0.86 (s, 3 H) LC-MS (ESI POS): 504.14 MH+ [α]D 25 +63.6 (c 0.36, MeOH)
Example 14
Figure US08481517-20130709-C00065
Preparation of Acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,3-dimethyl-butyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester (compound 56)
A solution of compound 20 (900 mg, 1.800 mmol), 3,3-dimethylbutyraldehyde (904 μl, 7.20 mmol), formic acid (552 μl, 14.40 mmol) and TEA (251 μl, 1.800 mmol) in acetonitrile (45 ml) is irradiated with microwaves (140° C., 15 minutes). The reaction is partitioned between AcOEt and NaHCO3 solution. The organic layers are then washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated to give a oil which is purified by silica gel chromatography (from DCM:MeOH 100:0 to 98.5:1.5) to give the title compound (721 mg, 1.316 mmol, 73.1% yield).
LC-MS (ESI POS): 548.2 MH+
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,3-Dimethyl-butyl)-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 57)
The title compound is prepared from compound 56 following the procedure described in Example 10 for the synthesis of compound 45.
(95 mg, 0.188 mmol, 69% yield) as solid are obtained.
1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1H), 6.29 (dd, 1H), 6.11 (s, 1H), 5.49-5.81 (m, 1H), 5.40 (dd, 1H), 4.79 (t, 1H), 4.28 (d, 1H), 4.13-4.20 (m, 1H), 4.10 (d, 1H), 3.03-3.15 (m, 1H), 2.83 (t, 1H), 2.54-2.59 (m, 1H), 2.39-2.46 (m, 1H), 2.35 (d, 1H), 2.10-2.31 (m, 3H), 1.90-2.05 (m, 2H), 1.69-1.89 (m, 2H), 1.51-1.68 (m, 2H), 1.48 (s, 3H), 1.30-1.40 (m, 1H), 1.25 (t, 2H), 0.86 (s, 3H), 0.84 (s, 9H)
LC-MS (ESI POS): 506.26 MH+
[α]D 25+51.70 (c=0.4, MeOH)
Intermediates listed in Table 10 are prepared as described for compound 56 starting from the suitable commercially available aldehydes or ketones. Intermediates 60 (4-benzylbenzaldehyde) and 63 (4-(4-Hydroxy-phenylsulfanylmethyl)-benzaldehyde) are prepared according to the procedure described in WO2009/0690302, which is incorporated herein by reference in its entirety.
TABLE 10
Compound Structure Yield Analytical
58
Figure US08481517-20130709-C00066
 		26% LC-MS (ESI POS): 562.2 MH+
59
Figure US08481517-20130709-C00067
 		100%  LC-MS (ESI POS): 548.1 MH+
60
Figure US08481517-20130709-C00068
 		84% LC-MS (ESI POS): 644.4 MH+
61
Figure US08481517-20130709-C00069
 		32% LC-MS (ESI POS): 558.0 MH+
62
Figure US08481517-20130709-C00070
 		90% LC-MS (ESI POS): 534.0 MH+
63
Figure US08481517-20130709-C00071
 		72% LC-MS (ESI POS): (ESI POS): 692.3 MH+
The compounds listed in Table 11 are prepared from the intermediates in Table 10 as described in Example 14 for the preparation of compound 57.
TABLE 11
Compound Structure Yield Analytical
64
Figure US08481517-20130709-C00072
 		13% 1H NMR (300 MHz, DMSO-d6) ppm 7.25 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.47-5.81 (m, 1 H), 5.38 (dd, 1 H), 4.79 (t, 1 H), 4.26 (dd, 1 H), 4.15-4.19 (m, 1 H), 4.11 (dd, 1 H), 2.96-3.19 (m, 1 H), 2.77 (t, 1 H), 2.36-2.46 (m, 1 H), 2.09-2.31 (m, 3 H), 1.70- 2.05 (m, 3 H), 1.53-1.70 (m, 1 H), 1.48 (s, 3 H), 1.05-1.44 (m, 12 H), 0.87 (s, 3 H), 0.77-0.85 (m, 6 H) LC-MS (ESI POS): 520.38 MH+ [α]D 25 +47.29 (c 0.28, MeOH)
65
Figure US08481517-20130709-C00073
 		57% 1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.47-5.79 (m, 1 H), 5.38 (dd, 1 H), 4.81 (t, 1 H), 4.26 (dd, 1 H), 4.14-4.20 (m, 1 H), 4.11 (dd, 1 H), 3.02-3.15 (m, 1 H), 2.66-2.72 (m, 1 H), 2.54-2.60 (m, 1 H), 2.48 (d, 1 H), 2.35 (d, 1 H), 2.19-2.30 (m, 1 H), 1.93-2.14 (m, 4 H), 1.72- 1.93 (m, 2 H), 1.51-1.70 (m, 1 H), 1.48 (s, 3 H), 1.14-1.40 (m, 7 H), 0.87 (s, 3 H), 0.77 (t, 6 H) LC-MS (ESI POS): 506.22 MH+ [α]D 25 +43.05 (c 0.21, MeOH)
66
Figure US08481517-20130709-C00074
 		29% 1H NMR (300 MHz, DMSO-d6) ppm 7.08-7.35 (m, 10 H) 6.29 (dd, 1 H) 6.12 (s, 1 H) 5.45-5.83 (m, 1 H) 5.39 (dd, 1 H) 4.81 (t, 1 H) 4.23 (dd, 1 H) 4.11-4.17 (m, 1 H) 4.11 (dd, 1 H) 3.89 (s, 2 H) 3.39 (s, 2 H) 3.04-3.21 (m, 1 H) 2.85 (t, 1 H) 2.54-2.61 (m, 1 H) 2.17-2.42 (m, 2 H) 1.92-2.09 (m, 2 H) 1.76-1.90 (m, 1 H) 1.52-1.76 (m, 3 H) 1.45-1.53 (m, 1 H) 1.48 (s, 3 H) 1.33 (dd, 1 H) 0.86 (s, 3 H) LC-MS (ESI POS): 602.37 MH+ [α]D 25 +55.4 (c 0.75 MeOH)
Example 15
Figure US08481517-20130709-C00075
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-8-[4-(4-hydroxy-phenylsulfanylmethyl)-benzyl]-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 67) and of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-8-[4-(4-hydroxy-phenylsulfinylmethyl)-benzyl]-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 68)
A solution of compound 63 (106 mg, 0.153 mmol) in MeOH (5 ml) is degassed with nitrogen for 15 minutes and cooled to 0° C. Then K2CO3 (10.59 mg, 0.077 mmol) is added and the mixture is stirred at 0° C. with continuous degassing for 1 hour. HCl 1N (0.5 ml) is added and the reaction mixture is concentrated. The crude is partitioned between a 5% NaHCO3 solution and AcOEt. The combined organic phases are concentrated and purified by silica gel flash chromatography (eluent AcOEt/Petroleum ether 4/6). The obtained product is further purified by preparative HPLC (Acetonitrile/Water, no CF3COOH) to afford title compound 67 (17 mg, 17.08% yield) and 68 (7 mg, 6.86% yield).
Compound 67:
1H NMR (300 MHz, DMSO-d6) ppm 9.52 (br. s., 1H), 7.26 (dd, 1H), 7.02-7.19 (m, 6H), 6.61-6.73 (m, 2H), 6.29 (dd, 1H), 6.13 (s, 1H), 5.48-5.81 (m, 1H), 5.40 (d, 1H), 4.83 (br. s., 1H), 4.17-4.29 (m, 1H), 4.02-4.21 (m, 2H), 4.00 (s, 2H), 3.39 (s, 2H), 3.06-3.22 (m, 1H), 2.77-2.91 (m, 1H), 2.55-2.68 (m, 2H), 2.35 (d, 1H), 2.16-2.30 (m, 1H), 1.93-2.10 (m, 2H), 1.84 (d, 1H), 1.50-1.77 (m, 3H), 1.49 (s, 3H), 1.34 (dd, 1H), 0.86 (s, 3H)
LC-MS (ESI POS): 650.41 MH+
[α]D 25+62.13 (C 0.16 MeOH)
Compound 68:
1H NMR (300 MHz, DMSO-d6) ppm 10.01 (s, 1H), 7.27-7.36 (m, 2H), 7.26 (d, 1H), 7.07-7.16 (m, 2H), 6.94-7.06 (m, 2H), 6.77-6.93 (m, 2H), 6.30 (d, 1H), 6.13 (s, 1H), 5.50-5.79 (m, 1H), 5.41 (br. s., 1H), 4.84 (br. s., 1H), 3.88-4.51 (m, 5H), 3.41 (br. s., 2H), 3.05-3.22 (m, 1H), 2.79-2.97 (m, 1H), 2.56-2.69 (m, 2H), 2.32-2.42 (m, 1H), 2.22-2.32 (m, 1H), 1.92-2.11 (m, 2H), 1.54-1.92 (m, 4H), 1.49 (s, 3H), 1.28-1.42 (m, 1H), 0.87 (s, 3H)
LC-MS (ESI POS): 666.38 MH+
Example 16
Figure US08481517-20130709-C00076
Preparation of (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-Hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one hydrochloride (compound 69)
Method A.
A mixture of Compound 20 (130 mg, 0.260 mmol) and conc. HCl (1 mL, 32.9 mmol) in dioxane (4 ml) and water (4 ml) is stirred at 50° C. for 7.5 hours. The solvent is evaporated and the crude is triturated with EtOH to give the title compound (30 mg, 0.066 mmol, 25.2% yield).
1H NMR (300 MHz, DMSO-d6) δ ppm 9.08 (br. s., 2H), 7.28 (dd, 1H), 6.30 (dd, 1H), 6.12 (s, 1H), 5.57 (dd, 1H), 5.47-5.82 (m, 1H), 5.11 (br. s., 1H), 4.33-4.52 (m, 1H), 4.07-4.31 (m, 2H), 3.33-3.51 (m, 3H), 2.92-3.16 (m, 2H), 2.57-2.67 (m, 1H), 2.11-2.30 (m, 1H), 1.57-1.95 (m, 5H), 1.49 (s, 3H), 1.42-1.54 (m, 1H), 0.94 (s, 3H)
LC-MS (ESI POS): 421.97 (MH+)
[α]D 20=+64.8 (c 0.2, H2O)
Method B.
In a closed vessel compound 20 (300 mg, 0.600 mmol) is dissolved in MeOH, HCl (0.045 ml, 0.180 mmol) in dioxane is added and the mixture is stirred at room temperature for 10 days, then further HCl (0.045 ml, 0.180 mmol) is added and the reaction mixture is stirred for further 2 days. The reaction mixture is concentrated to dryness affording the title compound (253 mg, 0.600 mmol, 100% yield).
LC-MS (ESI-POS): 421.97 (MH+)
Compound listed in Table 12 is prepared through the procedure previously described for compound 69 following (Method A).
TABLE 12
Compound Structure Yield Analytical
70
Figure US08481517-20130709-C00077
 		90% 1H NMR (300 MHz, DMSO-d6) δ ppm 10.47 (br. s., 1 H), 7.38-7.81 (m, 5 H), 7.30 (d, 1 H), 6.31 (dd, 1 H), 6.14 (s, 1 H), 5.40-5.82 (m, 2 H), 4.10-4.62 (m, 4 H), 3.15-3.88 (m, 8 H), 2.94-3.14 (m, 1 H), 2.68-2.93 (m, 1 H), 2.02-2.37 (m, 2 H), 1.56-1.88 (m, 3 H), 1.50 (s, 3 H), 0.89 (s, 3 H) LC-MS (ESI POS): 476.34 (MH+)
Example 17
Figure US08481517-20130709-C00078
Preparation of (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-Hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one hydrochloride (compound 69)
Compound 69 is prepared from compound 20 as described in Example 16 following Method B.
Acetic acid 4-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-8-ylmethyl]-phenyl ester (compound 71)
In a nitrogen atmosphere compound 69 (275 mg, 0.6 mmol) is dissolved in dry acetonitrile (10 ml), DIPEA (0.210 ml, 1.200 mmol) and 4(chloromethyl)phenylacetate (0.092 ml, 0.600 mmol) are added and the mixture is stirred at RT overnight. The reaction mixture is partitioned between 5% NaHCO3 solution and AcOEt. The organic phase is separated, dried over Na2SO4 and concentrated. The crude is purified by silica gel flash chromatography (eluent from DCM/AcOEt=7/3 to 1/1), then by preparative HPLC (neutral phase) to yield the title compound (38 mg, 0.067 mmol, 11% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.13-7.32 (m, 3H), 6.89-7.11 (m, 2H), 6.29 (dd, 1H), 6.13 (s, 1H), 5.48-5.74 (m, 1H), 5.40 (br. s., 1H), 4.83 (t, 1H), 4.25 (dd, 1H), 4.10-4.14 (m, 1H), 4.13 (dd, 1H), 3.44 (s, 2H), 3.07-3.23 (m, 1H), 2.88 (t, 1H), 2.59-2.69 (m, 1H), 2.55 (d, 1H), 2.39 (d, 1H), 2.26-2.33 (m, 1H), 2.24 (s, 3H), 1.93-2.11 (m, 2H), 1.79-1.90 (m, 1H), 1.51-1.78 (m, 3H), 1.49 (s, 3H), 1.35 (dd, 1H), 0.87 (s, 3H)
LC-MS (ESI POS): 570.36 MH+
[α]D 25+64.4 (c 0.37, MeOH)
Example 18
Figure US08481517-20130709-C00079
Preparation of Acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzoyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester (compound 72)
Compound 20 (110 mg, 0.237 mmol) is dissolved in dry DCM (3 ml) in a nitrogen atmosphere. TEA (0.099 ml, 0.712 mmol) and benzoyl chloride (0.041 ml, 0.356 mmol) are added and the mixture is stirred at RT for 1 hour. The reaction mixture is concentrated to dryness and the crude is purified by silica gel flash chromatography (DCM to DCM:MeOH=98:2) yielding the title compound (107 mg, 0.189 mmol, 79% yield).
1H NMR (300 MHz, DMSO-d6 353K) δ ppm 7.34-7.50 (m, 5H), 7.25 (dd, 1H), 6.28 (dd, 1H), 6.09-6.20 (m, 1H), 5.43-5.77 (m, 1H), 5.26 (br. s., 1H), 5.00 (d, 1H), 4.78 (d, 1H), 4.12-4.31 (m, 1H), 3.52-3.79 (m, 3H), 3.36-3.47 (m, 1H), 3.23-3.36 (m, 1H), 2.55-2.63 (m, 1H), 2.20-2.34 (m, 1H), 2.11 (s, 3H), 1.70-1.97 (m, 4H), 1.55-1.64 (m, 1H), 1.52 (s, 3H), 1.33-1.46 (m, 1H), 1.05 (s, 3H)
LC-MS (ESI POS): 568.3 (MH+)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzoyl-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 73)
Compound 72 is hydrolyzed as described in Example 4 for the preparation of compound 18 obtaining the title compound in 53% yield.
1H NMR (300 MHz, DMSO-d6) δ ppm 7.33-7.59 (m, 5H), 7.26 (d, 1H), 6.30 (d, 1H), 6.12 (s, 1H), 5.49-5.75 (m, 1H), 5.46 (br. s., 1H), 4.89-5.07 (m, 1H), 3.98-4.58 (m, 3H), 3.35-3.95 (m, 4H), 2.54-2.62 (m, 1H), 2.15-2.26 (m, 1H), 1.67-2.05 (m, 5H), 1.52-1.65 (m, 1H), 1.49 (s, 3H), 1.17-1.38 (m, 1H), 0.95 (s, 3H)
LC-MS (ESI POS): 526.39 (MH+)
[α]D 20=+6.3 (c 0.35, MeOH)
Compounds listed in Table 13 are prepared through a two steps procedure as previously described for compound 73.
TABLE 13
Compound Structure Yield Analytical
74
Figure US08481517-20130709-C00080
 		46% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.83 (dd, 1 H), 7.26 (dd, 1 H), 7.04 (d, 1 H), 6.61 (dd, 1 H), 6.29 (dd, 1 H), 6.10 (s, 1 H), 5.50-5.75 (m, 1 H), 5.48 (dd, 1 H), 4.98 (t, 1 H), 4.45 (dd, 1 H), 4.07-4.28 (m, 2 H), 3.50-4.00 (m, 5 H), 2.56-2.63 (m, 1 H), 2.23 (dd, 1 H), 1.70-2.04 (m, 4 H), 1.52-1.58 (m, 1 H), 1.49 (s, 3 H), 1.43-1.48 (m, 1 H), 0.99 (s, 3 H) LC-MS (ESI POS): 516.46 (MH+) [α]D 20 = +12.5 (c = 0.5 CHCl3)
75
Figure US08481517-20130709-C00081
 		47% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.75 (dd, 1 H), 7.54 (dd, 1 H), 7.26 (dd, 1 H), 7.13 (dd, 1 H), 6.29 (dd, 1 H), 6.10 (s, 1 H), 5.50-5.74 (m, 1 H), 5.48 (dd, 1 H), 4.99 (t, 1 H), 4.45 (dd, 1 H), 4.17-4.24 (m, 1 H), 4.14 (dd, 1 H), 3.90 (br. s., 1 H), 3.57-3.81 (m, 3 H), 3.33- 3.44 (m, 1 H), 2.56-2.63 (m, 1 H), 2.11- 2.27 (m, 1 H), 1.68-1.99 (m, 4 H), 1.51- 1.59 (m, 1 H), 1.49 (s, 3 H), 1.40-1.48 (m, 1 H), 0.98 (s, 3 H) LC-MS (ESI POS): 532.32 (MH+) [α]D 20 = +10.37 (c = 0.38, DMSO)
76
Figure US08481517-20130709-C00082
 		70% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.18-7.41 (m, 2 H), 6.72-7.10 (m, 3 H), 6.30 (dd, 1 H), 6.12 (s, 1 H), 5.50-5.79 (m, 1 H), 5.47 (s, 1 H), 4.93-5.03 (m, 1 H), 4.40 (br. s., 1 H), 3.93-4.27 (m, 2 H), 3.74 (br. s., 3 H), 3.38-3.67 (m, 4 H), 2.55-2.63 (m, 1 H), 2.14-2.31 (m, 1 H), 1.66-2.05 (m, 4 H), 1.52-1.66 (m, 2 H), 1.48 (s, 3 H), 1.16-1.41 (m, 1 H), 0.95 (s, 3 H) LC-MS (ESI POS): 556.42 (MH+) [α]D 20 = +11.67 (c = 0.3, MeOH)
77
Figure US08481517-20130709-C00083
 		50% 1H NMR (300 MHz, DMSO-d6) δ ppm 8.63 (dd, 1 H), 8.61 (br. s., 1 H), 7.83 (br. s., 1 H), 7.45 (dd, 1 H), 7.19-7.31 (m, 1 H), 6.30 (d, 1 H), 6.12 (s, 1 H), 5.50-5.80 (m, 1 H), 5.27-5.50 (m, 1 H), 4.85-5.13 (m, 1 H), 3.98-4.59 (m, 3 H), 3.42-3.88 (m, 4 H), 2.54-2.61 (m, 1 H), 2.11-2.32 (m, 1 H), 1.65-2.01 (m, 5 H), 1.54-1.64 (m, 1 H), 1.49 (s, 3 H), 1.28- 1.42 (m, 1 H), 0.96 (s, 3 H) LC-MS (ESI POS): 527.40 (MH+) [α]D 20 = +12.96 (c = 0.5 MeOH)
78
Figure US08481517-20130709-C00084
 		64% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.66-7.79 (m, 3 H), 7.54-7.66 (m, 2 H), 7.23 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.46-5.72 (m, 1 H), 5.43 (dd, 1 H), 5.02 (t, 1 H), 4.30 (dd, 1 H), 4.09-4.19 (m, 1 H), 4.03 (dd, 1 H), 3.18-3.28 (m, 2 H), 3.12 (d, 1 H), 2.96 (d, 1 H), 2.77- 2.87 (m, 1 H), 2.30-2.47 (m, 1 H), 2.07- 2.22 (m, 1 H), 1.79-1.89 (m, 1 H), 1.60- 1.76 (m, 2 H), 1.47-1.57 (m, 1 H), 1.45 (s, 3 H), 1.11-1.38 (m, 2 H), 0.87 (s, 3 H) LC-MS (ESI POS): 562.35 (MH+) [α]D 20 = +39.68 (c = 1, MeOH)
79
Figure US08481517-20130709-C00085
 		43% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.26 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.49-5.79 (m, 1 H), 5.45 (dd, 1 H), 5.02 (t, 1 H), 4.37 (dd, 1 H), 4.16-4.23 (m, 1 H), 4.13 (dd, 1 H), 3.43 (dd, 1 H), 3.30-3.37 (m, 4 H), 3.09 (dd, 1 H), 2.55- 2.63 (m, 1 H), 2.15-2.33 (m, 1 H), 1.54- 1.96 (m, 5 H), 1.49 (s, 3 H), 1.38-1.46 (m, 1 H), 1.17 (d, 3 H), 1.17 (d, 3 H), 0.93 (s, 3 H) LC-MS (ESI POS): 528.29 (MH+) [α]D 20 = +44.29 (c 0.28, MeOH)
80
Figure US08481517-20130709-C00086
 		31% 1H NMR (300 MHz, DMSO-d6) δ ppm 8.03 (dd, 1 H), 7.65 (dd, 1 H), 7.19-7.28 (m, 2 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.47-5.75 (m, 1 H), 5.45 (dd, 1 H), 5.05 (t, 1 H), 4.34 (dd, 1 H), 4.11-4.20 (m, 1 H), 4.06 (dd, 1 H), 3.30-3.37 (m, 1 H), 3.18 (d, 1 H), 3.02 (d, 1 H), 2.82-2.95 (m, 1 H), 2.33-2.47 (m, 1 H), 2.09-2.25 (m, 1 H), 1.85 (d, 1 H), 1.51-1.80 (m, 4 H), 1.46 (s, 3 H), 1.26-1.42 (m, 2 H), 0.89 (s, 3 H) LC-MS (ESI POS): 568.43 (MH+) [α]D 20 = +28.09 (c 0.22, MeOH)
81
Figure US08481517-20130709-C00087
 		43% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.29-7.44 (m, 5 H), 7.26 (d, 1 H), 6.31 (dd, 1 H), 6.15 (s, 1 H), 5.51-5.82 (m, 1 H), 5.45 (dd, 1 H), 5.03 (t, 1 H), 4.46 (s, 2 H), 4.34 (dd, 1 H), 4.16-4.21 (m, 1 H), 4.10 (dd, 1 H), 3.35-3.42 (m, 2 H), 3.27 (d, 1 H), 3.13 (d, 1 H), 2.92 (dd, 1 H), 2.55-2.62 (m, 1 H), 2.18- 2.30 (m, 1 H), 1.54-1.90 (m, 5 H), 1.49 (s, 3 H), 1.29-1.42 (m, 1 H), 0.91 (s, 3 H) LC-MS (ESI POS): 576.27 (MH+)
Example 19
Figure US08481517-20130709-C00088
Preparation of Acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-cyclohexylthiocarbamoyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester (compound 82)
20 (150 mg, 0.300 mmol) is suspended in dry DCM (4 ml) and TEA (167 μl, 1.200 mmol) is added followed by isothiocyanatocyclohexane (85 mg, 0.600 mmol). The reaction mixture is stirred at RT for 4 hours then it is washed with brine, dried over Na2SO4 and evaporated to give a residue that is purified by silica gel cartridge Petroleum Ether/AcOEt 6:4 to AcOEt leading to the title compound (91 mg, 0.150 mmol, 50.2% yield).
LC-MS (ESI POS): 605.2 (MH+)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carbothioic acid cyclohexylamide (compound 83)
Compound 82 is hydrolyzed as described in Example 4 for the preparation of compound 18 obtaining the title compound in 80% yield.
1H NMR (300 MHz, DMSO-d6) δ ppm 7.26 (dd, 1H), 6.84 (d, 1H), 6.29 (dd, 1H), 6.11 (s, 1H), 5.50-5.79 (m, 1H), 5.46 (dd, 1H), 5.00 (t, 1H), 4.42 (dd, 1H), 4.16-4.24 (m, 1H), 4.10 (dd, 1H), 3.98-4.06 (m, 1H), 3.61-3.79 (m, 2H), 3.46-3.59 (m, 2H), 2.38-2.47 (m, 1H), 2.17-2.25 (m, 1H), 1.51-1.97 (m, 10H), 1.49 (s, 4H), 1.00-1.31 (m, 6H), 0.97 (s, 3H)
LC-MS (ESI POS): 563.45 (MH+)
[α]D 20+30.06 (c=0.64 MeOH)
Compounds listed in Table 14 are prepared through a two steps procedure as previously described for compound 83.
TABLE 14
Compound Structure Yield Analytical
84
Figure US08481517-20130709-C00089
 		21% 1H NMR (300 MHz, DMSO-d6) δ ppm 8.16 (s, 1 H) 7.40-7.48 (m, 2 H) 7.27 (dd, 1 H) 7.14-7.24 (m, 2 H) 6.91 (tt, 1 H) 6.30 (dd, 1 H) 6.06-6.14 (m, 1 H) 5.50-5.77 (m, 1 H) 5.46 (dd, 1 H) 4.97 (t, 1 H) 4.44 (dd, 1 H) 4.06-4.24 (m, 2 H) 3.57-3.68 (m, 1 H) 3.53 (d, 1 H) 3.45 (d, 1 H) 3.31-3.38 (m, 2 H) 2.16- 2.27 (m, 1 H) 1.71-2.00 (m, 4 H) 1.50 (s, 3 H) 1.35-1.64 (m, 3 H) 0.98 (s, 3 H) LC-MS (ESI POS): 541.1 (MH+) [α]D 20 = +13.8 (c 0.25, CHCl3)
85
Figure US08481517-20130709-C00090
 		38% 1H NMR (300 MHz, DMSO-d6) δ ppm 8.92 (s, 1 H), 7.20-7.39 (m, 5 H), 6.95- 7.16 (m, 1 H), 6.30 (dd, 1 H), 6.12 (s, 1 H), 5.52-5.74 (m, 1 H), 5.48 (dd, 1 H), 5.03 (t, 1 H), 4.47 (dd, 1 H), 4.18-4.26 (m, 1 H), 4.16 (dd, 1 H), 3.61-3.96 (m, 4 H), 3.34-3.49 (m, 1 H), 2.54-2.61 (m, 1 H), 2.18-2.33 (m, 1 H), 1.72-2.02 (m, 4 H), 1.51-1.69 (m, 2 H), 1.50 (s, 3 H), 1.00 (s, 3 H) LC-MS (ESI POS): 557.01 (MH+) [α]D 20 = +19.7 (c 0.14 MeOH)
Example 20
Figure US08481517-20130709-C00091
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-isopropoxycarbonyloxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid isopropyl ester (compound 86)
A mixture of Compound 69 (191 mg, 0.453 mmol), TEA (0.063 ml, 0.453 mmol) and isopropyl chloroformate (0.453 ml, 0.453 mmol) in DCM (10 ml) is stirred at RT for 20 minutes. The mixture is evaporated and the crude title compound obtained (269 mg, 0.453 mmol) is used in the next step without any further purification.
LC-MS (ESI POS): 594.07 (MH+)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid isopropyl ester (compound 87)
A solution of Compound 86 (269 mg, 0.453 mmol) in MeOH (10 ml) is degassed bubbling nitrogen at RT for 20 minutes and K2CO3 (15.65 mg, 0.113 mmol) is added. After 20 minutes 1N HCl is added to pH=3. The mixture is partitioned between AcOEt and brine. The organic phase is separated, washed with brine, dried over Na2SO4 and concentrated to give a oil that is purified by silica gel chromatography (DCM:MeOH 98:2) to give the title compound (24 mg, 0.047 mmol, 10.44% yield).
1H NMR (300 MHz, DMSO-d6) δ ppm 7.26 (dd, 1H), 6.29 (dd, 1H), 6.10 (s, 1H), 5.49-5.80 (m, 1H), 5.45 (dd, 1H), 4.97 (t, 1H), 4.70 (spt, 1H), 4.40 (dd, 1H), 4.15-4.22 (m, 1H), 4.10 (dd, 1H), 3.33-3.56 (m, 3H), 3.12-3.27 (m, 2H), 2.56-2.62 (m, 1H), 2.14-2.25 (m, 1H), 1.63-1.96 (m, 4H), 1.49 (s, 3H), 1.34-1.46 (m, 2H), 1.14 (d, 3H), 1.13 (d, 3H), 0.95 (s, 3H)
LC-MS (ESI POS): 508.09 (MH+)
[α]D 20=+29.64 (c 0.22, MeOH)
Example 21
Figure US08481517-20130709-C00092
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-(2-Acetoxy-acetyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid benzyl ester (compound 88)
A mixture of compound 11 (86 mg, 0.155 mmol), benzyl chloroformate (44 μl, 0.311 mmol) and NaHCO3 (26.1 mg, 0.311 mmol) in Acetonitrile (10 ml) is stirred at 50° C. for 2 hours. The mixture is partitioned between AcOEt and water, then the organic phase is separated and the aqueous phase is extracted with AcOEt. The combined organic layers are washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated to give a colorless oil that is purified by silica gel chromatography (DCM:AcOEt 80:20) to give the title compound (72 mg, 0.120 mmol, 78% yield).
LC-MS (ESI POS): 598.4 (MH+)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid benzyl ester (compound 89)
Compound 88 is hydrolyzed as described in Example 4 for the preparation of compound 18 obtaining the title compound in 42% yield.
1H NMR (300 MHz, DMSO-d6) δ ppm 7.17-7.36 (m, 6H), 6.29 (dd, 1H), 6.12 (s, 1H), 5.50-5.79 (m, 1H), 5.45 (d, 1H), 5.03 (br. s., 2H), 4.96 (t, 1H), 4.41 (dd, 1H), 4.17-4.24 (m, 1H), 4.11 (dd, 1H), 3.45-3.59 (m, 1H), 3.38-3.45 (m, 3H), 2.14-2.30 (m, 1H), 1.67-1.95 (m, 5H), 1.48 (s, 3H), 1.36-1.46 (m, 3H), 0.96 (s, 3H)
LC-MS (ESI POS): 556.38 (MH+)
[α]D 20=+17.15 (c 0.33, MeOH)
Example 22
Figure US08481517-20130709-C00093
Preparation of Acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-benzooxazol-2-yl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester (compound 90)
Compound 20 (150 mg, 0.300 mmol), 2-chlorobenzo[d]oxazole (92 mg, 0.600 mmol) and K2CO3 (83 mg, 0.600 mmol) are placed in microwave vessel with DMF (2 ml) and the reaction mixture is heated at 130° C. for 1 hour by microwaves. The mixture is partitioned between AcOEt and brine. The organic phase is separated, dried over Na2SO4 and evaporated to give a residue that is purified by silica gel cartridge (Petroleum Ether/AcOEt 8:2 to AcOEt) giving a solid that, after trituration with petroleum ether, gave the title compound (160 mg, 0.276 mmol, 92% yield).
LC-MS (ESI POS): 581.1 (MH+)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzooxazol-2-yl-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 91)
Compound 90 is hydrolyzed as described in Example 4 for the preparation of compound 18 obtaining the title compound in 59% yield.
1H NMR (300 MHz, DMSO-d6) δ ppm 7.37 (d, 1H), 7.23-7.30 (m, 2H), 7.13 (td, 1H), 7.00 (td, 1H), 6.29 (dd, 1H), 6.08 (s, 1H), 5.51-5.78 (m, 1H), 5.39-5.59 (m, 1H), 4.99 (t, 1H), 4.48 (dd, 1H), 4.19-4.24 (m, 1H), 4.17 (dd, 1H), 3.75-3.85 (m, 1H), 3.70 (d, 1H), 3.59 (d, 1H), 3.37-3.53 (m, 2H), 2.55-2.62 (m, 1H), 2.15-2.26 (m, 1H), 1.73-2.06 (m, 4H), 1.52-1.62 (m, 2H), 1.50 (s, 3H), 1.01 (s, 3H)
LC-MS (ESI POS): 539.38 (MH+)
[α]437 20=+19.87 (c=0.3, MeOH)
Compound listed in Table 15 is prepared through a two steps procedure as previously described for compound 91.
TABLE 15
Compound Structure Yield Analytical
92
Figure US08481517-20130709-C00094
 		75% 1H NMR (300 MHz, DMSO-d6) δ ppm 8.32 (d, 2 H), 7.26 (dd, 1 H), 6.62 (t, 1 H), 6.29 (dd, 1 H), 6.09 (s, 1 H), 5.50- 5.80 (m, 1 H), 5.47 (dd, 1 H), 4.94 (t, 1 H), 4.44 (dd, 1 H), 4.19-4.25 (m, 1 H), 4.13 (dd, 1 H), 3.60-3.75 (m, 2 H), 3.45- 3.58 (m, 2 H), 3.34-3.42 (m, 1 H), 2.58- 2.67 (m, 1 H), 2.16-2.33 (m, 1 H), 1.74- 2.03 (m, 4 H), 1.50 (s, 3 H), 1.40-1.49 (m, 2 H), 1.01 (s, 3 H) LC-MS (ESI POS): 500.38 (MH+) [α]436 20 = −4.33 (c = 0.3, MeOH, 436 nm)
Example 23
Figure US08481517-20130709-C00095
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,12S)-8-Benzyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic acid (compound 93)
A mixture of compound 8 (460 mg, 0.899 mmol) and NaOH 6N (1350 μl, 11.10 mmol) in THF (20 ml) and water (10 ml) is stirred at RT for 3 days. Water is added and the organic solvent is evaporated. The basic aqueous solution (pH 12) is washed with AcOEt. The aqueous phase is then treated with HCl 6N until pH 6 when a solid precipitated. The solid is recovered by filtration and the aqueous phase is extracted with AcOEt, washed with brine, dried over Na2SO4 and then evaporated. The two fractions of obtained solid are combined and triturated with AcOEt (containing 2% MeOH) to give the title compound (150 mg, 0.301 mmol, 33.5% yield).
1H NMR (300 MHz, DMSO-d6) δ ppm 6.81-7.43 (m, 6H), 6.29 (dd, 1H), 6.13 (s, 1H), 5.47-5.82 (m, 1H), 5.24-5.47 (m, 1H), 3.96-4.25 (m, 1H), 3.47 (d, 1H), 3.42 (d, 1H), 2.94-3.10 (m, 1H), 2.81-2.92 (m, 1H), 2.64 (d, 1H), 2.36 (d, 1H), 2.21-2.32 (m, 2H), 1.92-2.11 (m, 2H), 1.77-1.85 (m, 1H), 1.54-1.69 (m, 3H), 1.50 (s, 3H), 1.31 (dd, 1H), 0.99 (s, 3H)
LC-MS (ESI POS): 498.1 (MH+)
[α]D 20=+46.87 (c=0.3, DMSO)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,12S)-8-Benzyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic acid chloromethyl ester (compound 94)
A mixture of Compound 93 (110 mg, 0.221 mmol), Potassium carbonate (61.1 mg, 0.442 mmol) and Bromochloromethane (71.9 μA 1.105 mmol) in DMA (3 ml) is stirred at RT under nitrogen overnight. The mixture is then diluted with AcOEt and washed with brine. The organic layer is then dried over Na2SO4 and evaporated to give the crude title compound.
LC-MS (ESI POS): 546.3 (MH+)
Intermediate reported in Table 16 is prepared as described for compound 93.
TABLE 16
Compound Structure Yield Analytical
95
Figure US08481517-20130709-C00096
 		92% 1H NMR (300 MHz, DMSO-d6) □ ppm 12.14 (s, 1 H), 7.11-7.49 (m, 5 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.49-5.83 (m, 1 H), 5.40 (dd, 1 H), 4.00-4.29 (m, 1 H), 3.50 (d, 1 H), 3.43 (d, 1 H), 2.97-3.12 (m, 1 H), 2.88 (t, 1 H), 2.66 (d, 1 H), 2.56-2.61 (m, 1 H), 2.36 (d, 1 H), 2.22-2.33 (m, 1 H), 1.91-2.12 (m, 2 H), 1.76-1.87 (m, 1 H), 1.53-1.72 (m, 3 H), 1.49 (s, 3 H), 1.31 (dd, 1 H), 0.99 (s, 3 H) LC-MS (ESI POS): 532.2 MH+
Compounds listed in Table 17 are prepared as previously described for Compound 94, starting from intermediate 93 or intermediate 95 and using the suitable alkylhalide.
TABLE 17
Compound Structure Yield Analytical
96
Figure US08481517-20130709-C00097
 		16% 1H NMR (300 MHz, DMSO-d6) ppm 7.21- 7.37 (m, 4 H), 7.18 (ddd, 1 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.91 (d, 1 H), 5.87 (d, 1 H), 5.54-5.77 (m, 1 H), 5.51 (d, 1 H), 4.04-4.21 (m, 1 H), 3.56 (d, 1 H), 3.40 (d, 1 H), 3.05-3.20 (m, 1 H), 2.96 (t, 1 H), 2.67 (d, 1 H), 2.53-2.62 (m, 1 H), 2.38 (d, 1 H), 2.22-2.34 (m, 1 H), 1.92-2.16 (m, 2 H), 1.79 (d, 1 H), 1.52-1.71 (m, 3 H), 1.49 (s, 3 H), 1.37 (dd, 1 H), 0.97 (s, 3 H) LC-MS (ESI POS): 580.19 MH+ [α]D 25 +83.04 (MeOH, c 0.27)
97
Figure US08481517-20130709-C00098
 		40% 1H NMR (300 MHz, DMSO-d6) ppm 7.10- 7.37 (m, 6 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.50-5.79 (m, 1 H), 5.44 (dd, 1 H), 4.13- 4.19 (m, 2 H), 4.08-4.13 (m, 1 H), 3.48- 3.57 (m, 2 H), 3.38-3.48 (m, 2 H), 3.24 (s, 3 H), 3.02-3.18 (m, 1 H), 2.87 (t, 1 H), 2.64 (d, 1 H), 2.54-2.61 (m, 1 H), 2.38 (d, 1 H), 2.22-2.33 (m, 1 H), 2.07 (dd, 1 H), 1.91-2.04 (m, 1 H), 1.80 (d, 1 H), 1.51-1.71 (m, 3 H), 1.49 (s, 3 H), 1.34 (dd, 1 H), 0.93 (s, 3 H) LC-MS (ESI POS): 556.18 MH+ [α]D 25 +90.4 (c 0.4, MeOH)
98
Figure US08481517-20130709-C00099
 		33% 1H NMR (300 MHz, DMSO-d6) ppm 7.00- 7.38 (m, 6 H), 6.29 (dd, 1 H), 6.13 (s, 1 H), 5.50-5.80 (m, 1 H), 5.40 (dd, 1 H), 4.71 (t, 1 H), 4.09-4.21 (m, 1 H), 4.04 (t, 2 H), 3.57 (qd, 2 H), 3.45 (s, 2 H), 3.01-3.19 (m, 1 H), 2.85 (t, 1 H), 2.64 (d, 1 H), 2.55-2.61 (m, 1 H), 2.41 (d, 1 H), 2.21-2.35 (m, 1 H), 2.05- 2.17 (m, 1 H), 1.94-2.05 (m, 1 H), 1.83 (d, 1 H), 1.53-1.75 (m, 3 H), 1.49 (s, 3 H), 1.33 (dd, 1 H), 0.94 (s, 3 H) LC-MS (ESI POS): 542.25 MH+ [α]D 25 +79.75 (MeOH, c 0.24)
Example 24
Figure US08481517-20130709-C00100
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-4a,6a-dimethyl-8-(3-methyl-butyl)-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic acid (Compound 99)
Compound 62 (597 mg, 1.119 mmol) is dissolved in dioxane (20 ml), NaOH (2.237 ml, 4.47 mmol) is added and the mixture is stirred at open air for 2 days. The reaction mixture is diluted with water and the pH adjusted to 5-6 by adding HCl 1N solution. Dioxane is evaporated and a solid precipitates upon concentration. The solid is recovered by filtration and dried in vacuo to yield the title compound (146 mg, 0.306 mmol, 27.3% yield).
LC-MS (ESI POS): 478.2 MH+
Intermediates listed in Table 18 are prepared as described in Example 24 for compound 99.
TABLE 18
Compound Structure Yield Analytical
100
Figure US08481517-20130709-C00101
 		92%  LC-MS (ESI POS): 534.0 MH+
101
Figure US08481517-20130709-C00102
 		68%  LC-MS (ESI POS): 502.0 MH+
102
Figure US08481517-20130709-C00103
 		85%  LC-MS (ESI POS): 405.9 MH+
103
Figure US08481517-20130709-C00104
 		92%* LC-MS (ESI POS): 526.0 MH+
93
Figure US08481517-20130709-C00105
 		84%  LC-MS (ESI POS): 497.2 MH+
95
Figure US08481517-20130709-C00106
 		96%  LC-MS (ESI POS): 532.3 MH+
*THF is used instead of Dioxane
Example 25
Figure US08481517-20130709-C00107
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic acid fluoromethyl ester (compound 104)
Na2CO3 (189 mg, 1.786 mmol) is added to a stirred solution of Compound 95 (190 mg, 0.357 mmol) in anhydrous N,N-dimethylformamide (3 ml) and after stirring at RT for 15 minutes the mixture is cooled to −20° C. under nitrogen. Bromofluoromethane (0.446 ml, 0.893 mmol) is added and the reaction stirred at −20° C. for 1 hour, then the reaction mixture is allowed to warm to RT overnight. The reaction is partitioned between water and ethyl acetate. The organic layer is dried over anhydrous Na2SO4, filtered and evaporated in vacuo. The crude product is purified on a silica gel cartridge (Hexane:AcOEt from 7/3 to 1/1), then it is triturated in H2O, recovered by filtration and dried, to give the title compound (94 mg, 0.167 mmol, 46.7% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.21-7.36 (m, 4H), 7.18 (dt, 1H), 6.30 (dd, 1H), 6.12 (s, 1H), 5.79 (dd, 1H), 5.79 (dd, 1H), 5.52-5.74 (m, 1H), 5.50 (dd, 1H), 4.08-4.22 (m, 1H), 3.53 (d, 1H), 3.46 (d, 1H), 3.07-3.20 (m, 1H), 2.93 (t, 1H), 2.70 (d, 1H), 2.54-2.62 (m, 1H), 2.43 (d, 1H), 2.21-2.35 (m, 1H), 2.10 (dd, 1H), 1.97-2.06 (m, 1H), 1.82 (d, 1H), 1.52-1.75 (m, 3H), 1.49 (s, 3H), 1.37 (dd, 1H), 0.97 (s, 3H)
LC-MS (ESI POS): 564.29 MH+
[α]D 25+78.6 (c 0.4, MeOH)
Compounds listed in Table 19 are prepared according to the previously described procedure for the preparation of compound 104, starting from intermediate 99 and from the intermediates listed in Table 18.
TABLE 19
Compound Structure Yield Analytical
105
Figure US08481517-20130709-C00108
 		52% 1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.78 (dd, 1 H), 5.79 (dd, 1 H), 5.51-5.72 (m, 1 H), 5.49 (dd, 1 H), 4.06-4.29 (m, 1 H), 3.01-3.15 (m, 1 H), 2.86 (dd, 1 H), 2.66 (d, 1 H), 2.54-2.61 (m, 1 H), 2.42 (d, 1 H), 2.14-2.34 (m, 3 H), 2.02 (dd, 1 H), 1.89-1.99 (m, 1 H), 1.85 (d, 1 H), 1.52-1.79 (m, 4 H), 1.49 (s, 3 H), 1.33 (dd, 1 H), 1.24 (q, 2 H), 0.97 (s, 3 H), 0.82 (d, 6 H) LC-MS (ESI POS): 510.35 MH+ [α]D 25 +63.2 (c 0.5, MeOH)
106
Figure US08481517-20130709-C00109
 		81% 1H NMR (300 MHz, DMSO-d6) ppm 7.26 (d, 1 H), 7.04 (tt, 1 H), 6.77-6.96 (m, 2 H), 6.30 (dd, 1 H), 6.13 (s, 1 H), 5.79 (d, 2 H), 5.53-5.80 (m, 1 H), 5.50 (d, 1 H), 4.15 (d, 1 H), 3.56 (d, 1 H), 3.47 (d, 1 H), 3.03-3.23 (m, 1 H), 2.95 (t, 1 H), 2.71 (d, 1 H), 2.55-2.64 (m, 1 H), 2.44 (d, 1 H), 2.20-2.36 (m, 1 H), 2.12 (dd, 1 H), 1.92-2.07 (m, 1 H), 1.76-1.89 (m, 1 H), 1.59- 1.76 (m, 2 H), 1.50 (s, 3 H), 1.55 (m, 1 H), 1.38 (dd, 1 H), 0.97 (s, 3 H) LC-MS (ESI POS): 566.28 MH+ [α]D 25 +69.3 (c 0.5, MeOH)
107
Figure US08481517-20130709-C00110
 		96% 1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1 H), 6.30 (dd, 1 H), 6.12 (s, 1 H), 6.03 (d, 1 H), 5.94 (dd, 1 H), 5.78 (dd, 1 H), 5.79 (dd, 1 H), 5.51-5.76 (m, 1 H), 5.50 (dd, 1 H), 4.09-4.22 (m, 1 H), 3.45 (d, 1 H), 3.36 (d, 1 H), 3.04-3.16 (m, 1 H), 2.96 (t, 1 H), 2.80 (d, 1 H), 2.55-2.67 (m, 1 H), 2.42 (d, 1 H), 2.21-2.32 (m, 1 H), 2.18 (s, 3 H), 2.02 (dd, 1 H), 1.89-1.98 (m, 1 H), 1.78- 1.88 (m, 1 H), 1.51-1.74 (m, 3 H), 1.49 (s, 3 H), 1.34 (dd, 1 H), 0.96 (s, 3 H) LC-MS (ESI POS): 534.28 MH+ [α]D 25 +60.93 (c 0.108, CHCl3)
108
Figure US08481517-20130709-C00111
 		34% 1H NMR (300 MHz, DMSO-d6) ppm 7.25 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.64-5.95 (m, 2 H), 5.51-5.72 (m, 1 H), 5.49 (dd, 1 H), 4.03-4.34 (m, 1 H), 3.00-3.15 (m, 1 H), 2.88 (t, 1 H), 2.68 (d, 1 H), 2.53-2.58 (m, 1 H), 2.41 (d, 1 H), 2.11-2.32 (m, 3 H), 1.89-2.06 (m, 2 H), 1.79-1.89 (m, 1 H), 1.51-1.79 (m, 2 H), 1.49 (s, 3 H), 1.33 (dd, 1 H), 1.20-1.29 (m, 3 H), 0.96 (s, 3 H), 0.84 (s, 9 H) LC-MS (ESI POS): 524.32 MH+ [α]D 25 +47.67 (c 0.3, MeOH)
Example 26
Figure US08481517-20130709-C00112
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-4a,6a-dimethyl-8-(5-methyl-furan-2-ylmethyl)-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic acid cyanomethyl ester (compound 109)
To a solution of compound 101 (110 mg, 0.219 mmol) in dry DMF (4 ml), Na2CO3 (46.5 mg, 0.439 mmol) is added and the suspension stirred at RT for 20 minutes, after which time bromoacetonitrile (0.015 ml, 0.219 mmol) is added. HPLC-MS after 2 hours and 30 minutes indicates that the reaction is almost complete (about 6% of starting material is present). Another addition of Na2CO3 (4.65 mg, 0.044 mmol) is done, followed by addition of Bromoacetonitrile (1.528 μl, 0.022 mmol). After stirring 1 hour, the conversion is complete. The reaction mixture is diluted with AcOEt and washed with brine. The aqueous layer is extracted with AcOEt twice, then washed with brine again. The organic layer is dried over Na2SO4 and evaporated. Crude material is purified via chromatographic column on silica gel (DCM, DCM/AcOEt 5/1, DCM/AcOEt 2/1), affording the title compound (82 mg, 0.152 mmol, 69%).
1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1H), 6.30 (dd, 1H), 6.11 (s, 1H), 6.03 (d, 1H), 5.94 (dq, 1H), 5.54-5.77 (m, 1H), 5.53 (dd, 1H), 5.01 (s, 2H), 4.06-4.25 (m, 1H), 3.44 (d, 1H), 3.37 (d, 1H), 3.03-3.17 (m, 1H), 2.96 (t, 1H), 2.77 (d, 1H), 2.55-2.67 (m, 1H), 2.39 (d, 1H), 2.22-2.33 (m, 1H), 2.18 (d, 3H), 2.01 (dd, 1H), 1.86-1.98 (m, 1H), 1.79 (d, 1H), 1.51-1.72 (m, 3H), 1.49 (s, 3H), 1.34 (dd, 1H), 0.95 (s, 3H)
LC-MS (ESI POS): 541.27 MH+
[α]D 25+94.39 (c 0.103, CHCl3)
Compound reported in Table 20 is prepared as described for compound 109 in Example 26.
TABLE 20
Compound Structure Yield Analytical
110
Figure US08481517-20130709-C00113
 		22% 1H NMR (300 MHz, DMSO-d6) d ppm 7.26 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.54- 5.80 (m, 1 H), 5.52 (dd, 1 H), 5.00 (s, 2 H), 4.07-4.26 (m, 1 H), 2.97-3.14 (m, 1 H), 2.88 (t, 1 H), 2.65 (d, 1 H), 2.54-2.60 (m, 1 H), 2.39 (d, 1 H), 2.14-2.32 (m, 2 H), 2.00 (dd, 1 H), 1.87-1.97 (m, 1 H), 1.51-1.86 (m, 4 H), 1.49 (s, 3 H), 1.15-1.40 (m, 4 H), 0.96 (s, 3 H), 0.84 (s, 9 H) LC-MS (ESI POS): 531.32 MH+ [α]D 25 +59.83 (c 0.23, CHCl3)
Example 27
Figure US08481517-20130709-C00114
Preparation of Acetic acid 2-((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-8-phenyl-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl)-2-oxo-ethyl ester (compound 111)
In a nitrogen atmosphere compound 20 (150 mg, 0.300 mmol) is suspended in Acetonitrile (4 ml). 2-(trimethylsilyl)phenyl trifluoromethanesulfonate (0.146 ml, 0.600 mmol) and CsF (182 mg, 1.200 mmol) are added and the mixture is stirred for 45 minutes at RT. Additional CsF (137 mg, 0.900 mmol) (not dried) is added and the mixture is stirred for 5 hours then it is poured in water. Acetonitrile is evaporated and the reaction mixture is partitioned between water and AcOEt. The organic layer is separated dried over Na2SO4 and concentrated. The crude is purified by silica gel flash chromatography (eluent DCM/MeOH 98/2) affording the title compound (49 mg, 0.091 mmol, 30.3% yield).
LC-MS (ESI POS): 540.2 (MH+)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-8-phenyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 112)
Compound 111 is hydrolyzed as described in Example 4 for the preparation of compound 18 obtaining the title compound, after preparative HPLC, in 5% yield.
1H NMR (300 MHz, DMSO-d6) δ ppm 7.27 (dd, 1H), 7.07-7.21 (m, 2H), 6.57-6.74 (m, 3H), 6.29 (dd, 1H), 6.08 (s, 1H), 5.50-5.84 (m, 1H), 5.39-5.47 (m, 1H), 4.45 (d, 1H), 4.17-4.25 (m, 1H), 4.13 (d, 1H), 3.44-3.54 (m, 2H), 3.26 (s, 2H), 3.01-3.09 (m, 1H), 2.35-2.46 (m, 1H), 2.15-2.26 (m, 2H), 1.71-2.00 (m, 4H), 1.50 (s, 3H), 1.41-1.48 (m, 2H), 1.00 (s, 3H)
LC-MS (ESI POS): 498.2 (MH+)
Example 28
Figure US08481517-20130709-C00115
Preparation of Acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-8-(3-methoxy-phenyl)-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester (compound 113) and of Acetic acid 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-8-(4-methoxy-phenyl)-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-6b-yl]-2-oxo-ethyl ester (compound 114)
Compound 20 (320 mg, 0.640 mmol) is suspended in acetonitrile (12 ml), cesium fluoride (292 mg, 1.920 mmol) and 4-methoxy-2-(trimethylsilyl)phenyl trifluoromethanesulfonate (210 mg, 0.640 mmol) are added and the mixture is stirred at RT for 48 hours. LC-MS shows that the reaction is not complete and the formation of a 1/1 mixture of regioisomers is detected. Pyridine (0.052 ml, 0.640 mmol) is added and the reaction mixture is stirred for 24 hours. Although the reaction is not complete, mixture is partitioned between water and AcOEt, the organic layer is separated, dried and concentrated. The crude is purified by silica gel flash chromatography (eluent DCM-MeOH=99/1) to yield a mixture title compounds 113 and 114 (124 mg, 0.218 mmol, 34.0% yield).
LC-MS (ESI POS): 570.2 MH+
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-8-(3-methoxy-phenyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 115) and of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-8-(4-methoxy-phenyl)-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 116)
Mixture of compounds 113 and 114 is hydrolyzed as described in Example 10 for the preparation of compound 45. Compounds 115 and 116 are isolated by purification of the crude via preparative HPLC obtaining the title compounds 115 (58 mg, 30%) and 116 (65 mg, 33%).
Compound 115:
1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1H), 7.03 (t, 1H), 6.29 (dd, 1H), 6.20-6.28 (m, 2H), 6.16 (t, 1H), 6.08 (s, 1H), 5.48-5.80 (m, 1H), 5.44 (dd, 1H), 4.90 (br. s., 1H), 4.45 (d, 1H), 4.17-4.23 (m, 1H), 4.12 (d, 1H), 3.69 (s, 3H), 3.44-3.52 (m, 1H), 3.32-3.43 (m, 1H), 3.25 (s, 2H), 3.05 (dd, 1H), 2.55-2.69 (m, 1H), 2.34-2.46 (m, 0H), 2.17-2.32 (m, 1H), 1.73-2.02 (m, 4H), 1.50 (s, 3H), 1.41-1.49 (m, 2H), 0.99 (s, 3H)
LC-MS (ESI POS): 528.26 MH+
[α]D 25+11.47 (c 0.75, MeOH, 546 nm)
Compound 116:
1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1H), 6.72-6.85 (m, 2H), 6.54-6.72 (m, 2H), 6.29 (dd, 1H), 6.08 (s, 1H), 5.49-5.75 (m, 1H), 5.44 (br. s., 1H), 4.43 (d, 1H), 4.17-4.24 (m, 1H), 4.13 (d, 1H), 3.65 (s, 3H), 3.40-3.50 (m, 1H), 3.30-3.40 (m, 1H), 3.18 (s, 2H), 2.91 (dd, 1H), 2.55-2.62 (m, 1H), 2.34-2.46 (m, 1H), 2.18-2.34 (m, 1H), 1.63-1.98 (m, 3H), 1.49 (s, 3H), 1.35-1.48 (m, 2H), 0.97 (s, 3H)
LC-MS (ESI POS): 528.23 MH+
[α]D 25+15.16 (c 1.0, MeOH, 546 nm)
Compound reported in Table 21 is prepared as previously described for compounds 115 and 116.
TABLE 21
Compound Structure Yield Analytical
117
Figure US08481517-20130709-C00116
 		51% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.26 (dd, 2 H), 6.38-7.11 (m, 4 H), 6.29 (dd, 1 H), 6.08 (s, 1 H), 5.48-5.77 (m, 1 H), 5.39-5.48 (m, 1 H), 4.90 (t, 1 H), 4.36-4.51 (m, 1 H), 4.02-4.26 (m, 2 H), 3.35-3.52 (m, 2 H), 3.17-3.25 (m, 1 H), 2.94-3.08 (m, 1 H), 2.54-2.61 (m, 1 H), 2.22-2.33 (m, 1 H), 2.16 and 2.21 (s, 3 H), 1.71-2.03 (m, 4 H), 1.50 (s, 3 H), 1.40-1.49 (m, 2 H), 0.98 and 0.99 (s, 3 H). LC-MS (ESI POS): 512.18 MH+
Example 29
Figure US08481517-20130709-C00117
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,6b,9,9a,10,10a,10b,11,12-tetradecahydro-8-aza-pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester (intermediate 118)
To a mixture of intermediate 6 (563 mg; 1.49 mmol) and a catalytic amount of Cu2O, in anhydrous THF (16 ml), ethyl isocyanate (326 μl; 2.98 mmol) is added and the mixture is stirred at 60° C. for 1 hour. The reaction mixture is filtered through a celite pad, washing with methanol and the solvent is evaporated. The residue is purified by silica gel flash chromatography in gradient elution from DCM to DCM/AcOEt 60:40, to afford of title compound (629 mg, 86% yield).
LC-MS (ESI POS): 492.3 (MH+)
Preparation of ((4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester (compound 119)
To a solution of intermediate 118 (629 mg; 1.28 mmol) in methanol (13 ml; 0.1 M), NaCNBH3 (169 mg; 2.56 mmol) is added at 0° C.; pH is adjusted to 5 by addition of acetic acid. The reaction mixture is stirred at 0° C. for 2 hours and at RT for 5 hours, then it is poured into brine (50 ml), and pH is adjusted to 7 by addition of a saturated solution of NaHCO3. The aqueous phase is extracted with AcOEt (3×60 ml) and the combined organic layers are concentrated. The crude material is purified by silica gel flash chromatography in gradient elution from DCM to DCM/MeOH 88:12, to afford pure title compound (335 mg, 53% yield mixture of stereoisomers).
1H NMR (300 MHz, DMSO-d6) δ ppm 9.52 (br. s., 1H) 7.27-7.36 (m, 1H) 6.18 (dd, 1H) 5.94 (s, 1H) 4.78 (br. s., 1H) 4.45-4.61 (m, 1H) 4.35-4.45 (m, 1H) 4.16-4.35 (m, 4H) 4.01-4.16 (m, 2H) 3.52-3.92 (m, 2H) 3.37-3.50 (m, 1H) 3.16-3.6 (m, 1H) 2.29-2.39 (m, 1H) 1.43-2.12 (m, 7H) 1.37 (s, 3H) 1.27 (t, 3H) 1.01-1.13 (m, 2H) 0.81-1.00 (m, 3H)
LC-MS (ESI POS): 458.15 (MH+)
Example 30
Figure US08481517-20130709-C00118
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-N-(2-thienoyl)-pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester (compound 120)
Under an inert atmosphere, Compound 119 (600 mg; 1.217 mmol) is dissolved in dry THF (15 ml) and 2-thienoyl chloride (195 μl; 1.825 mmol; d=1.37 g/ml) is added. The formed suspension is cooled to 0° C., triethylamine (169 μA; 1.217 mmol) is added and the reaction mixture is stirred at 0° C. for 15 minutes. The reaction mixture is poured into brine (35 ml) and the aqueous phase is extracted with AcOEt (3×60 ml). The combined organic extracts are dried and concentrated. The crude material is purified by silica gel flash chromatography in DCM/MeOH 98:2, to afford the title compound (560 mg 76% yield; mixture of diastereoisomer).
1H NMR (300 MHz, Chloroform-d) δ ppm 7.52 (dd, 1H), 7.44 (br. s., 1H), 6.98-7.21 (m, 2H), 6.23-6.56 (m, 2H), 5.14-5.54 (m, 1H), 4.74 (s, 1H), 4.42-4.47 (m, 1H), 4.45 (d, 1H), 4.05-4.34 (m, 4H), 3.92 (d, 1H), 3.61 (d, 1H), 2.34-2.60 m, 1H), 2.20-2.34 (m, 2H), 1.89-2.20 (m, 3H), 1.61-1.89 (m, 3H), 1.53 (s, 3H), 1.28 (t, 3H), 1.05 (s, 3H)
LC-MS (ESI POS): 604.15 (MH+)
Compounds listed in Table 22 are prepared through the procedure previously described for compound 120.
TABLE 22
Compound Structure Yield Analytical
121
Figure US08481517-20130709-C00119
 		35% 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 7.29- 7.56 (m, 5 H), 7.24 (d, 1 H), 6.33 (dd, 1 H), 6.09 (s, 1 H), 4.52 (br. s., 1 H), 4.41 (d, 2 H), 3.95-4.27 (m, 4 H), 3.69 (d, 1 H), 3.57 (d, 1 H), 2.50-2.71 (m, 1 H), 2.29-2.48 (m, 1 H), 1.92-2.23 (m, 3 H), 1.70-1.90 (m, 2 H), 1.50-1.67 (m, 1 H), 1.46 (s, 3 H), 1.08-1.40 (m, 6 H), 1.04 (s, 3 H) LC-MS (ESI POS): 562.22 (MH+)
122
Figure US08481517-20130709-C00120
 		30% 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 7.30- 7.55 (m, 3 H), 7.08 (d, 1 H), 6.50 (s, 1 H), 6.42 (dd, 1 H), 5.14-5.81 (m, 1 H), 4.03-4.68 (m, 6 H), 3.67-3.83 (m, 1 H), 3.53-3.66 (m, 1 H), 1.64-2.56 (m, 11 H), 1.54 (s, 3 H), 1.13- 1.43 (m, 3 H), 1.3 (s, 3 H) LC-MS (ESI POS): 598.02 (MH+)
123
Figure US08481517-20130709-C00121
 		91% 1H NMR (300 MHz, DMSO-d6 353K) δ ppm 7.75 (dd, 1 H), 7.25 (dd, 1 H), 7.05 (dd, 1 H), 6.59 (dd, 1 H), 6.27 (dd, 1 H), 6.12 (s, 1 H), 5.58 (dddd, 1 H), 5.25 (dd, 1 H), 4.76 (t, 1 H), 4.74 (s, 1 H), 4.21-4.32 (m, 2 H), 4.03-4.18 (m, 4 H), 3.85 (d, 1 H), .54 (d, 1 H), 2.53-2.64 (m, 1 H), 2.12-2.33 (m, 1 H), 1.95-2.12 (m, 2 H), 1.85 (m, 3 H), 1.55-1.71 (m, 1 H), 1.51 (s, 3 H), 1.20 (t, 3 H), 0.99 (s, 3 H) LC-MS (ESI POS): 588.19 (MH+)
124
Figure US08481517-20130709-C00122
 		51% 1H NMR (300 MHz, DMSO-d6 353K) δ ppm 6.88-7.36 (m, 6 H), 6.28 (dd, 1 H), 6.17 (d, 1 H), 5.58 (dddd, 1 H), 5.21 (d, 1 H), 4.69 (t, 1 H), 4.38-4.53 (m, 1 H), 4.25 (dd, 1 H), 4.15- 4.25 (m, 1 H), 3.95-4.13 (m, 3 H), 3.78-3.89 (m, 1 H), 3.29- 3.70 (m, 4 H), 2.35-2.47 (m, 1 H), 2.13-2.29 (m, 1 H), 1.60- 2.04 (m, 4 H), 1.50 (s, 3 H), 1.34-1.48 (m, 2 H), 1.19 (t, 3 H), 0.94 (s, 3 H) LC-MS (ESI POS): 612.14 (MH+)
125
Figure US08481517-20130709-C00123
 		46% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.14-7.39 (m, 2 H), 6.71-7.03 (m, 2 H), 6.22-6.41 (m, 1 H), 6.12 (s, 1 H), 5.49- 5.80 (m, 1 H), 5.46 (d, 1 H), 5.10 (t, 1 H), 4.23-4.43 (m, 1 H), 4.12-4.24 (m, 1 H), 3.72-4.12 (m, 7 H), 3.32-3.68 (m, 2 H), 2.8-2.46 (m, 1 H), 2.06-2.28 (m, 1 H), 1.71-2.02 (m, 4 H), 1.51-1.66 (m, 2 H), 1.48 (s, 3 H), 1.16 (t, 3 H), 0.90 (s, 3 H) LC-MS (ESI POS): 618.09 (MH+)
Example 31
Figure US08481517-20130709-C00124
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-8-furan-2-ylmethyl-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester (compound 126)
To a solution of Compound 119 (80 mg; 0.162 mmol) and 2-furaldehyde (14 μl; 0.162 mmol; d=1.158 g/ml) in methanol (2 ml) under nitrogen atmosphere, NaCNBH3 (12 mg; 0.195 mmol) is added. After 1 hour stirring at RT, acetic acid (10 μl; 0.174 mmol; d=1.05 g/ml) is added and the reaction mixture is stirred for further 2 hours at RT. The reaction mixture is poured into brine (20 ml) and the aqueous phase is extracted with AcOEt (3×30 ml). The combined organic extracts are dried over Na2SO4 and concentrated. The residue is purified by preparative HPLC to afford 13 mg of title compound (14% yield; mixture of diastereoisomers).
1H NMR (300 MHz, Chloroform-d) δ ppm 7.37 (dd, 1H), 7.11 (dd, 1H), 6.43-6.49 (m, 1H), 6.39 (dd, 1H), 6.33 (dd, 1H), 6.19 (d, 1H), 5.39-5.60 (m, 1H), 5.31 (ddd, 1H), 4.49 (d, 1H), 4.35-4.40 (m, 1H), 4.37 (d, 1H), 4.17-4.31 (m, 2H), 3.85 (d, 1H), 3.70 (d, 1H), 3.26 (t, 1H), 3.18 (d, 1H), 2.88 (d, 1H), 2.64 (d, 1H), 2.23-2.55 (m, 2H), 1.59-2.12 (m, 5H), 1.53 (s, 3H), 1.33 (t, 3H), 0.97 (s, 3H)
LC-MS (ESI POS): 574.31 (MH+)
Compounds listed in Table 23 are prepared through the procedure previously described for compound 126.
TABLE 23
Compound Structure Yield Analytical
127
Figure US08481517-20130709-C00125
 		53% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.39 (dd, 1 H), 7.24 (dd, 1 H), 6.77-6.97 (m, 2 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.49-5.79 (m, 1 H), 5.42 (d, 1 H), 4.83 (t, 1 H), 4.10 (q, 2 H), 4.02-4.32 (m, 3 H), 3.92 (d, 1 H), 3.65 (d, 1 H), 3.22 (dd, 1 H), 2.8-3.00 (m, 2 H), 2.55-2.64 (m, 1 H), 2.46 (d, 1 H), 2.16-2.35 (m, 1 H), 1.87-2.13 (m, 1 H), 1.51-1.87 (m, 5 H), 1.48 (s, 3 H), 1.21 (t, 3 H), 0.85 (s, 3 H) LC-MS (ESI POS): 90.14 (MH+)
128
Figure US08481517-20130709-C00126
 		24% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.44-7.64 (m, 1 H), 7.30 (d, 1 H), 6.29-6.44 (m, 1 H), 6.10-6.25 (m, 2 H), 5.93 (s, 1 H), 4.79 (t, 1 H), 4.69 (d, 1 H), 4.29 (dd, 1 H), 4.20- 4.26 (m, 1 H), 4.17 (dd, 1 H), 3.94-4.12 (m, 2 H), 3.63 (d, 1 H), 3.43 (d, 1 H), 3.12 (t, 1 H), 2.94 (d, 1 H), 2.65 (d, 1 H), 2.44 (d, 1 H), 2.22-2.37 (m, 1 H), 1.93-2.12 (m, 2 H), 1.77-1.93 (m, 1 H), 1.57-1.77 (m, 1 H), 1.37 (s, 3 H), 1.33- 1.57 (m, 2 H), 1.16-1.34 (m, 4 H), 0.89-1.16 (m, 3 H), 0.84 (s, 3 H) LC-MS (ESI POS): 538.42 (MH+)
129
Figure US08481517-20130709-C00127
 		40% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.39 (dd, 1 H), 7.30 (d, 1 H), 6.92 (dd, 1 H), 6.85 (d, 1 H), 6.16 (dd, 1 H), 5.93 (s, 1 H), 4.79 (t, 1 H), 4.68 (d, 1 H), 4.09-4.33 (m, 3 H), 4.09 (q, 2 H), 3.89 (d, 1 H), 3.58 (d, 1 H), 3.10-3.24 (m, 1 H), 2.90 (d, 1 H), 2.82 (d, 1 H), 2.53-2.60 (m, 1 H), 2.41- 2.48 (m, 1 H), 2.22-2.39 (m, 1 H), 1.91-2.12 (m, 2 H), 1.76-1.91 (m, 1 H), 1.39-1.74 (m, 5 H), 1.37 (s, 3 H), 1.20 (t, 3 H), 0.89-1.14 (m, 1 H), 0.83 (s, 3 H) LC-MS (ESI POS): 554.38 (MH+)
130
Figure US08481517-20130709-C00128
 		52% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.32 (d, 1 H), 7.20- 7.29 (m, 1 H), 7.06-7.20 (m, 2 H), 6.15 (dd, 1 H), 5.91 (s, 1 H), 4.35 (d, 1 H), 4.29-4.35 (m, 1 H), 4.23 (d, 1 H), 4.15 (m, 1 H), 3.22-3.33 (m, 1 H), 2.53-2.78 (m, 7 H), 2.28-2.39 (m, 2 H), 1.99-2.16 (m, 3 H), 1.94 (dd, 1 H), 1.50-1.80 (m, 8 H), 1.42 (s, 3 H), 1.22 (t, 3 H), 1.01-1.18 (m, 2 H), 0.91 (s, 3 H) LC-MS (ESI POS): 576.34 (MH+)
131
Figure US08481517-20130709-C00129
 		 7% 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 7.25 (d, 1 H), 6.29 (dd, 1 H), 5.81-6.11 (m, 1 H), 4.52 (d, 1 H), 4.43-4.53 (m, 1 H), 4.37 (d, 1 H), 4.23 (q, 2 H), 2.91-3.35 (m, 2 H), 2.48-2.79 (m, 2 H), 2.24-2.45 (m, 2 H), 2.04-2.23 (m, 3 H), 1.98 (dd, 1 H), 1.50-1.87 (m, 6 H), 1.32 (t, 3 H), 1.28 (s, 3 H), 1.17-1.41 (m, 3 H), 1.06-1.17 (m, 2 H), 0.99 (s, 3 H), 0.87 (t, 3 H) LC-MS (ESI POS): 514.42 (MH+)
Example 32
Figure US08481517-20130709-C00130
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Butyl-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester (compound 132)
Compound 119 (100 mg; 0.20 mmol) is dissolved in dry DMF (2 ml); butyl iodide (91 μl; 0.8 mmol; d=1.617 g/ml) and K2CO3 (41 mg; 0.3 mmol) are added. The reaction mixture is stirred under microwave heating at 100° C. for 20 minutes. The reaction mixture is partitioned between AcOEt and brine; the organic layer is washed with water, dried over Na2SO4 and concentrated. The crude is purified by preparative HPLC to give the title compound (88 mg, 80% yield; mixture of diastereoisomers).
1H NMR (300 MHz, DMSO-d6+Na2CO3) δ ppm 7.25 (dd, 1H), 6.28 (dd, 1H), 6.11 (s, 1H), 5.48-5.79 (m, 1H), 5.44 (br. s., 1H), 4.80 (br. s., 1H), 4.35 (d, 1H), 4.24 (d, 1H), 4.10-4.20 (m, 1H), 4.10 (q, 2H), 3.14 (dd, 1H), 3.07 (d, 1H), 2.70 (d, 1H), 2.37-2.47 (m, 1H), 2.24 (d, 2H), 2.05-2.19 (m, 1H), 1.53-2.06 (m, 6H), 1.49 (s, 3H), 1.21 (t, 3H), 1.27 (br. s., 5H), 0.86 (s, 3H), 0.81 (t, 3H)
LC-MS (ESI POS): 550.12 (MH+)
When a substituted alkylbromide is used as alkylating agent in place of a substitute alkyliodide, 0.5 eq of KI are used in the reaction mixture.
Compounds listed in Table 24 are prepared through a two steps procedure as previously described for compound 132.
TABLE 24
Com-
pound Structure Yield Analytical
133
Figure US08481517-20130709-C00131
 		18% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.04-7.45 (m, 6 H), 6.16 (dd, 1 H), 5.93 (s, 1 H), 4.14-4.28 (m, 1 H), 4.11-4.24 (m, 2 H), 4.06 (q, 2 H), 3.74 (d, 1 H), 3.21 (d, 1 H), 3.07-3.21 (m, 1 H), 2.79 (d, 1 H), 2.70-2.77 (m, 1 H), 2.51-2.60 (m, 1 H), .35 (d, 1 H), 2.22-2.36 (m, 1 H), 1.89-2.12 (m, 2 H), 1.74-1.87 (m, 1 H), 1.38-1.72 (m, 5 H), 1.37 (s, 3 H), 1.18 (t, 3 H), 1.05-1.29 (m, 2 H), 0.99 (dd, 1 H), 0.83 (s, 3 H) LC-MS (ESI POS): 548.18 (MH+)
134
Figure US08481517-20130709-C00132
 		15% 1H NMR (300 MHz, DMSO-d6 + Na2CO3) δ ppm 7.17-7.31 (m, 6 H), 6.28 (dd, 1 H), 6.12 (s, 1 H), 5.43-5.84 (m, 1 H), 4.22 (s, 2 H), 4.06-4.17 (m, 1 H), 4.07 (q, 2 H), 3.75 (d, 1 H), 2.96-3.25 (m, 2 H), 2.88 (d, 1 H), 2.84 (d, 1 H), 2.18-2.38 (m, 2 H) 1.86-2.18 (m, 1 H), 1.50-1.83 (m, 5 H), 1.48 (s, 3 H), 1.20-1.32 (m, 1 H), 1.19 (t, 3 H), 0.84 (s, 3 H) LC-MS (ESI POS): 584.21 (MH+)
135
Figure US08481517-20130709-C00133
 		29% 1H NMR (300 MHz, DMSO-d6) δ ppm 6.99-7.45 (m, 6 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.48-5.82 (m, 1 H), 5.42 (d, 1 H), 4.83 (t, 1 H), 4.39 (dd, 1 H), 4.20 (dd, 1 H), 4.10-4.19 (m, 1 H), 4.07 (q, 2 H), 3.17-3.24 (m, 1 H), 3.17 (d, 1 H), 2.92-3.10 (m, 4 H), 2.89 (d, 1 H), 2.74-2.84 (m, 1 H), 2.41 (d, 1 H), 2.17-2.28 (m, 1 H), 1.52-2.10 (m, 6 H), 1.49 (s, 3 H), 1.16 (t, 3 H), 0.85 (s, 3 H) LC-MS (ESI POS): 630.12 (MH+)
136
Figure US08481517-20130709-C00134
 		21% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.12-7.33 (m, 3 H), 6.75-6.97 (m, 3 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.49-5.81 (m, 1 H), 5.42 (dd, 1 H), 4.81 (t, 1 H), 4.36 (dd, 1 H), 4.21 (dd, 1 H), 4.10-4.18 (m, 1 H), 4.02 (qd, 2 H), 3.91-4.00 (m, 2 H), 3.0- 3.24 (m, 2 H), 2.94 (s, 1 H), 2.84 (ddd, 1 H), 2.55- 2.76 (m, 2 H), 2.16-2.38 (m, 1 H), 1.99 (d, 1 H), 1.52-1.91 (m, 6 H), 1.49 (s, 3 H), 1.17 (t, 3 H), 0.85 (s, 3 H) LC-MS (ESI POS): 614.14 (MH+)
137
Figure US08481517-20130709-C00135
 		74% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.09-7.31 (m, 6 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.47-5.80 (m, 1 H), 5.42 (dd, 1 H), 4.83 (t, 1 H), 4.37 (dd, 1 H), 4.26 (dd, 1 H), 4.10-4.20 (m, 1 H), 4.08 (q, 2 H), 3.12-3.23 (m, 1 H), 3.09 (d, 1 H), 2.77 (d, 1 H), 2.53-2.71 (m, 1 H), 2.38-2.48 (m, 1 H), 1.65-2.38 (m, 10 H), 1.57 (br. s., 3 H), 1.49 (s, 3 H), 1.17 (t, 3 H), 0.87 (s, 3 H) LC-MS (ESI POS): 612.16 (MH+)
Example 33
Figure US08481517-20130709-C00136
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-8-phenylcarbamoyl-2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester (compound 138)
To a solution of Compound 119 (70 mg; 0.142 mmol) in dry THF (4 ml), phenyl isocyanate (17 μl; 0.156 mmol; d=1.096 g/ml) is added and the reaction mixture is stirred at RT for 2 hours. The reaction mixture is poured into brine (20 ml) and the aqueous phase is extracted with AcOEt (3×35 ml). The combined organic extracts are dried over anhydrous sodium sulphate and concentrated. The residue is purified by preparative HPLC to afford the title compound (30 mg 34% yield).
1H NMR (300 MHz, DMSO-d6): ppm 8.37 (s, 1H), 7.34-7.58 (m, 2H), 7.13-7.34 (m, 3H), 6.82-7.04 (m, 1H), 6.30 (dd, 1H), 6.10 (s, 1H), 5.51-5.79 (m, 1H), 5.44-5.51 (m, 1H), 5.13 (t, 1H), 4.36 (s, 1H), 4.33 (dd, 1H), 3.95-4.22 (m, 3H),3.80 (d, 1H), 3.56-3.73 (m, 1H), 3.34-3.45 (m, 1H), 2.55-2.70 (m, 1H), 2.17-2.35 (m, 1H), 1.72-2.05 (m, 4H), 1.50 (s, 3H), 1.28-1.71 (m, 5H), 1.20 (t, 3H), 0.93 (s, 3H)
LC-MS (ESI POS):613.43 (MH+)
Compounds listed in Table 25 are prepared through the procedure previously described for compound 138.
TABLE 25
Com-
pound Structure Yield Analytical
139
Figure US08481517-20130709-C00137
 		30% 1H NMR (300 MHz, DMSO-d6) δ ppm 8.24 (s, 1 H), 7.43 (d, J = 7.63 Hz, 2 H), 7.32 (d, J = 10.27 Hz, 1 H), 7.13-7.27 (m, 2 H), 6.93 (t, J = 7.34 Hz, 1 H), 6.17 (dd, J = 10.12, 1.91 Hz, 1 H), 5.91 (s, 1 H), 4.72 (br. s., 1 H), 4.24-4.40 (m, 3 H), 3.93-4.18 (m, 3 H), 3.84 (d, J = 11.44 Hz, 1 H), 3.59 (d, J = 11.44 Hz, 1 H), 3.35 (d, J = 10.56 Hz, 1 H), 2.54-2.61 (m, 1 H), 2.25-2.39 (m, 1 H), 1.82-2.07 (m, 4 H), 1.72-1.80 (m, 1 H), 1.52-1.68 (m, 1 H), 1.40-1.50 (m, 1 H), 1.39 (s, 3 H), 1.19 (t, J = 7.19 Hz, 3 H), 0.99-1.15 (m, 2 H), 0.92 (s, 3 H) LC-MS (ESI POS):577.33 (MH+)
140
Figure US08481517-20130709-C00138
 		47% 1H NMR (300 MHz, DMSO-d6) δ ppm 9.08 (s, 1 H), 7.20- 7.51 (m, 5 H), 6.97-7.20 (m, 1 H), 6.17 (dd, J = 10.12, 1.91 Hz, 1 H), 5.93 (s, 1 H), 4.89 (s, 1 H), 4.74 (br. s., 1 H), 4.23-4.42 (m, 2 H), 3.93-4.23 (m, 4 H), 3.79 (d, J = 12.91 Hz, 1 H), 3.39 (d, = 9.10 Hz, 1 H), 2.55-2.67 (m, 1 H), 2.21-2.40 (m, 1 H), 1.86-2.15 (m, 3 H), 1.65-1.86 (m, 2 H), 1.57 (br. s., 1 H), 1.39-1.52 (m, 1 H), 1.39 (s, 3 H), 1.19 (t, J = 7.19 Hz, 3 H), 1.02-1.15 (m, 2 H), 0.93 (s, 3 H). LC-MS (ESI POS):593.19 (MH+)
141
Figure US08481517-20130709-C00139
 		46% 1H NMR (300 MHz, DMSO-d6) δ ppm 7.31 (d, 1 H), 6.17 (dd, 1 H), 5.93-5.98 (m, 1 H), 5.92 (s, 1 H), 4.71 (br. s., 1 H), 4.18-4.37 (m, 2 H), 4.11 (s, 1 H), 3.84-4.09 (m, 4 H), 3.55-3.63 (m, 1 H), 3.18-3.44 (m, 3 H), 2.54-2.62 (m, 1 H), 2.22-2.3 (m, 1 H), 1.90-2.04 (m, 2 H), 1.60-1.89 (m, 6 H), 1.46-1.58 (m, 2 H), 1.38 (s, 3 H), 1.27 (d, 2 H), 1.16 (t, 3 H), 0.95-1.20 (m, 6 H), 0.89 (s, 3 H) LC-MS (ESI POS):583.32 (MH+)
Example 34
Figure US08481517-20130709-C00140
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzenesulfonyl-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-pentaleno[2,1-a]phenanthrene-9-carboxylic acid ethyl ester (compound 142)
To a solution of Compound 119 (80 mg; 0.162 mmol) in dry DCM (5 ml), triethylamine (25 μl; 0.178 mmol; d=0.726 g/ml) and phenylsulfonyl chloride (21 μl; 0.162 mmol; d=1.377 g/ml) are added. After 6 hrs stirring at RT, under nitrogen atmosphere, further triethylamine (7 μl; 0.049 mmol; d=0.726 g/ml) and phenylsulfonyl chloride (6 μl; 0.049 mmol; d=1.377 g/ml) are added and the reaction mixture is stirred for further 30 minutes. The reaction mixture is diluted with DCM (40 ml) and the organic layer is washed with 1 N HCl, water and brine, dried and concentrated. The residue is purified by preparative HPLC to afford the title compound (31 mg, 30% yield).
1H NMR (300 MHz, Chloroform-d): δ ppm 7.70-7.92 (m, 2H), 7.56-7.64 (m, 1H), 7.45-7.56 (m, 2H), 7.04 (dd, 1H), 6.45-6.52 (m, 1H), 6.40 (dd, 1H), 5.31 (dddd, 1H), 4.35-4.41 (m, 1H), 4.39 (d, 1H), 4.18 (d, 1H), 4.15 (dq, 2H), 4.10 (d, 1H), 3.70 (d, 1H), 3.48 (d, 1H), 3.43 (dt, 1H), 2.17-2.48 (m, 1H), 1.78-2.10 (m, 3H), 1.48 (s, 3H), 1.43-1.77 (m, 3H), 1.29-1.40 (m, 1H), 1.27 (t, 3H), 0.95 (s, 3H)
LC-MS (ESI POS):634.24 (MH+)
Compounds listed in Table 26 are prepared the procedure previously described for compound 142.
TABLE 26
Com-
pound Structure Yield Analytical
143
Figure US08481517-20130709-C00141
 		37% 1H NMR (300 MHz, DMSO-d6) pm 7.31 (d, 1 H), 6.17 (dd, 1 H), 5.93 (s, 1 H), 5.06 (t, 1 H), 4.70 (d, 1 H), 4.32 (dd, 1 H), 4.22-4.29 (m, 1 H), 3.88-4.17 (m, 4 H), 3.51 (s, 2 H), 3.32-3.44 (m, 1 H), 3.00 (s, 3 H), 2.54-2.66 (m, 1 H), 2.18-2.39 (m, 1 H), 1.76-2.06 (m, 4 H), 1.57-1.74 (m, 1 H), 1.38 (s, 3 H), 1.32-1.55 (m, 1 H), 1.20 (t, 3 H), 1.03-1.29 (m, 3 H), 0.89 (s, 3 H) LC-MS (ESI POS): 536.19 (MH+)
144
Figure US08481517-20130709-C00142
 		45% 1H NMR (300 MHz, DMSO-d6) ppm 7.71-7.98 (m, 2 H), 7.38-7.71 (m, 3 H), 7.26 (d, 1 H), 6.18 (dd, 1 H), 5.98 (s, 1 H), 5.09 (t, 1 H), 4.67 (d, 1 H), 4.12-4.38 (m, 3 H), 3.79-4.12 (m, 3 H), 3.50 (d, 1 H), 3.32-3.40 (m, 2 H), 2.34-2.47 (m, 1 H), .13-2.33 (m, 1 H), 1.65-1.90 (m, 3 H), 1.42-1.60 (m, 1 H), 1.30 (s, 3 H), 1.20-1.39 (m, 3 H), 1.16 (t, 3 H), 0.81 (s, 3 H), 0.46-0.63 (m, 1 H), 0.15-0.48 (m, 1 H) LC-MS (ESI POS): 598.24 (MH+)
Example 35
Figure US08481517-20130709-C00143
Preparation of 4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-hexadecahydro-8-aza-pentaleno[2,1-a]phenanthrene-9-carboxylic acid (compound 145)
To a solution of compound 119 (66 mg; 0.113 mmol) in dry THF (3 ml) and water (1 ml) 1 N NaOH (400 μl) is added and the reaction mixture is stirred at RT overnight. The reaction mixture is poured into 1 N HCl (10 ml) and brine (10 ml), and the aqueous phase is extracted with AcOEt (3×40 ml). The combined organic extracts are dried and concentrated. Crude is purified by preparative HPLC, to afford title compound (15% yield).
1H NMR (300 MHz, MeOD) δ ppm 6.89-7.63 (m, 6H), 6.15-6.49 (m, 2H), 5.33-5.74 (m, 1H), 4.49 (d, 1H), 4.35 (d, 1H), 4.17-4.29 (m, 1H), 4.11 (d, 1H), 3.42 (d, 1H), 3.09 (d, 1H), 2.84-2.92 (m, 1H), 2.52-2.75 (m, 1H), 2.48 (d, 1H), 2.28-2.43 (m, 1H), 1.60-2.09 (m, 7H), 1.31 (s, 3H), 0.99 (s, 3H)
LC-MS (ESI POS): 556.27 (MH+)
Example 36
Figure US08481517-20130709-C00144
(Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-4a,6a-dimethyl-8-(5-methyl-furan-2-ylmethyl)-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic acid dimethylamide (compound 146)
To a solution of compound 101 (165.9 mg, 0.331 mmol) in dry DMF (6.615 ml), kept under nitrogen, HATU (138 mg, 0.364 mmol) is added, followed by N-methylmorpholine (0.036 ml, 0.331 mmol). The reaction is heated at 65° C. for 1 hour, then the mixture is allowed to cool down at RT and dimethylamine (2M solution in THF), (1.654 ml, 3.31 mmol) is added, the reaction is sealed and let stir overnight. The conversion is complete. The mixture is diluted with AcOEt, then poured onto brine and the aqueous layer is extracted with AcOEt twice. Combined organic extracts are washed with brine, dried over Na2SO4 and evaporated to dryness. The crude material is purified via chromatographic column over silica gel (AcOEt): the recovered product (160 mg) is triturated with water and filtered, affording the title compound (80 mg, 0.151 mmol, 46% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1H), 6.29 (dd, 1H), 6.12 (s, 1H), 6.01 (d, 1H), 5.95 (dq, 1H), 5.47-5.81 (m, 1H), 5.39 (dd, 1H), 4.08-4.32 (m, 1H), 3.48-3.65 (m, 1H), 3.45 (d, 1H), 3.39 (d, 1H), 3.04 (d, 1H), 2.85 (s, 6H), 2.55-2.68 (m, 1H), 2.36-2.47 (m, 2H), 2.20-2.33 (m, 2H), 2.18 (s, 3H), 1.99-2.13 (m, 1H), 1.87-1.99 (m, 1H), 1.76 (d, 1H), 1.52-1.68 (m, 1H), 1.48 (s, 3H), 1.37-1.47 (m, 1H), 1.27 (dd, 1H), 0.92 (s, 3H)
LC-MS (ESI POS): 529.34 MH+
[α]D 25+38.33 (c 0.3, MeOH)
The compounds listed in Table 27 are prepared as described in Example 36 for compound 146. Compounds 93, 95, 100 and 102 are reacted with the suitable commercially available amines.
TABLE 27
Com-
pound Structure Yield Analytical
147
Figure US08481517-20130709-C00145
 		 9% 1H NMR (300 MHz, DMSO-d6) ppm 7.07-7.43 (m, 7 H) 6.29 (dd, 1 H) 6.12 (s, 1 H) 5.47-5.82 (m, 1 H) 5.33-5.41 (m, 1 H) 4.02-4.19 (m, 1 H) 3.43 (s, 2 H) 3.00-3.22 (m, 3 H) 2.78 (t, 1 H) 2.53-2.56 (m, 1 H) 2.34-2.45 (m, 1 H) 2.24-2.33 (m, 2 H) 2.12 (dd, 1 H) 1.93-2.07 (m, 1 H) 1.72-1.87 (m, 1 H) 1.53-1.69 (m, 2 H) 1.49 (s, 4 H) 1.21-1.38 (m, 1 H) 0.96-1.07 (m, 3 H) 0.90 (s, 3 H) LC-MS (ESI POS): 525.25 MH+ [a]D 25 + 82.5 (c 0.19, MeOH)
148
Figure US08481517-20130709-C00146
 		27% 1H NMR (300 MHz, DMSO-d6) ppm 6.99-7.44 (m, 6 H) 6.30 (dd, 1 H) 6.14 (s, 1 H) 5.50-5.83 (m, 1 H) 5.40 (d, 1 H) 4.10- 4.26 (m, 1 H) 3.51-3.64 (m, 1 H) 3.51 (d, 1 H) 3.44 (d, 1 H) 3.30-3.39 (m, 2 H) 3.08-3.19 (m, 1 H) 2.95-3.09 (m, 1 H) 2.78 (s, 3 H) 2.04-2.46 (m, 5 H) 1.84-1.98 (m, 1 H) 1.51-1.78 (m, 3 H) 1.49 (s, 3 H) 1.24-1.39 (m, 1 H) 1.02 (t, 3 H) 0.93 (s, 3 H) LC-MS (ESI POS): 539.31 MH+ [a]D 25 + 35.58 (c 0.19, MeOH)
149
Figure US08481517-20130709-C00147
 		30% 1H NMR (300 MHz, DMSO-d6) ppm 7.89 (t, 1 H) 7.07-7.42 (m, 11 H) 6.29 (dd, 1 H) 6.13 (s, 1 H) 5.49-5.80 (m, 1 H) 5.40 (dd, 1 H) 4.33 (dd, 1 H) 4.22 (dd, 1 H) 4.07-4.16 (m, 1 H) 3.48 (d, 1 H) 3.42 (d, 1 H) 3.14-3.24 (m, 1 H) 2.91 (t, 1 H) 2.68- 2.76 (m, 1 H) 2.55-2.62 (m, 1 H) 2.37 (d, 1 H) 2.19-2.34 (m, 1 H) 1.94-2.10 (m, 2 H) 1.86 (d, 1 H) 1.52-1.72 (m, 3 H) 1.49 (s, 3 H) 1.27-1.39 (m, 1 H) 0.91 (s, 3 H) LC-MS (ESI POS): 587.26 MH+ [a]D 25 + 91.47 (c 0.34, MeOH)
150
Figure US08481517-20130709-C00148
 		41% 1H NMR (300 MHz, DMSO-d6) ppm 8.02 (s, 1 H) 7.04-7.47 (m, 11 H) 6.29 (dd, 1 H) 6.13 (s, 1 H) 5.45-5.86 (m, 1 H) 5.29- 5.43 (m, 1 H) 4.05-4.21 (m, 1 H) 3.56 (d, 1 H) 3.38 (d, 1 H) 3.19-3.26 (m, 1 H) 3.03 (t, 1 H) 2.88 (d, 1 H) 2.55-2.61 (m, 1 H) 2.13-2.38 (m, 2 H) 1.88-2.12 (m, 2 H) 1.75-1.88 (m, 1 H) 1.49 (s, 3 H) 1.42-1.72 (m, 3 H) 1.25-1.40 (m, 1 H) 1.08-1.20 (m, 4 H) 0.85 (s, 3 H) LC-MS (ESI POS): 613.27 MH+ [a]D 25 +83.2 (c 0.45 MeOH)
151
Figure US08481517-20130709-C00149
 		43% 1H NMR (300 MHz, DMSO-d6) ppm 8.06 (t, 1 H), 7.13-7.40 (m, 5 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.51-5.81 (m, 1 H), 5.46 (dd, 1 H), 4.10-4.20 (m, 1 H), 4.07 (d, 2 H), 3.49 (d, 1 H), 3.43 (d, 1 H), 3.08-3.24 (m, 1 H), 2.86 (t, 1 H), 2.55-2.68 (m, 2 H), 2.38 (d, 1 H), 2.20-2.34 (m, 1 H), 2.10 (dd, 1 H), 1.94-2.06 (m, 1 H), 1.74-1.86 (m, 1 H), 1.51-1.71 (m, 3 H), 1.49 (s, 3 H), 1.34 (dd, 1 H), 0.91 (s, 3 H) LC-MS (ESI POS): 570.39 MH+ [a]D 25 + 79.2 (c 0.2, MeOH)
152
Figure US08481517-20130709-C00150
 		35% 1H NMR (300 MHz, DMSO-d6) ppm 6.91-7.42 (m, 6 H), 6.30 (dd, 1 H), 6.14 (s, 1 H), 5.48-5.79 (m, 1 H), 5.32-5.48 (m, 1 H), 4.08-4.31 (m, 1 H), 3.38-3.63 (m, 3 H), 2.98-3.15 (m, 1 H), 2.82 (s, 6 H), 2.05-2.47 (m, 5 H), 1.83-1.98 (m, 1 H), 1.54-1.83 (m, 4 H), 1.49 (s, 3 H), 1.22-1.39 (m, 1 H), 0.93 (s, 3 H) LC-MS (ESI POS): 525.41 MH+ [a]D 25 + 13.1 (c 0.27, DMSO)
153
Figure US08481517-20130709-C00151
 		43% 1H NMR (300 MHz, DMSO-d6) ppm 7.11-7.38 (m, 5 H), 6.29 (dd, 1 H), 6.13 (s, 1 H), 5.46-5.82 (m, 1 H), 5.39 (dd, 1 H), 4.09-4.24 (m, 1 H), 3.42-3.61 (m, 2 H), 3.01-3.20 (m, 2 H), 2.83 (s, 6 H), 2.30-2.43 (m, 2 H), 2.10-2.23 (m, 3 H), 1.86- 2.03 (m, 2 H), 1.52-1.80 (m, 3 H), 1.49 (s, 3 H), 1.26-1.37 (m, 1 H), 0.93 (s, 3 H) LC-MS (ESI POS): 559.35 MH+ [a]D 25 + 32.25 (c 0.24, CHCl3)
154
Figure US08481517-20130709-C00152
 		47% 1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1 H), 7.03 (tt, 1 H), 6.86-6.98 (m, 2 H), 6.29 (dd, 1 H), 6.14 (s, 1 H), 5.51-5.83 (m, 1 H), 5.40 (dd, 1 H), 4.09-4.32 (m, 1 H), 3.54-3.61 (m, 1 H), 3.55 (d, 1 H), 3.49 (d, 1 H), 3.02-3.16 (m, 1 H), 2.82 (s, 6 H), 2.24-2.47 (m, 3 H), 2.06-2.24 (m, 3 H), 1.86-2.01 (m, 1 H), 1.51-1.82 (m, 3 H), 1.49 (s, 3 H), 1.25-1.38 (m, 1 H), 0.93 (s, 3 H) LC-MS (ESI POS): 561.37 MH+ [a]D 25 + 26.2 (c 0.20, CHCl3)
155
Figure US08481517-20130709-C00153
 		15% 1H NMR (300 MHz, DMSO-d6) ppm 7.25 (dd, 1 H), 6.29 (dd, 1 H), 6.10 (s, 1 H), 5.46-5.77 (m, 1 H), 5.38 (dd, 1 H), 4.10-4.27 (m, 1 H), 3.42-3.57 (m, 1 H), 3.00-3.21 (m, 1 H), 2.84 (s, 3 H), 2.55-2.70 (m, 3 H), 2.14-2.32 (m, 4 H), 1.89- 2.14 (m, 4 H), 1.76 (d, 1 H), 1.52-1.69 (m, 1 H), 1.48 (s, 3 H), 1.15-1.45 (m, 5 H), 0.91 (s, 3 H), 0.86 (s, 9 H) LC-MS (ESI POS): 519.37 MH+
156
Figure US08481517-20130709-C00154
 		38% 1H NMR (300 MHz, DMSO-d6) d ppm 7.08-7.30 (m, 6 H), 6.29 (dd, 1 H), 6.09 (s, 1 H), 5.46-5.79 (m, 1 H), 5.39 (dd, 1 H), 3.98-4.36 (m, 1 H), 3.50 (dd, 1 H), 3.13 (d, 1 H), 2.84 (s, 6 H), 2.53-2.62 (m, 1 H), 2.57 (t, 2 H), 2.09-2.42 (m, 5 H), 1.88-2.09 (m, 3 H), 1.58-1.85 (m, 4 H), 1.48 (s, 3 H), 1.42- 1.55 (m, 1 H), 1.24-1.41 (m, 1 H), 0.93 (s, 3 H) LC-MS (ESI POS): 553.17 MH+ [a]D 25 + 38.08 (c 0.24, CHCl3)
Example 37
Figure US08481517-20130709-C00155
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carboxylic acid methyl ester trifluoroacetate (compound 157)
Compound 93 (161 mg, 0.403 mmol) is dissolved in dimethyl carbonate (5 mL, 59.37 mmol), DBU (0.06 mL, 0.403 mmol) is added and the mixture is heated at 90° C. for 3 days. The formation of the product is detected by LC-MS. The reaction mixture is concentrated to dryness and purified by preparative HPLC to yield 45 mg of compound as TFA salt, which is further purified on a silica gel cartridge (eluent DCM/MeOH 98/2) affording the title compound, as TFA salt, (39 mg, 0.062 mmol, 15% yield).
1H NMR (300 MHz, DMSO-d6+Na2CO3) ppm 7.13-7.35 (m, 6H) 6.29 (dd, 1H) 6.09-6.15 (m, 1H) 5.45-5.83 (m, 1H) 4.14 (d, 1H) 3.61 (s, 3H) 3.45 (s, 2H) 3.04-3.15 (m, 1H) 2.87 (t, 1H) 2.62 (d, 1H) 2.42-2.48 (m, 1H) 2.38 (d, 1H) 2.22-2.34 (m, 1H) 1.91-2.14 (m, 2H) 1.55-1.85 (m, 3H) 1.43-1.53 (m, 1H) 1.49 (s, 3H) 1.34 (dd, 1H) 0.91 (s, 3H)
LC-MS (ESI POS): 512.18 MH+
[α]D 25+32.08 (c 0.49, MeOH)
Example 38
Figure US08481517-20130709-C00156
Preparation of [(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-(2-Acetoxy-acetyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-8-yl]-acetic acid ethyl ester (compound 158)
Compound 20 (160 mg, 0.320 mmol) is dissolved in DMF (5 ml), TEA (0.045 ml, 0.320 mmol), K2CO3 (44.2 mg, 0.320 mmol) and ethyl 2-chloroacetate (0.068 ml, 0.640 mmol) are added and the mixture is stirred at 60° C. for 2 hours. The reaction mixture is diluted with EtOAc and washed with water. The organic phase is separated and the aqueous phase is extracted with AcOEt. The combined organic layers are dried over Na2SO4 and concentrated. The crude is purified by silica gel flash chromatography (eluent from DCM:MeOH=99/1 to 99/2) affording the title compound (75 mg, 0.136 mmol, 43% yield).
LC-MS (ESI-POS): 550.2 MH+
Preparation of [(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-8-yl]-acetic acid ethyl ester (compound 159)
A solution of compound 158 (75 mg, 0.136 mmol) in ethanol (5 ml) is degassed with nitrogen for 15 minutes and cooled to 0° C. Then K2CO3 (9.43 mg, 0.068 mmol) is added and the mixture is stirred at 0° C. with continuous degassing for 1 hour. The reaction mixture is partitioned between water and AcOEt. The combined organic phases are concentrated and crude is purified by silica gel flash chromatography (eluent DCM/EtOH=99/1 to 95/5) to yield the title compound (31 mg, 0.061 mmol, 45% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1H), 6.29 (dd, 1H), 6.11 (s, 1H), 5.49-5.79 (m, 1H), 5.41 (d, 1H), 4.81 (t, 1H), 4.33 (dd, 1H), 4.10-4.21 (m, 1H), 4.13 (dd, 1H), 4.04 (q, 2H), 3.21 (d, 1H), 3.13-3.17 (m, 1H), 3.14 (d, 1H), 2.99 (t, 1H), 2.74 (d, 1H), 2.56-2.67 (m, 1H), 2.37-2.47 (m, 1H), 2.18-2.31 (m, 1H), 2.10 (dd, 1H), 1.91-2.06 (m, 1H), 1.81-1.91 (m, 1H), 1.52-1.80 (m, 2H), 1.49 (s, 3H), 1.40-1.48 (m, 1H), 1.33 (dd, 1H), 1.15 (t, 3H), 0.86 (s, 3H)
LC-MS (ESI POS): 508.31 MH+
[α]D 25+60.3 (c 0.35, CHCl3)
Example 39
Figure US08481517-20130709-C00157
Preparation of (6S,8S,9R,10S,11S,13S,145)-6,9-difluoro-17-(2-fluoroacetyl)-11-hydroxy-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15-decahydro-3H-cyclopenta[α]phenanthren-3-one (compound 160)
In a nitrogen atmosphere, compound 6 (100 mg, 0.264 mmol) is dissolved in acetonitrile (4 ml), Mesyl-Cl (32 μl, 0.411 mmol) and DIPEA (78 μl, 0.447 mmol) are added and the mixture is stirred at RT for 30 minutes. Potassium fluoride (154 mg, 2.64 mmol) is added and the mixture is stirred for 1 hour at 60° C. (complete conversion into chloride occurred). TBAF 1M in THF (529 μl, 0.529 mmol) is added and the mixture is stirred at 60° C. for 4 hours. The reaction mixture is partitioned between water and AcOEt, the organic layer is separated, dried over Na2SO4 and concentrated. The crude material is purified by silica gel flash chromatography (eluent DCM/AcOEt=1:1) to yield title compound (62 mg, 61.7% yield).
LC-MS (ESI POS): 381.0 (MH+)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-6b-(2-fluoro-acetyl)-5-hydroxy-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 161)
In a closed vessel, to a mixture of compound 160 (125 mg, 0.329 mmol) and N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine (0.318 ml, 1.314 mmol) in 1,4-dioxane (5 ml), 1 drop of TFA (cat) is added and the mixture is stirred at 100° C. for 1 hour. The reaction mixture is concentrated and purified by silica gel flash chromatography (eluent DCM/AcOEt 7/3) and then by preparative HPLC to afford the title compound (45 mg, 26.7% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.11-7.47 (m, 6H), 6.29 (dd, 1H), 6.12 (s, 1H), 5.49-5.77 (m, 1H), 5.40 (dd, 1H), 5.26 (dd, 1H), 5.11 (dd, 1H), 4.05-4.22 (m, 1H), 3.49 (d, 1H), 3.44 (d, 1H), 3.03-3.19 (m, 1H), 2.92 (t, 1H), 2.53-2.61 (m, 2H), 2.38 (d, 1H), 2.20-2.33 (m, 1H), 1.93-2.10 (m, 2H), 1.84 (d, 1H), 1.51-1.77 (m, 3H), 1.49 (s, 3H), 1.37 (dd, 1H), 0.91 (s, 3H)
LC-MS (ESI POS): 514.39 MH+
[α]D 25+84.2 (c 0.36 CHCl3)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-difluoro-6b-(2-fluoro-acetyl)-5-hydroxy-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 162)
A solution of intermediate 160 (225 mg, 0.591 mmol) and TFA (5 μl, 0.065 mmol) in dioxane (12 ml) is prepared (Solution A). A solution of N-(3-chlorobenzyl)-1-methoxy-N-((trimethylsilyl)methyl)methanamine (1126 mg, 4.14 mmol) in Dioxane (12 ml) is prepared (Solution B). The two solutions are reacted in the Flow reaction System setting each flow at 0.2 ml/min at 100° C. in the 10 ml reactor (Residence time: 25 min). The solvent is evaporated and the residue is triturated in hexane. The solvent is decanted and the obtained crude is purified by preparative HPLC first, then by silica gel flash chromatography (eluent: DCM/AcOEt 9/1). Trituration with petroleum ether gives the title compound (45 mg, 15.8% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.22-7.42 (m, 4H), 7.18 (dt, 1H), 6.29 (dd, 1H), 6.12 (s, 1H), 5.48-5.81 (m, 1H), 5.40 (d, 1H), 5.27 (dd, 1H), 5.11 (dd, 1H), 3.97-4.25 (m, 1H), 3.51 (d, 1H), 3.45 (d, 1H), 3.01-3.21 (m, 1H), 2.90 (t, 1H), 2.57-2.67 (m, 1H), 2.58 (d, 1H), 2.41 (d, 1H), 2.17-2.34 (m, 1H), 1.91-2.15 (m, 2H), 1.77-1.90 (m, 1H), 1.51-1.78 (m, 3H), 1.49 (s, 3H), 1.37 (dd, 1H), 0.91 (s, 3H)
LC-MS (ESI POS): 548.31 MH+
[α]D 25+72.72 (c 0.25, CHCl3)
Example 40
Figure US08481517-20130709-C00158
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-6b-(2-fluoro-acetyl)-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid vinyl ester (compound 163) METHOD A
Compound 161 (614 mg, 1.196 mmol) and NaHCO3 (100 mg, 1.196 mmol) are dissolved in acetonitrile (12 ml) and then vinyl chloroformate (0.204 ml, 2.391 mmol) is added. The reaction mixture is warmed at 50° C. for 1 hour. The solution is partitioned between AcOEt and water. The organic phase is separated and the aqueous solution is extracted with AcOEt. The combined organic phases are dried over Na2SO4 and then evaporated to give a residue that is purified by silica gel column chromatography (eluent AcOEt:petroleum ether 2/8 to 8/2) leading to the pure title compound (411 mg, 0.833 mmol, 69.7% yield).
LC-MS (ESI POS): 494.0 MH+
Example 41
Figure US08481517-20130709-C00159
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-hydroxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid vinyl ester (164)
A solution of compound 19 (1.175 g, 2.202 mmol) in MeOH is degassed with nitrogen at 0° C. for 15 minutes, then K2CO3 (0.152 g, 1.101 mmol) is added and the mixture is stirred at 0° C. for 1 hour, then the mixture is partitioned between AcOEt and water. The aqueous phase is extracted with AcOEt and the combined organic layers are washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated to give a solid which is triturated with petroleum ether to give the title compound (1.08 g, 100%).
LC-MS (ESI POS): 492.2 (MH+)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(2-methanesulfonyloxy-acetyl)-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid vinyl ester (165)
A mixture of 164 (840 mg, 1.709 mmol), methansulfonyl chloride (160 μA, 2.051 mmol) and DIPEA (448 μl, 2.56 mmol) in DCM is stirred at RT under nitrogen overnight. The solution is partitioned between DCM and water, then the aqueous phase is extracted with DCM. The combined organic phases are washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated to give the title compound (774 mg, 80% yield).
LC-MS (ESI POS): 570.0 (MH+)
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-6b-(2-fluoro-acetyl)-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid vinyl ester (compound 163) METHOD B
A mixture of 165 (774 mg, 1.359 mmol), TBAF 1M in THF (2038 μl, 2.038 mmol) and potassium fluoride (79 mg, 1.359 mmol) in dry THF (25 ml) is stirred under nitrogen at r.t. for 2 hours, then at reflux for 1 hour 30 minutes. The mixture is partitioned between AcOEt and water, then the aqueous phase is extracted with AcOEt; the combined organic layers are washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated to give an orange oil which is purified by silica gel chromatography (eluent: DCM/MeOH 98/2) to give the title compound (185 mg, 27.6% yield).
LC-MS (ESI POS): 494.1 (MH+)
Example 42
Figure US08481517-20130709-C00160
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-6b-(2-fluoro-acetyl)-5-hydroxy-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one hydrochloride (compound 166)
Compound 163 (294 mg, 0.596 mmol) is dissolved in DCM (20 ml) and then HCl 4.0 M in dioxane (2.98 ml, 11.91 mmol) is added. The solution is stirred at RT for 5 hours and then the solvent is evaporated and the residue is dried under vacuum for 16 hours. The solid is then dissolved in methanol (30 ml) and warmed at 45° C. for 20 minutes. Methanol is evaporated to give the title compound (274 mg, 0.596 mmol, 100% yield).
LC-MS (ESI POS): 424.0 (MH+)
Example 43
Figure US08481517-20130709-C00161
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-6b-(2-fluoro-acetyl)-8-(4-fluoro-benzyl)-5-hydroxy-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 167)
A mixture of compound 166 (145 mg, 0.315 mmol), 4-fluorobenzylbromide (0.059 ml, 0.473 mmol) and TEA (0.132 ml, 0.946 mmol) in DCM (10 ml) is stirred at RT overnight. The mixture is diluted with DCM and treated with 5% NaHCO3. The organic phase is then washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated and the crude is purified by silica gel flash chromatography (eluent DCM(AcOEt 7/3 to 1/1) to yield a solid that is triturated in Et2O. Title compound (54 mg, 32.2% yield) is recovered by filtration.
1H NMR (300 MHz, DMSO-d6) ppm 7.19-7.35 (m, 3H), 7.02-7.18 (m, 2H), 6.29 (dd, 1H), 6.12 (s, 1H), 5.49-5.79 (m, 1H), 5.39 (d, 1H), 5.27 (dd, 1H), 5.10 (dd, 1H), 4.07-4.23 (m, 1H), 3.47 (d, 1H), 3.42 (d, 1H), 3.04-3.17 (m, 1H), 2.91 (t, 1H), 2.54-2.65 (m, 2H), 2.36 (d, 1H), 2.19-2.33 (m, 1H), 1.90-2.08 (m, 2H), 1.84 (d, 1H), 1.51-1.73 (m, 3H), 1.49 (s, 3H), 1.36 (dd, 1H), 0.91 (s, 3H)
LC-MS (ESI POS): 532.31 MH+
[α]D 25+62.6 (c 0.4, MeOH)
Compound listed in Table 28 is prepared using the procedure previously described for compound 167 starting from the suitable commercially available benzylbromide.
TABLE 28
Com-
pound Structure Yield Analytical
168
Figure US08481517-20130709-C00162
 		31% 1H NMR (300 MHz, DMSO-d6) ppm 7.26 (d, 1 H), 7.05 (tt, 1 H), 6.83-6.99 (m, 2 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.51-5.81 (m, 1 H), 5.29 (dd, 1 H), 5.12 (dd, 1 H), 4.07-4.25 (m, 1 H), 3.54 (d, 1 H), 3.46 (d, 1 H), 3.05-3.19 (m, 1 H), 2.92 (t, 1 H), 2.58 (d, 1 H), 2.55- 2.67 (m, 1 H), 2.43 (d, 1 H), 2.23-2.34 (m, 1 H), 1.94-2.12 (m, 2 H), 1.84 (d, 1 H), 1.51- 1.76 (m, 4 H), 1.49 (s, 3 H), 1.32-1.43 (m, 1 H), 0.92 (s, 3 H) LC-MS (ESI POS): 550.41 MH+ [a]D 25 + 68.2 (c 0.25, MeOH)
Example 44
Figure US08481517-20130709-C00163
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,3-Dimethyl-butyl)-4b,12-difluoro-6b-(2-fluoro-acetyl)-5-hydroxy-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 169)
In a closed vessel, compound 166 (180 mg, 0.391 mmol), 3,3-dimethylbutanal (0.196 ml, 1.565 mmol) and TEA (0.055 ml, 0.391 mmol) are dissolved in acetonitrile (4 ml). Formic acid (0.120 ml, 3.13 mmol) is added and the mixture is heated under microwave irradiation for 15 minutes at 140° C. LC-MS shows that the reaction is complete. The reaction mixture is diluted with AcOEt and the organic phase is washed with a saturated solution of NaHCO3 and with brine. The organic layer is dried over Na2SO4 and filtered. The solvent is evaporated to give an orange oil which is purified by preparative HPLC (acetonitrile/water, neutral phase) to yield the title compound (55 mg, 0.108 mmol, 27.7% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1H), 6.29 (dd, 1H), 6.11 (s, 1H), 5.48-5.78 (m, 1H), 5.39 (dd, 1H), 5.31 (dd, 1H), 5.07 (dd, 1H), 4.05-4.24 (m, 1H), 2.99-3.13 (m, 1H), 2.87-2.97 (m, 1H), 2.59 (d, 1H), 2.54-2.59 (m, 1H), 2.33 (d, 1H), 2.14-2.30 (m, 3H), 1.86-2.06 (m, 2H), 1.52-1.86 (m, 4H), 1.49 (s, 3H), 1.34 (dd, 1H), 1.26 (t, 2H), 0.90 (s, 3H), 0.84 (s, 9H)
LC-MS (ESI POS): 508.46 MH+
[α]D 25+64.3 (c 0.24, MeOH)
Compounds listed in Table 29 are prepared using the procedure previously described for compound 169 starting from the suitable commercially available aldehydes. For compound 173, 4-((4-hydroxyphenylthio)methyl)benzaldehyde is prepared as described in WO2009/069032 A2, which is incorporated herein by reference in its entirety.
TABLE 29
Com-
pound Structure Yield Analytical
170
Figure US08481517-20130709-C00164
 		33% 1H NMR (300 MHz, DMSO-d6) ppm 7.25 (m, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.45-5.81 (m, 1 H), 5.38-5.43 (m, 1 H), 5.34 (dd, 1 H), 5.07 (dd, 1 H), 4.12-4.19 (m, 1 H), 2.99-3.14 (m, 1 H), 2.82-2.96 (m, 1 H), 2.57 (d, 2 H), 2.33 (d, 1 H), 2.16-2.30 (m, 3 H), 1.81-2.01 (m, 3 H), 1.51-1.81 (m, 3 H), 1.49 (s, 3 H), 1.40- 1.46 (m, 1 H), 1.18-1.40 (m, 3 H), 0.91 (s, 3 H), 0.82 (d, 6 H) LC-MS (ESI POS): 494.34 MH+ [a]D 25 + 61.7 (c 0.5, MeOH)
171
Figure US08481517-20130709-C00165
 		22% 1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (d, 1 H), 6.03 (d, 1 H), 5.95 (dq, 1 H), 5.50- 5.76 (m, 1 H), 5.40-5.44 (m, 0 H), 5.29 (dd, 1 H), 5.08 (dd, 1 H), 4.08-4.20 (m, 1 H), 3.45 (d, 1 H), 3.36 (d, 1 H), 3.03-3.17 (m, 1 H), 2.96 (t, 1 H), 2.67 (d, 1 H), 2.54-2.64 (m, 1 H), 2.37 (d, 1 H), 2.22-2.31 (m, 1 H), 2.19 (s, 3 H), 1.79-2.01 (m, 4 H), 1.51-1.78 (m, 3 H), 1.49 (s, 3 H), 1.34 (dd, 1 H), 0.90 (s, 3 H) LC-MS (ESI POS): 518.4 MH+ [a]D 25 + 57.0 (c 0.34, MeOH)
172
Figure US08481517-20130709-C00166
 		39% 1H NMR (300 MHz, DMSO-d6) ppm 7.08-7.33 (m, 6 H), 6.29 (dd, 1 H), 6.10 (s, 1 H), 5.47-5.77 (m, 1 H), 5.39 (dd, 1 H), 5.31 (dd, 1 H), 5.09 (dd, 1 H), 4.08-4.22 (m, 1 H), 2.99-3.17 (m, 1 H), 2.84 (t, 1 H), 2.55-2.66 (m, 4 H), 2.41 (d, 1 H), 2.11-2.33 (m, 3 H), 1.93-2.09 (m, 2 H), 1.53-1.93 (m, 6 H), 1.49 (s, 3 H), 1.36 (dd, 1 H), 0.92 (s, 3 H) LC-MS (ESI POS): 542.31 MH+ [a]D 25 + 47.4 (c 0.3, MeOH)
173
Figure US08481517-20130709-C00167
 		30% 1H NMR (300 MHz, DMSO-d6) ppm 9.51 (br. s., 1 H), 7.26 (d, 1 H), 7.01-7.20 (m, 6 H), 6.56-6.80 (m, 2 H), 6.29 (dd, 1 H), 6.13 (s, 1 H), 5.49-5.83 (m, 1 H), 5.40 (br. s., 1 H), 5.24 (dd, 1 H), 5.09 (dd, 1 H), 4.07-4.24 (m, 1 H), 4.00 (s, 2 H), 3.35-3.49 (m, 2 H), 3.01-3.17 (m, 1 H), 2.90 (t, 1 H), 2.55-2.67 (m, 2 H), 2.36 (d, 1 H), 2.19-2.32 (m, 1 H), 1.92-2.10 (m, 2 H), 1.84 (d, 1 H), 1.51-1.75 (m, 3 H), 1.49 (s, 3 H), 1.36 (dd, 1 H), 0.91 (s, 3 H) LC-MS (ESI POS): 652.24 MH+ [a]D 25 + 68.3 (c 0.8, MeOH)
174
Figure US08481517-20130709-C00168
 		41% 1H NMR (300 MHz, DMSO-d6) ppm 7.39 (dd, 1 H), 7.26 (dd, 1 H), 6.92 (dd, 1 H), 6.89 (dd, 1 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.48-5.83 (m, 1 H), 5.38-5.45 (m, 1 H), 5.27 (dd, 1 H), 5.09 (dd, 1 H), 4.02-4.22 (m, 1 H), 3.68 (s, 2 H), 3.03-3.19 (m, 1 H), 2.92 (t, 1 H), 2.54-2.64 (m, 2 H), 2.39-2.47 (m, 1 H), 2.20-2.36 (m, 1 H), 2.14 (dd, 1 H), 1.92-2.06 (m, 1 H), 1.84 (d, 1 H), 1.51-1.76 (m, 3 H), 1.49 (s, 3 H), 1.38 (dd, 1 H), 0.91 (s, 3 H) LC-MS (ESI POS): 520.23 MH+ [a]D 25 + 77.1 (c 0.4, MeOH)
175
Figure US08481517-20130709-C00169
 		32% 1H NMR (300 MHz, DMSO-d6) □ ppm 7.26 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.47-5.78 (m, 1 H), 5.38- 5.42 (m, 0 H), 5.29 (dd, 1 H), 5.07 (dd, 1 H), 4.03-4.25 (m, 1 H), 2.97-3.14 (m, 1 H), 2.79 (dd, 1 H), 2.54-2.60 (m, 1 H), 2.40-2.48 (m, 2 H), 2.18-2.33 (m, 1 H), 1.93- 2.17 (m, 4 H), 1.83-1.92 (m, 1 H), 1.51-1.83 (m, 3 H), 1.49 (s, 3 H), 1.09-1.46 (m, 7 H), 0.91 (s, 3 H), 0.78 (t, 6 H) LC-MS (ESI POS): 508.30 MH+ [a]D 25 + 43.2 (c 0.22, MeOH)
Example 45
Figure US08481517-20130709-C00170
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid vinyl ester (compound 176)
In a closed vessel, a mixture of compound 165 (592 mg, 1.039 mmol) and sodium iodide (2181 mg, 14.55 mmol) in acetone (25 ml) is heated under microwave irradiation for 3 hours at 110° C. The reaction mixture is partitioned between AcOEt and a 5% solution of Na2S2O5. The organic phase is washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated to give the title compound (495 mg, 100%).
LC-MS (ESI POS): 476.0 MH+
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one hydrochloride (compound 177)
A solution of compound 176 (495 mg, 1.041 mmol) and HCl 4M in dioxane (5205 μl, 20.82 mmol) in DCM (20 ml) is stirred at RT for 30 minutes. The solvent is evaporated and the crude is dried in vacuo for 16 hours. The crude is dissolved in MeOH (30 ml) and stirred at 45° C. for 30 minutes. The solvent is evaporated and the crude is triturated with AcOEt/Et2O (1/1 mixture) to afford the title compound (457 mg, 99%).
LC-MS (ESI POS): 406.0 MH+
Example 46
Figure US08481517-20130709-C00171
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-8-(3-chloro-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 178)
A mixture of compound 177 (143 mg, 0.324 mmol), 1-(bromomethyl)-3-chlorobenzene (55.1 μl, 0.421 mmol) and TEA (113 μl, 0.809 mmol) in DCM (10 ml) is stirred under nitrogen at RT overnight. The crude is purified by silica gel chromatography (eluent: AcOEt/petroleum ether 1/1) and by trituration with diisopropylether to afford (79 mg, 46.1% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.11-7.43 (m, 5H), 6.30 (dd, 1H), 6.13 (s, 1H), 5.64-5.84 (m, 1H), 5.41 (dd, 1H), 4.17 (dd, 1H), 3.47 (s, 2H), 3.05-3.22 (m, 1H), 2.71-2.85 (m, 2H), 2.53-2.62 (m, 2H), 2.20-2.35 (m, 1H), 2.11 (d, 2H), 2.08 (s, 3H), 1.69-1.94 (m, 2H), 1.51-1.69 (m, 2H), 1.49 (s, 3H), 1.27-1.40 (m, 1H), 0.87 (s, 3H)
LC-MS (ESI POS): 530.25 MH+
[α]D 25+62.69 (c 0.26, MeOH)
Compound listed in Table 30 is prepared using the procedure previously described for compound 178 starting from the suitable commercially available benzylhalide.
TABLE 30
Com-
pound Structure Yield Analytical
179
Figure US08481517-20130709-C00172
 		47% 1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1 H), 7.04 (tt, 1 H), 6.79-6.98 (m, 2 H), 6.30 (dd, 1 H), 6.13 (s, 1 H), 5.49-5.80 (m, 1 H), 5.40 (dd, 1 H), 4.05-4.35 (m, 1 H), 3.49 (s, 2 H), 3.04-3.21 (m, 1 H), 2.69-2.88 (m, 1 H), 2.54-2.66 (m, 3 H), 2.21-2.36 (m, 1 H), 2.12 (dd, 1 H), 2.09 (s, 3 H), 2.00-2.07 (m, 1 H), 1.72-1.92 (m, 2 H), 1.51-1.68 (m, 2 H), 1.49 (s, 3 H), 1.27-1.39 (m, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 532.3 MH+ [a]D 25 + 69.7 (c 0.28, MeOH)
Example 47
Figure US08481517-20130709-C00173
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-6b-Acetyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-8-(5-methyl-furan-2-ylmethyl)-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 180)
In a closed vessel, a mixture of compound 177 (306 mg, 0.692 mmol), 5-methylfurfural (344 μl, 3.46 mmol), TEA (97 μl, 0.692 mmol) and formic acid (266 μl, 6.92 mmol) in acetonitrile (15 ml) is heated under microwave irradiation for 15 minutes at 140° C. LC-MS shows that the reaction is complete. The solution is partitioned between AcOEt and a saturated solution of NaHCO3, the aqueous phase is extracted with AcOEt and the combined organic layers are washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated to give a oil which is purified by silica gel chromatography (eluent AcOEt/petroleum ether 1/1). Trituration with petroleum ether affords the title compound (236 mg, 0.472 mmol, 68.2% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1H), 6.30 (dd, 1H), 6.12 (s, 1H), 6.02 (d, 1H), 5.94 (dq, 1H), 5.63 (m, 1H), 5.41 (dd, 1H), 4.09-4.24 (m, 1H), 3.43 (d, 1H), 3.33 (d, 1H), 3.02-3.20 (m, 1H), 2.81 (t, 1H), 2.64 (d, 1H), 2.39-2.47 (m, 2H), 2.20-2.34 (m, 1H), 2.19 (s, 3H), 2.09 (s, 3H), 1.93-2.06 (m, 2H), 1.74-1.93 (m, 2H), 1.49 (s, 3H), 1.39-1.65 (m, 2H), 1.30 (dd, 1H), 0.85 (s, 3H)
LC-MS (ESI POS): 500.32 MH+
[α]D 25+49.17 (c 2.4, MeOH)
Compounds listed in Table 31 are prepared using the procedure previously described for compound 180 starting from the suitable commercially available aldehydes.
TABLE 31
Com-
pound Structure Yield Analytical
181
Figure US08481517-20130709-C00174
 		61% 1H NMR (300 MHz, DMSO-d6) ppm 7.26 (dd, 1 H), 6.29 (dd, 1 H), 6.11 (s, 1 H), 5.45-5.84 (m, 1 H), 5.40 (d, 1 H), 4.18 (dd, 1 H), 3.05-3.13 (m, 1 H), 2.67-2.75 (m, 1 H), 2.39-2.48 (m, 2 H), 2.16-2.30 (m, 3 H), 2.10 (s, 3 H), 1.94-2.14 (m, 2 H), 1.87 (br. s., 2 H), 1.49 (s, 3 H), 1.42-1.58 (m, 2 H), 1.21-1.34 (m, 4 H), 0.86 (br. s., 3 H), 0.84 (s, 9 H) LC-MS (ESI POS): 490.38 MH+ [a]D 25 + 51.48 (c 0.31, MeOH)
182
Figure US08481517-20130709-C00175
 		50% 1H NMR (300 MHz, DMSO-d6) ppm 7.27 (dd, 1 H), 6.29 (dd, 1 H), 6.1 (s, 1 H), 5.46-5.81 (m, 1 H), 5.40 (dd, 1 H), 4.02-4.30 (m, 1 H), 3.01-3.15 (m, 1 H), 2.65-2.73 (m, 1 H), 2.53-2.60 (m, 1 H), 2.43-2.47 (m, 2 H), 2.15-2.31 (m, 3 H), 2.10 (s, 3 H), 1.82-2.07 (m, 4 H), 1.51-1.67 (m, 2 H), 1.49 (s, 3 H), 1.39-1.47 (m, 1 H), 1.16-1.34 (m, 3 H), 0.86 (s, 3 H), 0.83 (d, 3 H), 0.82 (d, 3 H) LC-MS (ESI POS): 476.29 MH+ [a]D 25 + 68.32 (c 0.25, MeOH)
183
Figure US08481517-20130709-C00176
 		45% 1H NMR (300 MHz, DMSO-d6) ppm 7.19-7.31 (m, 3 H), 7.05-7.18 (m, 3 H), 6.29 (dd, 1 H), 6.10 (s, 1 H), 5.48-5.80 (m, 1 H), 5.41 (dd, 1 H), 3.98-4.31 (m, 1 H), 2.93-3.20 (m, 1 H), 2.64 (dd, 1 H), 2.53-2.59 (m, 4 H), 2.41 (d, 1 H), 2.13-2.35 (m, 3 H), 2.10 (s, 3 H), 1.96-2.09 (m, 2 H), 1.86-1.95 (m, 2 H), 1.52-1.72 (m, 3 H), 1.49 (s, 3 H), 1.39-1.48 (m, 1 H), 1.32 (dd, 1 H), 0.87 (s, 3 H) LC-MS (ESI POS): 524.33 MH+ [a]D 25 + 59.4 (c 0.24, MeOH)
184
Figure US08481517-20130709-C00177
 		47% 1H NMR (300 MHz, DMSO-d6) ppm 7.38 (dd, 1 H), 7.27 (dd, 1 H), 6.92 (dd, 1 H), 6.88 (m, 1 H), 6.30 (dd, 1 H), 6.13 (s, 1 H), 5.46-5.82 (m, 1 H), 5.40 (d, 1 H), 4.01-4.32 (m, 1 H), 3.65 (s, 2 H), 3.03-3.22 (m, 1 H), 2.69-2.86 (m, 1 H), 2.54-2.63 (m, 2 H), 2.38-2.46 (m, 1 H), 2.25-2.35 (m, 1 H), 2.20 (dd, 1 H), 2.07 (s, 3 H), 1.99-2.06 (m, 1 H), 1.70-1.96 (m, 2 H), 1.51-1.67 (m, 2 H), 1.49 (s, 3 H), 1.34 (dd, 1 H), 0.86 (s, 3 H) LC-MS (ESI POS): 502.22 MH+ [a]D 25 + 92.8 (c 0.25, MeOH)
Example 48
Figure US08481517-20130709-C00178
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-4a,6a-dimethyl-6b-(2-methylsulfanyl-acetyl)-2-oxo-2,4b,5,6,6a,6b,7,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-8-carboxylic acid vinyl ester (compound 185)
A mixture of compound 164 (203 mg, 0.413 mmol), methansulfonyl chloride (38.6 μl, 0.496 mmol) and DIPEA (108 μl, 0.620 mmol) in dry DMF (3 ml) is stirred at RT under nitrogen for 1 hour. Further methansulfonyl chloride (16.09 μl, 0.207 mmol) and DIPEA (54.1 μl, 0.310 mmol) are added and the mixture is stirred at RT for 2 hours. Sodiumethanethiolate (87 mg, 1.239 mmol) is added and the mixture is stirred at RT for 16 hours. The reaction the mixture is partitioned between AcOEt and brine, then the aqueous phase is extracted with AcOEt and the combined organic layers are washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated to give a oil which is purified by silica gel chromatography (eluent: AcOEt/petroleum ether 2/3) to afford the title compound (118 mg, 0.226 mmol, 54.8% yield).
LC-MS (ESI POS): 544.3 M+Na+
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-4a,6a-dimethyl-6b-(2-methylsulfanyl-acetyl)-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one hydrochloride (compound 186)
A mixture of compound 185 (122 mg, 0.234 mmol) and HCl 4M in Dioxane (2 ml, 8.00 mmol) in DCM (10 ml) is stirred at RT for 2 hours, then the solvent is evaporated and the crude is dried in vacuo for 16 hours. MeOH (15 ml) is added and the solution is stirred at 45° C. for 20 minutes. The solvent is evaporated to afford the title compound (106 mg, 93% yield).
LC-MS (ESI POS): 452.3 MH+
Example 49
Figure US08481517-20130709-C00179
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-6b-(2-methylsulfanyl-acetyl)-4b,5,6,6a,6b,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthren-2-one (compound 187)
A solution of compound 186 (103 mg, 0.211 mmol), 3-chorobenzylbromide (66.0 μl, 0.317 mmol) and TEA (88 μl, 0.633 mmol) in DCM (10 ml) is stirred under nitrogen at RT for 16 hours. The solution is diluted with DCM and washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated and the crude is purified by silica gel chromatography (eluent: DCM/MeOH 99/1). Trituration with petroleum ether affords the title compound (36 mg, 29.6% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.04-7.40 (m, 5H), 6.29 (dd, 1H), 6.12 (s, 1H), 5.45-5.80 (m, 1H), 5.39 (dd, 1H), 4.08-4.25 (m, 1H), 3.63 (d, 1H), 3.41-3.54 (m, 3H), 3.08-3.24 (m, 1H), 2.89 (t, 1H), 2.61 (d, 1H), 2.56-2.61 (m, 1H), 2.44 (d, 1H), 2.22-2.36 (m, 1H), 2.06-2.16 (m, 2H), 2.05 (s, 3H), 1.52-1.94 (m, 4H), 1.49 (s, 3H), 1.35 (dd, 1H), 0.90 (s, 3H)
LC-MS (ESI POS): 576.21 MH+
[α]D 25+83.36 (c 0.28, MeOH)
Example 50
Figure US08481517-20130709-C00180
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3,3-Dimethyl-butyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-fluoromethyl ester (compound 188)
A mixture of compound 102 (177 mg, 0.360 mmol), HATU (151 mg, 0.396 mmol) and N-methylmorpholine (0.044 ml, 0.396 mmol) in dry DMF (4 ml) is stirred at 60° C. under nitrogen for 40 minutes. After cooling to RT, anhydrous sodium hydrogensulfide (60.6 mg, 1.080 mmol) is added and the solution is stirred at RT for 1 hour. Bromofluoromethane (0.360 ml, 0.720 mmol, solution 2M in DMF) is added and the mixture is stirred at RT for 1 hour. The reaction mixture is partitioned between AcOEt and brine, the aqueous phase is extracted with AcOEt and the combined organic layers are dried over Na2SO4 and filtered. After evaporation of the solvent, the crude is purified by preparative HPLC (CH3CN/H2O, No CF3COOH) to afford the title compound (52 mg, 0.096 mmol, 26.8% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.25 (dd, 1H), 6.30 (dd, 1H), 6.11 (s, 1H), 5.94 (dd, 1H), 5.89 (dd, 1H), 5.54-5.76 (m, 1H), 5.53 (dd, 1H), 4.06-4.25 (m, 1H), 3.11-3.24 (m, 1H), 2.97 (t, 1H), 2.83 (d, 1H), 2.55-2.62 (m, 1H), 2.38 (d, 1H), 2.19-2.31 (m, 3H), 1.88-2.06 (m, 3H), 1.53-1.82 (m, 2H), 1.49 (s, 3H), 1.31-1.47 (m, 2H), 1.20-1.30 (m, 2H), 0.95 (s, 3H), 0.84 (s, 9H).
LC-MS (ESI POS): 540.6 MH+
[α]D 25+68.6 (c 0.34, MeOH)
Compounds listed in Table 32 are prepared using the procedure previously described for compound 188 starting from the suitable carboxylic acids 99,100,101 previously described.
TABLE 32
Com-
pound Structure Yield Analytical
189
Figure US08481517-20130709-C00181
 		30% 1H NMR (300 MHz, DMSO-d6) ppm 7.25 (dd, 1 H), 6.30 (dd, 1 H), 6.11 (s, 1 H), 5.94 (dd, 1 H), 5.89 (dd, 1 H), 5.53-5.77 (m, 1 H), 5.53 (dd, 1 H), 4.10-4.28 (m, 1 H), 3.13-3.25 (m, 1 H), 2.95 (t, 1 H), 2.82 (d, 1 H), 2.56-2.67 (m, 1 H), 2.38 (d, 1 H), 2.17-2.31 (m, 3 H), 1.88-2.09 (m, 3 H), 1.52-1.84 (m, 5 H), 1.49 (s, 3 H), 1.36 (dd, 1 H), 1.18-1.29 (m, 1 H), 0.95 (s, 3 H), 0.82 (d, 6 H) LC-MS (ESI POS): 526.39 MH+ [a]D 25 + 59.17 (c 0.29, CHCl3)
190
Figure US08481517-20130709-C00182
 		23% 1H NMR (300 MHz, DMSO-d6) ppm 7.25 (dd, 1 H), 6.30 (dd, 1 H), 6.12 (s, 1 H), 6.04 (d, 1 H), 5.94 (dq, 1 H), 5.94 (dd, 1 H), 5.89 (dd, 1 H), 5.55-5.74 (m, 1 H), 5.53 (dd, 1 H), 4.07-4.26 (m, 1 H), 3.45 (d, 1 H), 3.38 (d, 1 H), 3.15-3.25 (m, 1 H), 3.02 (t, 1 H), 2.93 (d, 1 H), 2.56-2.68 (m, 1 H), 2.42 (d, 1 H), 2.21-2.33 (m, 1 H), 2.18 (d, 3 H), 1.89-2.06 (m, 3 H), 1.52-1.77 (m, 3 H), 1.49 (s, 3 H), 1.30-1.42 (m, 1 H), 0.94 (s, 3 H) LC-MS (ESI POS): 550.25 MH+ [a]D 25 + 61.7 (c 0.45, MeOH)
191
Figure US08481517-20130709-C00183
 		20% 1H NMR (300 MHz, DMSO-d6) ppm 7.25 (dd, 1 H), 7.05 (tt, 1 H), 6.83-6.98 (m, 2 H), 6.30 (dd, 1 H), 6.13 (s, 1 H), 5.96 (dd, 1 H), 5.91 (dd, 1 H), 5.54-5.78 (m, 1 H), 5.52 (dd, 1 H), 4.01-4.25 (m, 1 H), 3.59 (d, 1 H), 3.46 (d, 1 H), 3.20-3.26 (m, 1 H), 3.03 (t, 1 H), 2.83 (d, 1 H), 2.56-2.70 (m, 1 H), 2.43 (d, 1 H), 2.21-2.37 (m, 1 H), 1.89-2.13 (m, 3 H), 1.51-1.76 (m, 3 H), 1.49 (s, 3 H), 1.41 (dd, 1 H), 0.96 (s, 3 H) LC-MS (ESI POS): 582.4 MH+ [a]D 25 + 84.15 (c0.26,CHCl3)
Example 51
Figure US08481517-20130709-C00184
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-chloromethyl ester (compound 192) METHOD A
A mixture of compound 95 (600 mg, 1.128 mmol), HATU (472 mg, 1.241 mmol) and N-methylmorpholine (124 μl, 1.128 mmol) in dry DMF (10 ml) is stirred at 70° C. for 3 hours. Further HATU (86 mg, 0.226 mmol) is added and the reaction mixture is stirred at 70° C. for 1 hour. After cooling to RT, anhydrous sodiumhydrogensulfide (190 mg, 3.38 mmol) is added. The resulting solution is stirred at RT for 3 h, then bromochloromethane (220 μl, 3.38 mmol) is added and the resulting mixture is stirred at RT for 48 hours. The reaction mixture is partitioned between AcOEt and brine; the aqueous phase is separated and extracted with AcOEt. The combined organic layers are washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated to give an oil which is purified by silica gel chromatography (DCM/AcOEt 95/5) to afford the title compound (164 mg, 24.3%).
1H NMR (300 MHz, DMSO-d6) ppm 7.27 (d, 1H) 7.15-7.35 (m, 4H) 6.29 (dd, 1H) 6.12 (s, 1H) 5.54-5.84 (m, 1H) 5.52 (d, 1H) 5.17 (s, 2H) 4.08-4.26 (m, 1H) 3.51-3.64 (m, 1H) 3.37-3.47 (m, 1H) 3.18-3.24 (m, 1H) 3.04 (t, 1H) 2.80 (d, 1H) 2.62 (d, 1H) 2.38 (d, 1H) 2.22-2.33 (m, 1H) 1.96-2.12 (m, 2H) 1.90 (d, 1H) 1.52-1.82 (m, 3H) 1.49 (s, 3H) 1.40 (dd, 1H) 0.97 (s, 3H).
LC-MS (ESI POS): 596.23 MH+
[α]D 25+86.9 (c 0.2, CHCl3)
Compound listed in Table 33 is prepared using the procedure previously described for compound 192 starting from compound 93 previously described.
TABLE 33
Com-
pound Structure Yield Analytical
195
Figure US08481517-20130709-C00185
 		70% LC-MS (ESI POS): 562.1 MH+
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-iodomethyl ester (compound 193)
A mixture of compound 192 (220 mg, 0.369 mmol) and sodium iodide (498 mg, 3.32 mmol) in acetone (20 ml) is stirred at reflux for 6 hours, at RT overnight, then at reflux for 8 hours, and at RT overnight. The reaction mixture is partitioned between AcOEt and a 5% solution of Na2S2O5. The aqueous phase is extracted with AcOEt and the combined organic layers are washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated affording the title compound (240 mg, 95% yield). The crude is not purified any further.
LC-MS (ESI POS): 596.23 MH+
Compound listed in Table 34 is prepared using the procedure previously described for compound 193 starting from compound 195 previously described.
TABLE 34
Com-
pound Structure Yield Analytical
196
Figure US08481517-20130709-C00186
 		81 % LC-MS (ESI POS): 654.2 MH+
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-fluoromethyl ester trifluoroacetate (compound 194)
A mixture of compound 193 (240 mg, 0.349 mmol) and AgF (89 mg, 0.698 mmol) in dry acetonitrile (15 ml) is stirred at RT in the dark under nitrogen for 1 hour and 30 minutes. The reaction mixture is decanted and the residual Ag salts are washed several times with dioxane. The organic layers are combined and the solvent is evaporated. The resulting crude is purified by preparative HPLC to give the title compound (20 mg, 0.029 mmol, 8.26% yield).
1H NMR (300 MHz, DMSO-d6 Na2CO3) ppm 7.21-7.38 (m, 4H), 7.17 (dt, 1H), 6.29 (dd, 1H), 6.12 (s, 1H), 5.96 (dd, 1H), 5.90 (dd, 1H), 5.47-5.77 (m, 1H), 4.10-4.23 (m, 1H), 3.56 (d, 1H), 3.45 (d, 1H), 2.95-3.05 (m, 1H), 2.83 (d, 1H), 2.56-2.62 (m, 1H), 2.42 (d, 1H), 2.22-2.32 (m, 1H), 1.87-2.14 (m, 3H), 1.53-1.76 (m, 4H), 1.49 (s, 3H), 1.35-1.45 (m, 1H), 0.96 (s, 3H)
LC-MS (ESI POS): 580.27 MH+
Compound listed in Table 35 is prepared using the procedure previously described for compound 194 starting from compound 196 previously described. The reaction is quenched with HCl in dioxane before purification by preparative HPLC.
TABLE 35
Com-
pound Structure Yield Analytical
197
Figure US08481517-20130709-C00187
 		11% 1H NMR (300 MHz, DMSO-d6) ppm 10.19 (br. s., 1 H) 7.32-7.62 (m, 5 H) 7.26 (d, 1 H) 6.32 (d, 1 H) 6.14 (s, 1 H) 5.96 (d, 2 H) 5.45- 5.81 (m, 2 H) 4.27-4.66 (m, 2 H) 4.09-4.27 (m, 1 H) 3.53-4.01 (m, 3 H) 3.40-3.50 (m, 1 H) 2.78-3.12 (m, 1 H) 2.55-2.68 (m, 2 H) 2.23-2.40 (m, 1 H) 1.98-2.24 (m, 1 H) 1.92 (d, 1 H) 1.54-1.83 (m, 3 H) 1.50 (s, 3 H) 0.95 (s, 3 H) LC-MS (ESI POS): 546.3 MH+
Example 52
Figure US08481517-20130709-C00188
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,12S)-8-Benzyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-chloromethyl ester (compound 195) METHOD B
A mixture of compound 93 (257 mg, 0.517 mmol), HATU (196 mg, 0.517 mmol) and N-methylmorpholine (56.8 μl, 0.517 mmol) in dry DMF (5 ml) is stirred at 70° C. under nitrogen for 1 hour. Further HATU (40 mg, 0.105 mmol) is added and the resulting mixture is stirred at 70° C. for 30 minutes. The solution is cooled to RT and it is poured into a solution of thioacetic acid (74.2 μl, 1.033 mmol) in dry DMF (2 ml). The resulting solution is stirred at RT under nitrogen for 2 hours. Potassium thioacetate (59.0 mg, 0.517 mmol) is added and the mixture is stirred at RT for 2 hours. NaHCO3 (87 mg, 1.033 mmol) and bromochloromethane (101 μl, 1.550 mmol) are added. The resulting mixture is stirred at RT under nitrogen overnight. The reaction mixture is partitioned between AcOEt and brine; the aqueous phase is extracted with AcOEt and the combined organic layers are washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated and the crude is purified by silica gel chromatography (AcOEt/petroleum ether 3/7) to give a solid which is further triturated with petroleum ether to afford the title compound (32 mg, 10.9%).
1H NMR (300 MHz, DMSO-d6) ppm 7.08-7.47 (m, 6H) 6.29 (dd, 1H) 6.12 (s, 1H) 5.54-5.77 (m, 1H) 5.52 (d, 1H) 5.17 (s, 2H) 4.03-4.24 (m, 1H) 3.55 (d, 1H) 3.41 (d, 1H) 3.18-3.24 (m, 1H) 3.02 (t, 1H) 2.79 (d, 1H) 2.61-2.69 (m, 1H) 2.31-2.44 (m, 1H) 2.28 (s, 1H) 1.83-2.14 (m, 3H) 1.51-1.76 (m, 3H) 1.49 (s, 3H) 1.33-1.45 (m, 1H) 0.97 (s, 3H).
LC-MS (ESI POS): 562.18 MH+
[α]D 25+94.48 (c 0.29, MeOH)
Example 53
Figure US08481517-20130709-C00189
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-(3-Chloro-benzyl)-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-(2-oxo-propyl) ester (compound 198)
A mixture of compound 95 (200 mg, 0.376 mmol), HATU (172 mg, 0.451 mmol) and N-methylmorpholine (41.3 μl, 0.376 mmol) in dry DMF (4 ml) is stirred at 70° C. for 1 hour; after cooling to RT anhydrous sodiumhydrogensulfide (63.2 mg, 1.128 mmol) is added and the mixture is stirred at RT for 3 hours. Chloroacetone (60.0 μl, 0.752 mmol) is added and a solid precipitates immediately. The mixture is partitioned between AcOEt and brine. The aqueous phase is extracted with AcOEt and then the combined organic layers are washed with brine, dried over Na2SO4 and filtered. The solvent is evaporated to give a oil which is purified by silica gel chromatography (AcOEt/petroleum ether 2/3) and then triturated with AcOEt and petroleum ether (1/9 mixture) to afford the title compound (140 mg, 61.6% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.01-7.42 (m, 5H), 6.29 (dd, 1H), 6.12 (s, 1H), 5.52-5.79 (m, 1H), 5.50 (dd, 1H), 4.09-4.22 (m, 1H), 3.85 (s, 2H), 3.56 (d, 1H), 3.42 (d, 1H), 3.13-3.24 (m, 1H), 2.98 (t, 1H), 2.80 (d, 1H), 2.55-2.67 (m, 1H), 2.42 (d, 1H), 2.23-2.34 (m, 1H), 2.20 (s, 3H), 1.85-2.13 (m, 3H), 1.53-1.77 (m, 3H), 1.49 (s, 3H), 1.38 (dd, 1H), 0.96 (s, 3H)
LC-MS (ESI POS): 604.27 MH+
[α]D 25+79.04 (c 0.23, MeOH)
Compounds listed in Table 36 are prepared by the procedure previously described for compound 198 starting from the proper carboxylic acid previously described (93, 95) and using the suitable commercially available alkylhalide as the alkylating agent (for 201 alkylation occurs in the presence of NaHCO3).
TABLE 36
Com-
pound Structure Yield Analytical
199
Figure US08481517-20130709-C00190
 		33% 1H NMR (300 MHz, DMSO-d6) ppm 7.10-7.41 (m, 5 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.51-5.80 (m, 1 H), 5.49 (dd, 1 H), 4.50 (dt, 2 H), 4.07-4.25 (m, 1 H), 3.58 (d, 1 H), 3.41 (d, 1 H), 3.15-3.26 (m, 3 H), 3.00 (t, 1 H), 2.81 (d, 1 H), 2.55-2.69 (m, 1 H), 2.39 (d, 1 H), 2.20-2.34 (m, 1 H), 1.87-2.13 (m, 3 H), 1.60-1.79 (m, 2 H), 1.53- 1.61 (m, 1 H), 1.49 (s, 3 H), 1.35-1.44 (m, 1 H), 0.95 (s, 3 H) LC-MS (ESI POS): 594.25 MH+ [a]D 25 + 93.57 (c 0.23, CHCl3)
200
Figure US08481517-20130709-C00191
 		65% 1H NMR (300 MHz, DMSO-d6) ppm 7.21-7.37 (m, 4 H), 7.16-7.22 (m, 1 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.54 (dd, 1 H), 5.50-5.78 (m, 1 H), 4.10-4.25 (m, 1 H), 4.03 (s, 2 H), 3.57 (d, 1 H), 3.44 (d, 1 H), 3.18-3.25 (m, 1 H), 3.04 (t, 1 H), 2.81 (d, 1 H), 2.56-2.68 (m, 1 H), 2.40 (d, 1 H), 2.21-2.34 (m, 1 H), 1.95-2.14 (m, 2 H), 1.90 (d, 1 H), 1.52-1.77 (m, 3 H), 1.49 (s, 3 H), 1.41 (dd, 1 H), 0.97 (s, 3 H) LC-MS (ESI POS): 587.17 MH+ [a]D 25 + 63.05 (c 0.21, MeOH)
201
Figure US08481517-20130709-C00192
 		22% 1H NMR (300 MHz, DMSO-d6) ppm 7.08-7.44 (m, 6 H) 6.29 (dd, 1 H) 6.13 (s, 1 H) 5.56-5.80 (m, 1 H) 5.53 (d, 1 H) 4.14 (d, 1 H) 4.02 (s, 2 H) 3.55 (d, 1 H) 3.42 (d, 1 H) 3.13-3.24 (m, 1 H) 3.05 (t, 1 H) 2.81 (d, 1 H) 2.60-2.67 (m, 1 H) 2.37 (d, 1 H) 2.24-2.32 (m, 1 H) 1.97-2.12 (m, 2 H) 1.90 (d, 1 H) 1.53-1.80 (m, 3 H) 1.49 (s, 3 H) 1.34-1.46 (m, 1 H) 0.97 (s, 3 H) LC-MS (ESI POS): 553.22 MH+ [a]D 25 + 101.0 (c 0.23, MeOH)
Example 54
Figure US08481517-20130709-C00193
Preparation of (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-8-Benzyl-4b,12-difluoro-5-hydroxy-4a,6a-dimethyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,10,10a,10b,11,12-tetradecahydro-4aH-8-aza-pentaleno[2,1-a]phenanthrene-6b-carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester (compound 202)
A solution of compound 93 and 1,1-carbonyldiimidazole (74.3 mg, 0.458 mmol) in dry DMF (3 ml) is stirred under nitrogen at RT for 1 hour and at 65° C. for 1 hour 30 minutes. The mixture is cooled to RT and 4-dimethylaminopyridine (46.7 mg, 0.382 mmol) and a solution of 3-mercaptodihydrofuran-2(3H)-one (54.1 mg, 0.458 mmol) in dry DMF (1.2 ml) are added. The mixture is stirred at RT for 1 hour then at 70° C. for 48 hours. The mixture is diluted with AcOEt and washed with brine. The organic phase is dried over Na2SO4 and filtered. The solvent is evaporated to give a brown oil which is purified by silica gel chromatography (AcOEt/petroleum ether 45/55) to afford the title compound (30 mg, 0.050 mmol, 13.14% yield).
1H NMR (300 MHz, DMSO-d6) ppm 7.10-7.39 (m, 6H), 6.29 (dd, 1H), 6.12 (s, 1H), 5.54-5.80 (m, 1H), 5.48-5.54 (m, 1H), 4.23-4.50 (m, 3H), 4.08-4.19 (m, 1H), 3.57 (d, 1H), 3.39 (d, 1H), 3.12-3.25 (m, 1H), 3.00 (t, 1H), 2.79 (d, 1H), 2.60-2.71 (m, 1H), 2.32-2.44 (m, 1H), 2.09-2.32 (m, 3H), 1.82-2.12 (m, 3H), 1.52-1.78 (m, 3H), 1.49 (s, 3H), 1.32-1.44 (m, 1H), 0.98 and 0.99 (s, 3H)
LC-MS (ESI POS): 598.27 MH+
Compound listed in Table 37 is prepared by the procedure previously described for compound 202 using the commercially available sodiumethanthiolate (DMAP is not used in this case).
TABLE 37
Com-
pound Structure Yield Analytical
203
Figure US08481517-20130709-C00194
 		15% 1H NMR (300 MHz, DMSO-d6) ppm 7.08-7.34 (m, 6 H), 6.29 (dd, 1 H), 6.12 (s, 1 H), 5.50-5.80 (m, 1 H), 5.47 (br. s., 1 H), 4.09-4.23 (m, 1 H), 3.52 (d, 1 H), 3.40 (d, 1 H), 3.16-3.25 (m, 1 H), 2.95 (t, 1 H), 2.85 (qd, 2 H), 2.77 (d, 1 H), 2.38 (d, 1 H), 2.21-2.33 (m, 1 H), 1.98-2.10 (m, 2 H), 1.95 (d, 1 H), 1.51-1.72 (m, 4 H), 1.49 (s, 3 H), 1.37 (dd, 1 H), 1.19 (t, 3 H), 0.94 (s, 3 H) LC-MS (ESI POS): 542.12 MH+ [a]D 25 + 93.8 (MeOH, c 0.3)
Legend
*NMR
s = singlet
d = doublet
t = triplet
q = quartet
dd = doublet of doublets
m = multiplet
br = broad
Pharmacological Activity of the Compounds of the Invention In Vivo Studies Example 55 Lipopolysaccharide (LPS)-Induced Lung Neutrophilia
The potency of the compounds described in the present invention was evaluated in vivo in an acute model of lung inflammation following a method described by A. Miller-Larsson and coworkers (Am. J. Respir. Crit. Care Med., vol 162. pp, 1455-1461, 2000, which is incorporated herein by reference in its entirety) with minor modifications. The tests were performed on Sprague-Dawley male rats (200 g). Intratracheal instillation of LPS resulted in a statistically significant increase in neutrophil concentration in BALF, a hallmark of acute ongoing pulmonary inflammation.
For the dose of glucocorticoid producing a 75% inhibition (ED75 dose) assessment test, compounds (0.01-3 μmoles/Kg of body weight) were administered intratracheally as suspension (0.2% Tween 80 in NaCl 0.9%) 1 hour before LPS challenge. A dose-response curve of the inhibitory effect of the test compounds on LPS-induced lung neutrophilia was performed and the ED75 dose of glucocorticoid was taken as a measure of potency in this bioassay. The ED75 dose values for the most potent compounds described in this patent are comprised between 0.2 and 1.5 μmoles/Kg of body weight.
In Vitro Studies Example 56 Glucocorticoid Receptor (GR) Translocation Assay Protocol
A quantitative measurement of GR nuclear translocation of the compounds of the present invention was performed according to ASSAY Drug Devel. Technol., 4(3), 263-272, 2006, which is incorporated herein by reference in its entirety, through a novel cell-based GR-translocation assay in Enzyme Fragment Complementation (EFC) format developed by DiscoveRx (Fremont, Calif.). The DiscoveRx assay uses EFC of b-galactosidase (b-gal) as an indicator of GR-translocation in engineered CHO-K1 biosensor cells. The enzyme acceptor (EA) fragment of b-gal resides in the nucleus, as designed through the use of a proprietary set of sequence additions and modifications. The small peptide enzyme donor (ED) fragment of b-gal is fused directly to the C-terminus of GR, and is localized in the cytoplasm is the absence of receptor signaling. Upon binding to a GR ligand, the complex translocates to the nucleus, where intact enzyme activity is restored by complementation and b-gal activity is detected.
CHO-K1 cells stably expressing NLS-enzyme acceptor fragment (EA) of b-gal and GR-enzyme donor (ED) fragment of b-gal were maintained in F12 medium (Invitrogen, Carlsbad, Calif.) at 37° C. under a humidified atmosphere containing 5% CO2 and 95% air. The medium contained 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin 50 μg/ml streptomycin, and 250 μg/ml hygromycin and 500 μg/ml G418 (Invitrogen).
GR-translocation was measured using the PathHunter Detection Kit containing cell membrane permeabilizing reagent and beta-gal substrate (DiscoveRx, Fremont, Calif.). All compounds were screened using varying concentrations ranging from 10−11 to 10−6 M. The assay was performed in 48-wells (105 cells/well). Incubation with screened compounds was performed at 37° C. for two hours. Detection was made by adding the detection buffer from the kit supplied by DiscoveRx and incubating at RT for one hour. Luminescence was detected by using a CENTRO LB 960 microplate reader (Berthold Technologies). Statistical analysis and determinations of EC50s were performed by using Prism-version 3.0 Graphpad Software (San Diego, Calif.). The compounds assayed with the GR translocation assay displayed a EC50 comprised between 1 nM and 20 nM.
Example 57 Inhibition of LPS-Induced Nitric Oxide Production in RAW 264.7 Macrophages
An in vitro model based on macrophagic murine cell line RAW 264.7 was used for testing the anti-inflammatory effects of the corticosteroids of the present invention. During the inflammatory process, large amounts of nitric oxide (NO) are generated by the inducible isoforms of NO synthase (iNOS). Bacterial lipopolysaccaride (LPS) is commonly used in experimental settings to stimulate inflammatory responses in macrophages.
Cells were grown in a culture medium (RPMI supplemented with heat-inactivated 10% fetal calf serum, 2 mM glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin) without phenol red. Cell stimulation was elicited by incubating cells for 24 hours with LPS to final concentrations ranging from 100 ng/ml. Treatments with the compounds of the invention were carried out by adding such compounds vehicled in DMSO (0.1% final concentration) to the final desired concentrations 15 minutes before LPS exposure. As an index of nitric oxide production, the concentration of nitrite was measured in the conditioned media by using the Griess colorimetric reaction (J. Neuroimmunol., 150, 29-36, 2004, which is incorporated herein by reference in its entirety). Statistical analysis and determinations of IC50s were performed by using Prism-version 3.0 Graphpad Software (San Diego, Calif.). The IC50 values tested on the compounds of the invention are comprised between 0.2 and 20 nM.
Kinetic Characterisation: Lung Retention.
Lung retention was measured by means of two parameters: the MRTL (Mean Residence Time in the Lung), i.e. the residence of the compound in the lung, which is the time of the last measurable concentration of the compound in the rat lung after intratracheal administration of 1 μmol/kg, determined after lung homogenization, and the C48L/C0.5L (%), i.e. the percentage of the amount of the compound in the lung 48 hours after intratracheal administration vs the amount the same compound in the lung 0.25 hours after administration. MRTL and C48L/C0.5L (%) are two meaningful and predictive parameters of the duration of a drug's effect after single dose pulmonary administration. The compounds of the invention showed very slow lung elimination with MRTL higher than 20 hours and C48L/C0.5L higher than 20%.
Where a numerical limit or range is stated herein, the endpoints are included. Also, all values and subranges within a numerical limit or range are specifically included as if explicitly written out.
Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
All patents and other references mentioned above are incorporated in full herein by this reference, the same as if set forth at length.

Claims (15)

The invention claimed is:
1. A compound of formula (I):
Figure US08481517-20130709-C00195
wherein:
R1 is (CH2)n—V—(CH2)n′—Z—R4, wherein:
n and n′ are independently 0, 1 or 2;
V is absent or is selected from the group consisting of —O—, —S—, —OCOO, and NH;
Z is a single bond or is selected from the group consisting of —S—, —O—, carbonyl, carboxyl, (C3-C8)cycloalkyl, —NR5—, and —NR5C(O)—, wherein R5 is H or is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl, aryl(C1-C6)alkyl, aryl(C3-C8)cycloalkylene and heteroaryl, optionally substituted by CN;
R4 is:
—H, —OH, —CN, —SH, halogen,
(C1-C6)alkyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylcarboxyl, (C1-C6)alkylcarbonyl and (C3-C8)cycloalkyl, wherein one or more of the hydrogen atoms of the alkyl groups may be optionally substituted by one or more groups selected from oxo, —CN, —SH or halogen; or
a mono-, bi- or tricyclic saturated, partially saturated or fully unsaturated ring, optionally substituted by one or more halogen atoms or oxo groups; and wherein when R4 and R5 are both (C1-C6)alkyl, they may form a 4-8 membered heterocycle together with the nitrogen atom to which they are bonded;
R2 is (CH2)m—W—W′—R6, wherein:
m=0 or 1 to 6;
W is a single bond or is selected from the group consisting of —S—, —O—, carbonyl, and thiocarbonyl;
W′ is absent, NH or arylene group;
M is absent or is selected from the group consisting of (C1-C6)alkylsulfanyl, (C1-C6)alkylsulfonyl and (C1-C6)alkylsulfinyl;
R6 is:
H;
(C1-C6)alkyl;
a mono-, bi- or tricyclic saturated, partially unsaturated or fully unsaturated ring, having 3 to 10 ring atoms, and optionally containing at least one ring atom which is selected from the group consisting of N, NH, S, and O and wherein any of the above rings is optionally substituted by one or more groups selected from oxo, OH, CN, COOH, (C1-C6)alkoxy, halo(C1-C6)alkoxy, aryl(C1-C6)alkyl, (C1-C6)alkyl, halo(C1-C6)alkyl, cyano, OCO(C1-C6)alkyl and halogen;
—OR7
—OCOR7
—COR7
—COOR8
—CONR9R10
—CSNR9R10
—S(O)2R11
wherein R7, R8 and R11 are independently selected from the group consisting of (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C8)cycloalkyl, (C1-C6)alkylaryl, aryl(C1-C6)alkyl and a saturated, partially unsaturated or fully unsaturated optionally fused ring having 3 to 10 ring atoms and optionally containing at least one ring atom which is selected from the group consisting of N, NH, S, and O, which groups may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, (C1-C6)alkyl, aryl, heteroaryl, hydroxy, amino and alkoxy; and wherein R9 and R10 are independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl(C1-C6)alkyl and a saturated, partially unsaturated or fully unsaturated optionally fused ring having 3 to 10 ring atoms and optionally containing at least one ring atom which is selected from the group consisting of N, NH, S and O, which groups may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, (C1-C6)alkyl, and hydroxyl, and when R9 and R10 are both (C1-C6)alkyl, they may form a 4-8 membered heterocycle together with the nitrogen atom to which they are bonded;
R3 is selected from the group consisting of:
H;
aryl;
C(O)OR12 wherein R12 is selected from the group consisting of H, (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl and heteroaryl;
C(O)NR13R14 wherein R13 and R14 are independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl(C1-C6)alkyl and a saturated, partially unsaturated or fully unsaturated optionally fused ring having 3 to 10 ring atoms and optionally containing at least one ring atom selected from the group consisting of N, NH, S and O, which groups may be optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, (C1-C6)alkyl, and hydroxy and when R13 and R14 are both (C1-C6)alkyl, they may form a 4-8 membered heterocycle together with the nitrogen atom to which they are bonded;
X and Y are independently selected from the group consisting of H and halogen;
or a pharmaceutically acceptable salt thereof.
2. A compound or pharmaceutically acceptable salt according to claim 1, represented by formula (I′),
Figure US08481517-20130709-C00196
wherein the configuration of the carbon atom in position 5 is S, in position 6a is S, in position 6b is S, in position 9a is R, in position 10a is S, in position 10b is S, in position 4a is S when X is halogen or 4a is R when X is hydrogen, in position 4b is R when X is halogen or 4b is S when X is hydrogen and in position 12 is S when X is halogen, and wherein the symbol represents an unspecified bond, which indicates an asymmetric carbon atom in position 9, wherein the configuration may be R or S, and wherein the values of R1, R2, R3, X and Y are as defined in claim 1.
3. A compound or pharmaceutically acceptable salt according to claim 1, wherein:
R1 is (CH2)n—V—(CH2)n′—Z—R4, wherein:
n and n′ are independently 0, 1 or 2;
V is absent or is selected from the group consisting of —O—, —S—, —OCOO and —NH;
Z is a single bond or is selected from the group consisting of O, carbonyl, carboxyl, (C3-C8)cycloalkyl, —S— and —NR5, wherein R5 is selected from the group consisting of H, (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl, aryl(C1-C6)alkyl, aryl(C3-C8)cycloalkyl and heteroaryl, optionally substituted by CN;
R4 is selected from the group consisting of H, CN, OH, COR8, halogen, (C1-C6)alkyl, aryl and hetero(C3-C8)cycloalkyl which may be optionally substituted by one or more halogen atoms or oxo and wherein R8 is (C1-C6)alkyl optionally substituted by halogen;
R2 is (CH2)m—W—W′-M-R6, wherein:
m=0 to 4;
W is a single bond or is selected from the group consisting of —O—, carbonyl or thiocarbonyl;
W′ is absent, NH or is aryl;
M is absent or is selected from the group consisting of (C1-C6)alkylsulfanyl and (C1-C6)alkylsulfinyl;
R6 is selected from the group consisting of H, linear or branched (C1-C6)alkyl, (C3-C8)cycloalkyl, hetero(C3-C8)cycloalkyl, aryl and heteroaryl, wherein (C3-C8)cycloalkyl, hetero(C3-C8)cycloalkyl, aryl and heteroaryl are optionally substituted by one or more groups selected from halogen atoms, oxo, OH, CN, COOH, (C1-C6)alkoxy, halo(C1-C6)alkoxy, aryl(C1-C6)alkyl, (C1-C6)alkyl, halo(C1-C6)alkyl, —OCO(C1-C6)alkyl or halogen; —OR7, —OCOR7, —COR7, —COOR8, —CONR9R10, —CSNR9R10, —S(O)2R11 wherein R7, R8 and R11 are independently selected from the group consisting of (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C8)cycloalkyl, aryl(C1-C6)alkyl, (C1-C6)alkylheteroaryl, aryl, hetero(C3-C8)cycloalkyl and heteroaryl having 3 to 10 ring atoms wherein at least one ring atom is a heteroatomic group selected from the group consisting of N, NH, S, and O, which groups may be optionally substituted with one or more substituents selected from the group consisting of halogen and (C1-C6)alkyl; R9 and R10 are independently selected from the group consisting of (C1-C6)alkyl and (C3-C8)cycloalkyl;
R3 is selected from the group consisting of H and C(O)OR12 wherein R12 is H or (C1-C6)alkyl;
X and Y are independently selected from the group consisting of H and fluorine.
4. A compound or pharmaceutically acceptable salt according to claim 1, wherein:
R1 is (CH2)n—V—(CH2)n′—Z—R4, wherein:
n=1,
n′=0,
Z is —O—,
R4 is (C1-C6)alkylcarbonyl or (C1-C6)alkylcarboxyl;
R2 is (CH2)m—W—W′-M-R6, wherein:
m=0 or 1,
W is a bond, carbonyl or thiocarbonyl,
W′ and M are absent,
R6 is H, (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl, heteroaryl, or —OR7, wherein R7 is (C1-C6)alkyl or (C1-C6)alkylaryl.
5. A compound or pharmaceutically acceptable salt according to claim 1, wherein:
R1 is (CH2)n—V—(CH2)n′—Z—R4, wherein:
n=1,
n′=0,
V is absent,
Z is —O— and
R4 is (C1-C6)alkylcarbonyl;
R2 is (CH2)m—W—W′-M-R6, wherein:
m=0,
W is carbonyl,
R6 is —OR7, wherein R7 is (C1-C6)alkylaryl, and
W′ and M are absent.
6. A compound or pharmaceutically acceptable salt according to claim 1, wherein R1 is (CH2)n—Z—R4, wherein:
n=0,
Z is —O—,
and R4 is (C1-C6)alkyl, wherein one or more hydrogen atoms are substituted by halogen.
7. A compound or pharmaceutically acceptable salt according to claim 1, wherein:
R2 is (CH2)m—W—W′-M-R6, wherein:
m=1,
W is a single bond,
W′ is aryl,
M is (C1-C6)alkylsulfanyl or (C1-C6)alkylsulfinyl, and
R6 is aryl optionally substituted by OH.
8. A compound or pharmaceutically acceptable salt according to claim 1, wherein:
R1 is (CH2)n—V—(CH2)n—Z—R4, wherein:
n and n′=0,
V is absent,
Z is —O—, and
R4 is (C1-C6)alkyl, wherein one or more hydrogen atoms are substituted by halogen.
9. A compound or pharmaceutically acceptable salt according to claim 1, wherein:
R1 is (CH2)n—V—(CH2)n—Z—R4, wherein:
n and n′=0,
V is absent, and
Z is —NR5, wherein R5 is H or is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, aryl, aryl(C1-C6)alkyl, aryl(C3-C8)cycloalkyl, and heteroaryl, optionally substituted by CN.
10. A pharmaceutical composition, comprising a compound or pharmaceutically acceptable salt as defined in claim 1 and one or more pharmaceutically acceptable carriers and/or excipients.
11. A combination comprising a compound or pharmaceutically acceptable salt as defined in claim 1 and one or more active ingredients selected from the group of a β2-agonist, an antimuscarinic agent, a PDE4 inhibitor, a P38 MAP kinase inhibitor, and an IKK2 inhibitor.
12. A device, comprising a pharmaceutical composition according to claim 10, wherein said device is a single-dose dry powder inhaler, a multi-dose dry powder inhaler, a metered dose inhaler, or a soft mist inhaler.
13. A method for the treatment of a disease selected from the group consisting of asthma and chronic obstructive pulmonary disease, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt according to claim 1.
14. A method according to claim 13, wherein said disease is asthma.
15. A method according to claim 13, wherein said disease is chronic obstructive pulmonary disease.
US13/020,988 2010-02-05 2011-02-04 Pyrrolidine compounds,pharmaceutical compositions containing the same, devices containing the same, and methods of treating asthma or chronic obstructive pulmonary disease by administering the same Expired - Fee Related US8481517B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10152731 2010-02-05
EP10152731 2010-02-05
EP10152731.5 2010-02-05

Publications (2)

Publication Number Publication Date
US20110201580A1 US20110201580A1 (en) 2011-08-18
US8481517B2 true US8481517B2 (en) 2013-07-09

Family

ID=42244408

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/020,988 Expired - Fee Related US8481517B2 (en) 2010-02-05 2011-02-04 Pyrrolidine compounds,pharmaceutical compositions containing the same, devices containing the same, and methods of treating asthma or chronic obstructive pulmonary disease by administering the same

Country Status (10)

Country Link
US (1) US8481517B2 (en)
EP (1) EP2531516A2 (en)
KR (1) KR20120116462A (en)
CN (1) CN102741268A (en)
AR (1) AR080139A1 (en)
BR (1) BR112012019473A2 (en)
CA (1) CA2788986A1 (en)
RU (1) RU2012133250A (en)
TW (1) TW201139369A (en)
WO (1) WO2011095535A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155747B2 (en) 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR085817A1 (en) * 2011-03-15 2013-10-30 Chiesi Farma Spa ISOXAZOLIDINE DERIVATIVES
CN103380142A (en) 2011-03-15 2013-10-30 奇斯药制品公司 Isoxazolidine derivatives
EP2739640A1 (en) 2011-08-01 2014-06-11 Chiesi Farmaceutici S.p.A. Anti -inflammatory steroids condensed in position 16,17 with pyrrolidine ring
CN108659083A (en) * 2017-03-31 2018-10-16 天津药业研究院有限公司 A kind of synthetic method of Loteprednol etabonate
CN108659084A (en) * 2017-03-31 2018-10-16 天津药业研究院有限公司 A kind of preparation method of 17 β-carboxylic acids chloromethane esters steroidal compounds
CN112142820A (en) * 2019-06-29 2020-12-29 天津药业研究院股份有限公司 Synthetic method of triamcinolone acetonide
BR112023013247A2 (en) * 2021-01-07 2023-10-03 Immunext Inc STEROID PAYLOADS, STEROID LINDERS, ADCS CONTAINING THE SAME AND THEIR USES
CN115785188B (en) * 2022-12-20 2024-06-07 湖南科益新生物医药有限公司 Preparation method of budesonide
CN117050128A (en) * 2023-08-15 2023-11-14 黄冈人福药业有限责任公司 Preparation method and equipment of 11β-hydroxy-pregnant-1,4,16-triene-3,20-dione-21-acetate

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018757A (en) 1976-05-20 1977-04-19 E. R. Squibb & Sons, Inc. Steroidal[16α,17-c][2H]pyrroles
GB1578446A (en) 1976-02-13 1980-11-05 Squibb & Sons Inc Steroidal(16 ,17-d)isoxazolidines
US4474702A (en) 1984-01-20 1984-10-02 E. R. Squibb & Sons, Inc. [16,17-a]Cyclopentano pregnenes
WO2006005611A2 (en) 2004-07-14 2006-01-19 Novartis Ag Glucocorticoid 16alpha,17.alpha.-isoxazolidines as anti-inflammatory agents
US20110065678A1 (en) 2009-09-11 2011-03-17 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2838548A (en) 1958-02-19 1958-06-10 Upjohn Co 6 alpha-fluoro-16 alpha-hydroxy-4-pregnenes
US2864838A (en) 1958-02-19 1958-12-16 Upjohn Co 6 methyl 16 oxy delta4 pregnenes and delta1, 4 pregnadienes
EP2225256B1 (en) 2007-11-30 2013-01-09 Pfizer Limited Novel glucocorticoid receptor agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1578446A (en) 1976-02-13 1980-11-05 Squibb & Sons Inc Steroidal(16 ,17-d)isoxazolidines
US4018757A (en) 1976-05-20 1977-04-19 E. R. Squibb & Sons, Inc. Steroidal[16α,17-c][2H]pyrroles
US4474702A (en) 1984-01-20 1984-10-02 E. R. Squibb & Sons, Inc. [16,17-a]Cyclopentano pregnenes
WO2006005611A2 (en) 2004-07-14 2006-01-19 Novartis Ag Glucocorticoid 16alpha,17.alpha.-isoxazolidines as anti-inflammatory agents
US20110065678A1 (en) 2009-09-11 2011-03-17 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
European Search Report in Application No. 10152731.5, issued Jun. 29, 2010.
Green, M.J. et al., "Journal of Medicinal Chemistry", vol. 25. No. 12 (1982), p. 1492-1495.
U.S. Appl. No. 13/421,128, filed Mar. 15, 2012, Ghidini, et al.
U.S. Appl. No. 13/421,150, filed Mar. 15, 2012, Ghidini, et al.
U.S. Appl. No. 13/561,134, filed Jul. 30, 2012, Ghidini, et al.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155747B2 (en) 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
US9469669B2 (en) 2012-09-13 2016-10-18 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives

Also Published As

Publication number Publication date
US20110201580A1 (en) 2011-08-18
TW201139369A (en) 2011-11-16
WO2011095535A3 (en) 2011-11-17
KR20120116462A (en) 2012-10-22
RU2012133250A (en) 2014-02-10
WO2011095535A2 (en) 2011-08-11
EP2531516A2 (en) 2012-12-12
CN102741268A (en) 2012-10-17
CA2788986A1 (en) 2011-08-11
AR080139A1 (en) 2012-03-14
BR112012019473A2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
US8481517B2 (en) Pyrrolidine compounds,pharmaceutical compositions containing the same, devices containing the same, and methods of treating asthma or chronic obstructive pulmonary disease by administering the same
EP2475676B1 (en) Pregnane derivatives condensed in the 16,17 position with an N-substituted isoxazolidine ring as anti-inflammatory agents
US10280193B2 (en) Isoxazolidine derivatives
US8835412B2 (en) Isoxazolidine derivatives
US8710037B2 (en) Pyrrolidine derivatives, pharmaceutical compositions containing the same, and methods of using the same
NZ615423B2 (en) Isoxazolidine derivatives
HK1176939A (en) Pregnane compounds condensed in position 16, 17 with a pyrolidine ring with glucocorticoid activity
HK1166085B (en) Isoxazolidine derivatives
HK1218759B (en) Isoxazolidine derivatives
HK1196969A (en) Anti-inflammatory steroids condensed in position 16, 17 with pyrrolidine ring

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHIESI FARMACEUTICI S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GHIDINI, ELEONORA;RIZZI, ANDREA;VIRDIS, ANDREA;AND OTHERS;SIGNING DATES FROM 20110321 TO 20110325;REEL/FRAME:026199/0321

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20170709